---
document_datetime: 2023-12-11 09:36:19
document_pages: 103
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/vyxeos-epar-public-assessment-report_en.pdf
document_name: vyxeos-epar-public-assessment-report_en.pdf
version: success
processing_time: 132.8649844
conversion_datetime: 2025-12-25 09:22:36.144858
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 June 2018 EMA/486480/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Vyxeos

International non-proprietary name: daunorubicin / cytarabine

Procedure No. EMEA/H/C/004282/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

●

30 Churchill Place

Canary Wharf

Telephone

+44 (0)20 3660 6000

Send a question via our website

●

London E14 5EU

Facsimile

●

United Kingdom

+44 (0)20 3660 5520

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                | 7                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................7   |                                                                                                         |
| 1.2. Steps taken for the assessment of the product                                                                      | ........................................................8                                               |
| 2. Scientific discussion..............................................................................                  | 10                                                                                                      |
| 2.1. Problem statement.............................................................................................     | 10                                                                                                      |
| 2.1.1. Disease or condition                                                                                             | ........................................................................................ 10             |
| 2.1.2. Epidemiology..................................................................................................   | 10                                                                                                      |
| 2.1.3. Biologic features/Aetiology and pathogenesis......................................................               | 10                                                                                                      |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis............................................                 | 11                                                                                                      |
| 2.1.5. Management...................................................................................................    | 11                                                                                                      |
| 2.2. Quality aspects                                                                                                    | .................................................................................................. 13   |
| 2.2.1. Introduction.................................................................................................... | 13                                                                                                      |
| 2.2.2. Active Substance.............................................................................................    | 13                                                                                                      |
| 2.2.3. Finished Medicinal Product................................................................................       | 18                                                                                                      |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                      | 23                                                                                                      |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ...................... 23                                                                               |
| 2.2.6. Recommendations for future quality development                                                                   | ............................................... 24                                                      |
| 2.3. Non-clinical aspects............................................................................................   | 24                                                                                                      |
| 2.3.1. Introduction.................................................................................................... | 24                                                                                                      |
| 2.3.2. Pharmacology.................................................................................................    | 24                                                                                                      |
| 2.3.3. Pharmacokinetics ............................................................................................    | 28                                                                                                      |
| 2.3.4. Toxicology...................................................................................................... | 32                                                                                                      |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................               | 38                                                                                                      |
| 2.3.6. Discussion on non-clinical aspects .....................................................................         | 39                                                                                                      |
| 2.3.7. Conclusion on the non-clinical aspects                                                                           | ............................................................... 41                                      |
| 2.4. Clinical aspects                                                                                                   | .................................................................................................. 41   |
| 2.4.1. Introduction.................................................................................................... | 41                                                                                                      |
| 2.4.2. Pharmacokinetics                                                                                                 | ............................................................................................ 44         |
| 2.4.3. Methods......................................................................................................... | 44                                                                                                      |
| 2.4.4. Pharmacodynamics..........................................................................................       | 51                                                                                                      |
| 2.4.5. Discussion on clinical pharmacology...................................................................           | 52                                                                                                      |
| 2.4.6. Conclusions on clinical pharmacology.................................................................            | 53                                                                                                      |
| 2.5. Clinical efficacy                                                                                                  | .................................................................................................. 54   |
| 2.5.1. Dose response study........................................................................................      | 54                                                                                                      |
| 2.5.2. Main study ..................................................................................................... | 56                                                                                                      |
| 2.5.3. Discussion on clinical efficacy............................................................................      | 75                                                                                                      |
| 2.5.4. Conclusions on the clinical efficacy                                                                             | .................................................................... 76                                 |
| 2.6. Clinical safety                                                                                                    | .................................................................................................... 76 |

<div style=\"page-break-after: always\"></div>

| 2.6.1. Discussion on clinical safety.............................................................................. 93       |
|-----------------------------------------------------------------------------------------------------------------------------|
| 2.6.2. Conclusions on the clinical safety ...................................................................... 96         |
| 2.7. Risk Management Plan........................................................................................ 97        |
| 2.8. Pharmacovigilance ............................................................................................. 97     |
| 2.9. Product information............................................................................................ 97     |
| 2.9.1. User consultation ............................................................................................ 97    |
| 3. Benefit-Risk Balance............................................................................. 98                     |
| 3.1. Therapeutic Context ........................................................................................... 98     |
| 3.1.1. Disease or condition ........................................................................................ 98     |
| 3.1.2. Available therapies and unmet medical need....................................................... 98                 |
| 3.1.3. Main clinical studies......................................................................................... 98    |
| 3.2. Favourable effects.............................................................................................. 98    |
| 3.3. Uncertainties and limitations about favourable effects............................................. 99                 |
| 3.4. Unfavourable effects........................................................................................... 99     |
| 3.5. Uncertainties and limitations about unfavourable effects ......................................... 99                  |
| 3.6. Effects Table...................................................................................................... 99 |
| 3.7. Benefit-risk assessment and discussion............................................................... 100              |
| 3.7.1. Importance of favourable and unfavourable effects............................................ 100                    |
| 3.7.2. Balance of benefits and risks .......................................................................... 100         |
| 3.7.3. Additional considerations on the benefit-risk balance ......................................... 101                  |
| 3.8. Conclusions..................................................................................................... 101   |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

Abbreviation

Definition

7 + 3

7-day continuous infusion of cytarabine at a dose of 100 to 200 mg/m2/day in combination with an anthracycline for 3 days Adverse Drug Reaction

ADR

AE

Adverse event

ALL

Acute lymphoblastic leukemia

ALT

Serum Alanine Aminotransferase, also s-ALAT

AML

Acute myeloid leukemia

AML-MRC

AML with myelodysplasia related changes

ANC

Absolute neutrophil count

APL

Acute Promyelocytic Leukaemia

Ara-CTP

Cytocine Arabinoside Triphosphate

Ara-U

1-β-d-arabinofuranosyluracil

AS

Active substance

ASMF

Active substance master file

AST

Serum Aspartate Aminotransferase, also s-ASAT

AUC

Area under the plasma concentration time curve

AUClast

Area under the curve from time zero to the last measurable concentration

AUCtau

Area under the plasma concentration time curve for the dosing interval

BLQ

Below Limit of Quantification

BSA

Body Surface Area

BSE

Bovine Spongiform Encephalopathy

CHMP

Committee for Human Medicinal Products

Chol

cholesterol

CI

Confidence interval

CL

Clearance

Cmax

Maximum Concentration

CMMoL

Chronic Myelomonocytic Leukaemia

CNS

Central Nervous System

CPP(s)

Critical process parameters

CR

Complete remission

CrCL

Creatinine Clearance

CQA

Critical Quality Attributes

CRi

Complete remission with incomplete platelet or neutrophil recovery

CV

Coefficient of Variation

DCM

methylene chloride

DLT

Dose Limiting Toxicity

DNA

DeoxytiboNucleic Acid

DSC

Differential Scanning Calorimetry

DSMB

Data and Safety Monitoring Board

DSPC

distearoylphosphatidylcholine

DSPG(-Na)

Distearoylphosphatidylglycerol (sodium)

ECG

Electrocardiogram

ECHO

Echocardiography

EDTA

Ethylenediaminetetraacetic acid

EFS

Event-free survival

EMA

European Medicines Agency

ER

Exposure Response

FDA

Food and Drug Administration

GC

Gas Chromatography

GCP

Good Clinical Practice

GLP

Good Laboratory Practice

HDW

Hemoglobin concentration distribution width

HMA

Hypomethylating Agent

HPLC

High performance liquid chromatography

HRQoL

Health-related Quality of life

HSCT

Hematopoietic stem cell transplant

ICH

International Conference on Harmonisation

ICP-MS

Inductively coupled plasma mass spectrometry

ILS

Increase in life span

IP

Intraperitoneal

IPCs

In-process controls

IR

Infrared

ITT

Intent to Treat Population

IV

Intravenous

LC/fluorescence

High performance liquid chromatography with fluorescence detection

LC/MS

High performance liquid chromatography with mass spectrometry

LC/MS/MS

High performance liquid chromatography with tandem mass spectrometry

LC/UV

High performance liquid chromatography with ultraviolet detection

LVEF

Left ventricular ejection fraction

MCB

Master Cell Bank

MDS

Myelodysplastic syndrome

MLFS

Morphologic Leukemia-Free State

MPN

Myeloproliferative Neoplasm

MPS

Mononuclear phagocyte system

MST

Median Survival Time

MTD

Maximum tolerated dose

MUGA

Multigated acquisition scan

N/A

Not Available or Not Relevant

NMR

Nuclear Magnetic Resonance

OOS

out-of-specification

OS

Overall Survival

PDCO

Paediatric Committee

Ph.Eur.

European Pharmacopoeia

PIP

Paediatric Investigation Plan

PK

Pharmacokinetic

PP(s)

process parameters

PT

Preferred term

Q3Dx3

Once every 3 days for a total of 3 doses

QTcF

Fridericia's corrected QT-interval

QTTP

Quality Target Product Profile

RBC

Red blood cells

RDW

Red cells distribution width

RNA

RiboNucleic Acid

SAE

Serious adverse event

s-Bil

Serum Bilirubine Concentration

SCE

Sister chromatid exchange

s-Crea

Serum Creatinine Concentration

SD

Standard Deviation

SmPC

Summary of Product Characteristics

SOC

System Organ Class

SOI

Start of infusion

t-AML

Therapy related AML

TEA

triethanolamine

TEAE

Treatment-emergent adverse event

TL

Total Lipid

TLC

Thin layer chromatography

t 1/2

Elimination half time

tmax

time of the maximum concentration

TSE

Transmissible Spongiform Encephalopathy

ULN

Upper Limit of Normal (Reference Range)

UV

Ultraviolet

USP/NF

United States Pharmacopoeia/National Formulary

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

V Volume of distribution WBC White blood cell WCB Working Cell bank XR(P)D X-Ray (Powder) Diffraction

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Jazz Pharmaceuticals Ireland Limited submitted on 2 November 2017 an application for marketing authorisation to the European Medicines Agency (EMA) for Vyxeos ®  (daunorubicin:cytarabine) liposome for injection, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004 . The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 23 July 2015.

Vyxeos (daunorubicin:cytarabine) liposome for injection, was designated as an orphan medicinal product EU/3/11/942 on 11 January 2012 in the following condition: treatment of acute myeloid leukaemia.

The applicant applied for the following indication: Vyxeos is indicated as monotherapy for the treatment of adults with high-risk acute myeloid leukaemia (AML) as defined by therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that daunorubicin / cytarabine was considered to be a known active substance.

The application submitted is composed of administrative information, complete quality data, non-clinical data and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of  Vyxeos as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the Orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.

(http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/004282/human\\_med\\_ 002273.jsp&amp;mid=WC0b01ac058001d124)

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0299/2017 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0299/2017 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant submitted a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## Protocol Assistance

The applicant received Protocol Assistance from the CHMP:

| Scientific advice         | date              | Area                               |
|---------------------------|-------------------|------------------------------------|
| EMA/CHMP/SAWP/727423/2011 | 22 September 2011 | quality, non-clinical and clinical |
| EMA/CHMP/SAWP/833734/2015 | 17 December 2015  | non-clinical and clinical          |

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Robert James Hemmings Co-Rapporteur:  Tuomo Lapveteläinen

| The application was received by the EMA on                                                                                                                                                                                                        | 2 November 2017   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Accelerated Assessment procedure was agreed-upon by CHMP on                                                                                                                                                                                       | 14 September 2017 |
| The procedure started on                                                                                                                                                                                                                          | 23 November 2017  |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on In accordance with Article 6(3) of Regulation (EC) No 726/2004, the Rapporteur declared that they had completed their assessment report in less than 80 days       | 22 January 2018   |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on In accordance with Article 6(3) of Regulation (EC) No 726/2004, the Co-Rapporteur declared that they had completed their assessment report in less than 80 days | 23 January 2018   |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                                                                               | 29 January 2018   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                                                                          | 8 February 2018   |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                                                                           | 20 February 2018  |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                                                                               | 22 March 2018     |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                                                                           | 12 April 2018     |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on                                                                                                                                                         | 24 April 2018     |

<div style=\"page-break-after: always\"></div>

| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                        | 30 April 2018   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                       | 17 May 2018     |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on The accelerated assessment procedure was reverted to a standard assessment procedure.        | 31 May 2018     |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                        | 4 June 2018     |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                       | 13 June 2018    |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Vyxeos on | 28 June 2018    |
| The CHMP adopted a report on similarity of Vyxeos with Vidaza, Ceplene, Dacogen, Rydapt and Mylotarg (see Appendix 1) on                                                               | 31 May 2018     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Vyxeos is intended for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

## 2.1.2. Epidemiology

AML is the most frequent form of leukaemia, accounting for approximately 25% of all leukaemias in adults in the Western world. The annual crude incidence of AML is 3.7 per 100000, and the number of new cases per year in European Union is estimated to be 18400. The estimated number of cases of AML in 2008 was 53486, and the prevalence after 5 years from diagnosis was 4.1 per 100000 (RARECARE 2016).

The incidence of AML increases sharply with age, ranging from 1.8 cases per 100000 people aged under 65 years of age to 17.6 cases per 100,000 people over 65 years of age. More than half of the subjects with newly diagnosed AML in developed countries are over 65 years of age, with a median age at diagnosis of 67, and AML is more common in men than in women.

Overall, the 5-year survival rate for AML is 19%. The mortality rate strongly correlates with age: 5-year survival rates are 3% to 8% in patients aged 60 years and older compared with 5-year survival rates of up to 50% for younger patients.

## 2.1.3. Biologic features/Aetiology and pathogenesis

Acute myeloid leukemia is a biologically heterogeneous disease that can be classified into 3 distinct categories based on clinical ontogeny: de novo AML which arises in the absence of an identified exposure or prodromal stem cell disorder (like in MDS). Secondary AML (s-AML) represents transformation of an antecedent diagnosis of myelodysplastic syndrome (AML-MRC) or myeloproliferative neoplasm (MPN), therapy-related AML (t-AML) develops as a late complication in patients with prior exposure to leukaemogenic therapies. Recently the presence several of several mutations (in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2) were found to be highly specific for the diagnosis of s-AML (1).

High-risk AML constitutes a biologically distinct subset of disease and comprises a sizeable percentage of cases of adult AML. Based on retrospective review of large registries and given the lack of progress or variation in treatment over the past 25 years, a distinct profile of cytogenetic and molecular features can be used to assign risk. Although high-risk disease features cluster among clinical phenotypes, such as among patients over age 60, those with antecedent haematological disorders, and those who have received prior treatment with cytotoxic chemotherapy, high-risk karyotype or the expression of mutated flt3, kit, and other molecular markers explain both the poor response to induction chemotherapy and the high relapse rate previously attributed to clinical variables alone.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Acute myeloid leukaemia is a form of leukaemia - i.e., cancer of the white blood cells - characterised by infiltration of proliferative, clonal, abnormally differentiated, and occasionally poorly differentiated haematopoietic cells of myeloid lineage in the bone marrow, blood, and other tissues.

In AML, leukaemic blasts replace normal blood cells in bone marrow and peripheral blood, which leads to anaemia, neutropenia, and thrombocytopenia. This is associated with symptoms of fatigue, shortness of breath, disturbed wound healing, infections and bleedings. If left untreated, AML results in death within a few weeks to months.

AMLs are classified according to the World Health Organisation (WHO) classification from 2001, revised in 2008 and in 2016 (2). The classification incorporates morphological criteria, cytogenetic data, molecular genetics, immunophenotype data and clinical information into a diagnostic algorithm to delineate clinically significant disease entities.

The procedures used to diagnose and classify AML are: morphologic assessment of bone marrow specimens and blood smears (with ≥ 20% blasts in the bone marrow or peripheral blood being diagnostic of AML), analysis of the expression of cell-surface and cytoplasmic markers (by flow cytometry), identification of chromosomal findings (through cytogenetic testing), and screening for selected molecular genetic alterations. Following 2010 ELN recommendations several molecular markers are used as part of standard clinical practice for risk stratification (3):

- Alterations in nucleophosmin-1 (NPM1);
- Alternations in CCAAT/enhancer-binding protein alpha (CEBPA); and
- Alterations in Fms-like tyrosine kinase 3 (FLT3).

In addition to these three mutational screenings which are currently being used in routine practice, screening of several other mutations such as RUNX1, TP53, ASXL1 are proposed in the these current 2017 ELN recommendations.

Prognostic factors in AML can be subdivided into those that are related to the patient and those that are related to the disease. Patient-associated factors (e.g., increasing age, coexisting conditions, and poor performance status) commonly predict treatment-related early death, whereas disease-related factors (e.g., white-cell count, prior myelodysplastic syndrome or cytotoxic therapy for another disorder, and leukaemiccell genetic changes including alterations in FLT3) predict resistance to current standard therapy.

## 2.1.5. Management

Treatment should be planned with curative intent whenever possible. Intensive chemotherapy is divided into an induction phase and consolidation. Potential candidates for allogeneic stem cell transplantation (ASCT) must be identified early at diagnosis or during induction. For more than four decades, the combination of cytarabine (100 to 200 mg/m 2 /day) by continuous infusion on Days 1 through 7 together with daunorubicin (45 to 60 mg/m 2 ) on Days 1 through 3 (known as 7 + 3 regimen) has comprised the backbone of induction therapy. For patients who respond to induction therapy, post-remission options comprise haematopoietic stem cell transplantation (HSCT) or consolidation therapy (in the EU often with high-dose cytarabine). Although AML patients who receive HSCT generally have better outcome relatively few patients receive this potentially curative treatment because factors like older age, comorbidities, and toxicity of prior therapy prevent further treatment.

<div style=\"page-break-after: always\"></div>

In the EU (European Union), approved agents include decitabine (Dacogen) which is authorised for the treatment of adult patients with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy. Azacitidine (Vidaza) is also authorised for the treatment of adult patients who are not eligible for HSCT with AML with 20-30 % blasts and multi-lineage dysplasia, according to WHO classification and AML with &gt;30% marrow blasts according to the WHO classification. In addition, histamine dihydrochloride (Ceplene) is authorised for adult patients with AML in first remission concomitantly treated with interleukin-2 (IL-2). Midostaurin (Rydapt) is authorised in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy followed by midostaurin single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation positive. Finally, Mylotarg is authorised in combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia (APL).

## About the product

Vyxeos is a liposomal formulation of a fixed combination of daunorubicin and cytarabine in a 1:5 molar ratio. The 1:5 molar ratio has been shown in vitro and in vivo to maximise synergistic antitumour activity in AML (SmPC, section 5.1).

Daunorubicin has antimitotic and cytotoxic activity, which is achieved by forming complexes with DNA, inhibiting topoisomerase II activity, inhibiting DNA polymerase activity, affecting regulation of gene expression, and producing DNA-damaging free radicals (SmPC, section 5.1).

Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only during the S-phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA synthesis. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to proliferating mammalian cells in culture (SmPC, section 5.1).

Vyxeos liposomes exhibit a prolonged plasma half-life following intravenous infusion, with greater than 99% of the daunorubicin and cytarabine in the plasma remaining encapsulated within the liposomes. Vyxeos delivers a synergistic combination of daunorubicin and cytarabine to leukaemia cells for a prolonged period of time. Based on data in animals, Vyxeos liposomes accumulate and persist in high concentration in the bone marrow, where they are preferentially taken up intact by leukaemia cells in an active engulfment process. In leukaemia-bearing mice, the liposomes are taken up by leukaemia cells to a greater extent than by normal bone marrow cells. After internalisation, Vyxeos liposomes undergo degradation, releasing daunorubicin and cytarabine within the intracellular environment, enabling the medicinal products to exert their synergistic antineoplastic activity (SmPC, section 5.1).

The applicant applied for the following indication: Vyxeos is indicated as monotherapy for the treatment of adults with high-risk acute myeloid leukaemia (AML) as defined by therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). The recommended indication for approval is: Vyxeos is intended for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukaemia (t-AML) or AMLwith myelodysplasia-related changes (AML-MRC) (see SmPC, section 4.1).

Vyxeos dosing is based on the patient's body surface area (BSA) according to the following schedule: First induction: daunorubicin 44 mg/m 2  and cytarabine 100 mg/m 2  on days 1, 3, and 5; Second induction: daunorubicin 44 mg/m 2  and cytarabine 100 mg/m 2  on days 1 and 3; Consolidation: daunorubicin 29 mg/m2 and cytarabine 65 mg/m 2  on days 1 and 3 (SmPC, section 4.2).

<div style=\"page-break-after: always\"></div>

Consolidation therapy is recommended for patients achieving remission who have recovered to absolute neutrophil count (ANC) &gt; 500/µL and the platelet count has recovered to greater than 50,000/µL in the absence of unacceptable toxicity. A subsequent course of consolidation may be administered in patients who do not show disease progression or unacceptable toxicity within the range of 5 to 8 weeks after the start of the first consolidation. Treatment should be continued as long as the patient continues to benefit or until disease progression, up to maximum of 2 consolidation courses (SmPC, section 4.2).

## Type of Application and aspects on development

The CHMP agreed to the applicant's request for an accelerated assessment as the product was considered to be of major public health interest.

This was based on the therapeutic advantage over conventional 3+7 regimen with a survival benefit in the claimed indication of patients with untreated therapy related AML of with myelodysplasia related changes.  A survival benefit over the existing standard of care that has been used over the last 40 years is remarkable for this disease. In addition, it has the potential of reduced long term toxicity associated with anthracyclines although long term data is needed before it can be confirmed.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is a sterile lyophilised liposomal product presented as powder for concentrate for solution for infusion containing 44 mg of daunorubicin (as HCl salt) and 100 mg of cytarabine as the active substances. Vyxeos is the first liposomal product containing two active substances as a fixed-combination product.

Other ingredients are: distearoylphosphatidylcholine, distearoylphosphatidylglycerol, cholesterol, copper gluconate, triethanolamine and sucrose, as described in section 6.1 of the SmPC.

The product is available in a 50 mL Ph. Eur. Type 1 colourless glass vial, sealed with a grey chlorobutyl stopper with a Flurotec coating on the product contact surface and sealed with an aluminium flip-off seal, as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

## Cytarabine

## General information

The chemical name of cytarabine is 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2yl]-1,2-dihydropyrimidin-2-one corresponding to the molecular formula C9H13N3O5. It has a relative molecular mass 243.22 g/mol and has the following structure (Figure 1):

<div style=\"page-break-after: always\"></div>

Figure 1. Structure of cytarabine

<!-- image -->

Cytarabine is the subject of a monograph in Ph. Eur. (0760).  Information on the active substance was provided in an active substance master file (ASMF).

The structure of the active substance was elucidated by a combination of elemental analysis, mass spectrometry, NMR spectroscopy, IR spectroscopy and UV spectroscopy. Cytarabine is sufficiently characterised and its structure is adequately elucidated.

Cytarabine appears as white to almost white, crystalline powder. It is non hygroscopic and is freely soluble in water.

Cytarabine has four chiral centres. Cytidine, one of essential starting material, is a synthetic product with four chiral centers. The synthetic process changes the stereochemistry of the pair of hydroxyl groups from cytidine to cytarabine. The stereochemistry of the active substance produced by the manufacturer conforms to β form and was confirmed by NMR.

The crystalline state of cytarabine was investigated by means of Differential Scanning Calorimetry (DSC) and X-Ray Diffraction (XRD). The manufacturing process results always to the same crystalline form.

## Manufacture, characterisation and process controls

Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory.

Cytarabine is manufactured synthetically using cytidine as a starting material through three chemical steps from cytidine (starting material).

The synthetic steps are followed by purification and crystallisation of the crude cytarabine, drying, pulverising and final packaging. Critical and non-critical process steps and parameters have been identified. The proposed in-process controls (IPCs) have been presented and are justified. The control strategy ensures consistent quality of the active substance. The characterisation of the active substance and its impurities are in accordance with the relevant ICH guidelines.

The potential impurities are controlled in the active substance and intermediate specifications as well as in the in-process control during the manufacturing of the active substance by validated test methods. It has been demonstrated that the impurities are adequately controlled during manufacturing of the active substance. The proposed tests and acceptance criteria for the active substance, the active substance intermediates, and in process controls are considered acceptable.

The active substance is packed in air-tight, polyethylene bag (two ply), and placed in a light resistant tin can (outermost packaging). The primary packaging material is in compliance with the Ph. Eur., and EU Regulation 10/2011, respectively, as supported by evidence provided by the supplier.

<div style=\"page-break-after: always\"></div>

## Specification

The active substance specification inludes appropriate tests and limits for appearance (visual), identification (UV, IR, HPLC), appearance of solution (Ph. Eur.), specific optical rotation (Ph. Eur.), loss on drying (Ph.  Eur.), sulfated ash (Ph. Eur.), chromatographic purity (HPLC) and assay (Ph. Eur.).

The proposed active substance specifications as applied by the finished product manufacturer or the active substance manufacturer comply with the current Ph. Eur. monograph for cytarabine.

The analytical procedures used in the control of the active substance have been satisfactorily described and validated in accordance with the relevant ICH guidelines. Information regarding the reference standards used in the analytical testing is satisfactory.

Batch analysis data for three commercial scale batches of the active substance were provided. The results are within the specifications and confirm consistency of the manufacturing process from batch to batch.

## Stability

Stability data on three production scale batches of cytarabine stored in the intended commercial packaging for up to 36 months under long term conditions (25.0 ± 2.0 °C / 60.0 % RH ± 5.0 %) and for up to 6 months under accelerated conditions (40.0 ± 2.0 °C / 75.0 % RH ± 5.0 %) was provided according to the ICH guidelines.

Samples were tested for parameters such as characters, identification (UV, IR, TLC), appearance of solution, specific rotation, related substances, loss on drying and assay.  The test methods are stability indicating. All tested parameters consistently meet the required Ph. Eur. specifications under both accelerated and longterm conditions. No significant changes to any of the measured parameters were observed under long term and accelerated conditions and all remained within specification.

According to Ph. Eur. monograph, cytarabine should be protected from light; no formal photostability study was performed, this is acceptable.

The stability results justify the proposed retest period in the proposed container.

## Daunorubicin hydrochloride

## General information

The chemical name of daunorubicin hydrochloride is ( 8S,10S )-8-acetyl-10-{[( 2R,4S,5S,6S )-4-amino-5hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12dione hydrochloride corresponding to the molecular formula C27H29NO10.HCl. It has a relative molecular mass 563.98 g/mol and has the following structure (Figure 2):

<div style=\"page-break-after: always\"></div>

Figure 2. Structure of daunorubicin hydrochloride

<!-- image -->

Daunorubicin hydrochloride is the subject of a monograph in Ph. Eur. (0662). Information on the active substance was provided in an active substance master file (ASMF).

The structure of the active substance was elucidated by a combination IR spectroscopy, UV spectroscopy, 1 H- and  13 C-NMR spectroscopy, mass spectrometry and differential scanning calorimetry (DSC). The crystalline state of the substance was consistently confirmed using X-Ray Powder Diffraction (XRPD). Daunorubicin hydrochloride is sufficiently characterised and its structure is adequately elucidated.

Daunorubicin hydrochloride appears as orange-red powder, hygroscopic crystalline powder. It is freely soluble in water and methanol, slightly soluble in alcohol, practically insoluble in acetone.

Daunorubicin has six chiral centres. The stereochemistry of the active substance is guaranteed by the fermentation process that is widely known to be highly stereoselective. The fermentation process used employs the strain Streptomyces peucetius that is referenced in the Ph. Eur. Monograph 0662. The stereochemistry of the active substance is that provided by the Ph. Eur. Monograph.

The crystalline state of daunorubicin hydrochloride was investigated by means of X-Ray Powder Diffraction technique on three production batches. The diffractograms showed the same crystalline form as that described in literature. The manufacturing process results always to the same crystalline form. However since daunorubicin hydrochloride is solubilised in buffer solution during manufacture of the finished product it is acknowledged that polymorphism of the active substance is not considered as critical attribute for the manufacture of Vyxeos.

## Manufacture, characterisation and process controls

Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory.

Daunorubicin hydrochloride is manufactured in three main stages. In the first stage, crude daunorubicin hydrochloride (or Intermediate I) is obtained starting from fermentation of Streptomyces peucetius . After the fermentation phases, the fermentation broth undergoes a number of hydrolysis, filtration, pH adjustment and extraction and purification steps, which result in crude daunorubicin hydrochloride (or Intermediate I).

In the second stage, crude daunorubicin hydrochloride undergoes a pre-final crystallisation to obtain prefinal crystallization daunorubicin hydrochloride (or Intermediate II).

In the third step, pre-final crystallization daunorubicin hydrochloride is dissolved, recrystallised and sieved to obtain the final active substance.

<div style=\"page-break-after: always\"></div>

The Master Cell Bank (MCB) is sufficiently characterised. The preparation of Master Cell Bank and Working Cell bank (WCB) has been clearly reported. The specification for MCB and WCB is presented and is considered satisfactory.

Critical and non-critical process steps and parameters have been identified. The proposed IPCs have been presented and are justified. They include the controls of parameters in the fermentation phases, recovery and synthetic phase.

The control strategy ensures consistent quality of the active substance. The characterisation of the active substance and its impurities are in accordance with the relevant ICH guidelines.

The potential impurities are controlled in the active substance and intermediate specifications as well as in the in-process control during the manufacturing of the active substance by validated test methods. It has been demonstrated that the impurities are adequately controlled during manufacturing of the active substance. The proposed tests and acceptance criteria for the active substance, the active substance intermediates I and II, and in process controls are considered acceptable and justified. It is specified in the Ph. Eur. monograph that the production process of daunorubicin hydrochloride should be designed to eliminate or minimise the presence of histamine. During daunorubicin manufacture it is considered essential to minimise the level of histamine in the final produced daunorubicin hydrochloride in order to avoid unwanted effects from histamine. The ASMF Holder should provide, as post-approval commitment, evidence that the Ph. Eur. monograph recommendation is met.

The active substance is packed in Type III glass bottles, closed with polypropylene cap equipped with polyethylene gasket. The bottle is then put in a transparent polyethylene bag and placed in a cardboard drum and stored at 5 ± 3 °C. The glass bottles and polyethylene gasket used as primary packaging materials are in compliance with the Ph. Eur., and EU Regulation 10/2011, respectively, as supported by evidence provided by the supplier.

## Specification

The active substance specification includes appropriate tests and limits for appearance (visual), identification (IR, HPLC), identification of chlorides (Ph. Eur.), crystallinity (microscopy), pH (Ph. Eur.), water content (Ph. Eur.), related substances (Ph. Eur.), residual solvents (Ph. Eur.), assay (Ph. Eur.) and microbiological testing (Ph. Eur.).

The proposed active substance specifications as applied by the finished product manufacturer or the active substance manufacturer comply with the current Ph. Eur. monograph for daunorubicin hydrochloride.

The analytical procedures used in the control of the active substance have generally been satisfactorily described and validated in accordance with the relevant ICH guidelines. Information regarding the reference standards used in the analytical testing is satisfactory.

Batch analysis data for six commercial scale batches of the active substance were provided. The results are within the specifications and confirm consistency of the manufacturing process from batch to batch.

## Stability

Stability  data  on  six  production  scale  batches  of  daunorubicin  hydrochloride  stored  in  the  intended commercial packaging for up to 12 months under long term conditions (5° ± 3°C) and for up to 6 months under accelerated conditions (25 °C, 60 % RH) was provided according to the ICH guidelines.

<div style=\"page-break-after: always\"></div>

Samples were tested for appearance (accelerated condition only), assay, related substances, water content, pH and microbiological testing. The test methods are stability indicating. No significant changes to any of the measured parameters were observed under long term and accelerated conditions and all remained within specification.

According  to  Ph.Eur.  monograph  daunorubicin  hydrochloride  should  be  protected  from  light;  no  formal photostability study was performed, this is acceptable.

The stability results justify the proposed retest period in the proposed container.

## 2.2.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

Vyxeos is a sterile lyophilised liposome formulation intended for parenteral administration. Each single-use 50 mL vial contains 100 mg cytarabine and 44 mg daunorubicin in a 5:1 molar ratio at a concentration of 100 units per vial, where 1 unit contains 1.0 mg cytarabine and 0.44 mg daunorubicin (as the free base).

The product after reconstitution with 19 mL of sterile Water for Injection is a purple colloidal dispersion of liposomes with daunorubicin and cytarabine encapsulated in the liposomes providing 5 units/mL (5.0 mg/mL cytarabine and 2.2 mg/mL daunorubicin (as the free base)). The liposome membrane is composed of distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG) and cholesterol in a 7:2:1 molar ratio.

Vyxeos is a liposomal formulation of cytarabine:daunorubicin intended for the treatment of acute myeloid leukemia. The rationale for developing Vyxeos was based on the principle of ratiometric dosing, in which specific drug:drug ratios provide synergistic activity. The anti-tumor ratio-dependent synergy of cytarabine and daunorubicin was defined in cell-based screening assays in vitro. This ratio of the drugs was encapsulated in liposomes. Nano-scale drug delivery vehicles, such as liposomes, are known to prolong the circulation of drugs in vivo . The small size (~100 nm diameter) and specific lipid composition of the Vyxeos liposomes result in long circulation times in vivo .

The Quality Target Product Profile (QTTP) was reviewed and contained a summary of the quality characteristics that were used to guide pharmaceutical development for Vyxeos in accordance with ICH Q8.

## Critical Quality Attributes (CQA)

Based on the QTPP, the critical quality attributes (CQA) to ensure the quality, safety and efficacy of the finished product were identified.

The selection of cytarabine and daunorubicin was based on the established clinical practice which has been the standard first-line induction treatment for acute myeloid leukaemia (AML) for over 40 years.

In addition, a panel of tumour cell lines was utilised to examine drug ratio-dependent synergy for various cytarabine:daunorubicin molar ratios.

Data analysed using the median effect analysis method showed that the cytarabine:daunorubicin 5:1 molar ratio was the most consistently synergistic ratio evaluated, with 53% of cell lines tested displaying synergy and 33% antagonism. The maintenance of the 5:1 molar ratio of cytarabine:daunorubicin during drug release from the liposome is confirmed based on both in vitro and in vivo evalution in mice and rats.

<div style=\"page-break-after: always\"></div>

Since both ASs are water soluble, encapsulation within a liposome carrier was identified as a possible solution to maintain fixed drug ratios in vivo . The liposomal membrane composition chosen for the encapsulation of cytarabine and daunorubicin was based on prior formulation experience. Therefore the brief discussion provided on the selection of lipids was accepted. The lipids comprising the liposomes are Distearoylphosphatidylcholine (DSPC), Distearoylphosphatidylglycerol sodium salt (DSPG-Na) and cholesterol (Chol). Both DSPC and DSPG have a relatively high phase transition temperature (~ 55 ° C) and the negatively charged lipid (DSPG) is used to help minimise liposome aggregation.

In vitro developmental data relating to a prior floxuridine and irinotecan liposomal formulation was presented to support the chosen lipid ratio of DSPC:DSPG:Chol (70:20:10, mol:mol) instead of new data using cytarabine and daunorubicin. This was considered acceptable because, importantly, the underlying strategy of Vyxeos is for intact liposomes containing the 5:1 molar ratio to be taken up by leukemia cells. Therefore, Vyxeos liposomes are designed for high retention of the drug cargo and low in vivo release rates as they circulate in the plasma. Based on PK calculations, at least 99% of the drug in the plasma is encapsulated within Vyxeos liposomes. Subsequent in vivo studies confirm the maintenance of the 5:1 molar ratio (cytarabine:daunorubicin).

Based on previous formulation studies performed, different drug loading techniques have been evaluated for the loading of cytarabine and daunorubicin respectively. The excipients used are conventional excipients used for the manufacture of liposomal formulation and are known in the literature for use with anti-cancer agents, therefore the choice of excipients is considered acceptable.  There are no novel excipients used in the manufacture of Vyxeos. Diastearoylphosphatidyl choline (DSPC) and distearoylphosphatidylglycerol (DSPG) have been used in different parenteral medicinal products approved globally for many years. No chemical or physical incompatibilities have been noted between cytarabine and daunorubicin or between cytarabine or daunorubicin and the excipients in Vyxeos. Compatibility of cytarabine and daunorubicin with the excipients was confirmed in real time and accelerated stability studies.

Characterisation studies of Vyxeos liposomes were performed. A summary of the characterization studies concerning relevant physicochemical properties for Vyxeos liposome for injection including liposome morphology; lamellarity; characterization of bilamellar structure; surface charge; trapped volume; phase transition temperature were presented. The characterisation of liposomes correlates with observed cryo-EM images pre- and post-drug loading revealing the formation of bilamellar liposomes.

Early Phase 1 and Phase 2 clinical trials were conducted with a slightly different liquid formulation.  The change to the lyophilised formulation, which can be stored at 2-8 °C, was made prior to the Phase 3 clinical trials to provide better product stability, ease of commercial distribution and ease of preparation in the clinic. A comparison of the formulations used in the clinical trials programme and container/closures were summarised. The commercial finished product formulation and container/closure system are the same as those used for the Phase 3 clinical studies.

Each manufacturing step has been discussed individually and each unit operation is categorised as either critical or non-critical.

Sufficient information has been presented to demonstrate that stereoisomerisation of either cytarabine or daunorubicin is not possible during the finished product manufacturing process.

Following inspection deficiencies at the ASs manufacturing sites, new manufacturers were identified as alternate commercial manufacturers for cytarabine and daunorubicin. The comparability of the ASs has been discussed in detail and the quality of the ASs sourced from the different manufacturers is considered comparable. A satisfactory comparability investigation for the finished product followed by the second process

<div style=\"page-break-after: always\"></div>

performance qualification with a product batch manufactured with the ASs from the new suppliers was also performed.

The in vitro release (IVR) assay is one of the critical controls for Vyxeos. An assessment of the relationship of mean particle size with IVR has been performed. It should be noted that IVR / in vivo correlations (IVIVC) have not been established. An updated satisfactory method development report of the in vitro drug release method has been provided and supported by relevant data during the procedure. The method development report is in line with the EMA ' Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product ' (EMA/CHMP/806058/2009/Rev. 02) and contains a full discussion of the method development strategy, determination of release media and demonstration of the discriminatory nature of the method to formulation and process variants. The proposed in vitro drug release method is used for the evaluation of the release characteristics of the two substances, and to discriminate between liposome batches with different formulations or compositions. The discriminatory of the IVR method is demonstrated by varying the formulation and the manufacturing process parameters. Due to the nature of the finished product, a multipoint specification limit / multiple sampling time-points are required for the IVR analysis of both active substances.

The reconstituted product is administered by intravenous (IV) infusion to patients after dilution with either 0.9% Sodium Chloride Injection, or 5% Dextrose in intravenous infusion bags. The physicochemical stability, including the compatibility of Vyxeos liposomes with the diluents, infusion bags and administration sets was evaluated. The results showed that the diluted Vyxeos solution is compatible with representative infusion bags and administration sets.

Vyxeos finished product is packaged in a 50 mL Ph. Eur. Type 1 colourless glass vial, sealed with a 20 mm 4432/50 grey chlorobutyl stopper with a Flurotec coating on the product contact surface and sealed with a 20 mm aluminium flip-off seal. The vial is then packaged into a cardboard carton to protect from light exposure.  The primary packaging system has been evaluated with respect to extractables and leachables and taking into account the total number of dosing days. No significant amount of leaching components from the product contacting packaging components was observed.

The declarations from the suppliers of the glass vial and rubber stopper are also provided, confirming compliance with the Ph. Eur. requirements, including Ph. Eur. 3.2.1. 'Glass containers for pharmaceutical use' , Ph. Eur. 3.2.9. 'Rubber closures for containers for aqueous parenteral preparations for powders and for freeze-dried powders ', and BSE/TSE-free statement.

## Manufacture of the product and process controls

The manufacturing process comprises the following main stages: preparation of liposomes, preparation of cytarabine and daunorubicin solutions, liposomes loading with cytarabine and daunorubicin, sterilisation, lyophilisation and packaging. Critical process parameters (CPPs) affecting the finished product critical quality attributes are presented. Ranges or target values for other non-critical process parameters (PPs) are also included. The proposed IPCs for the manufacturing process were established based on historical process performance data from commercial scale batches or in some cases the required finished product characteristics. A summary of the in-process limits, including the action limit and acceptance limit of the identified critical in-process parameters was clearly presented in tabular format.

The proposed in-process limits are generally supported by the relevant batch analysis during in-process testing, but because various batches from development have been pooled together, the calculation mean may be affected. In view of the limited commercial batches currently available, it is acceptable to revise the

<div style=\"page-break-after: always\"></div>

IPCs following the manufacture of 26 commercial batches (post-approval commitment). This would provide reassurance of the suitability of the proposed IPCs.

It was not possible to compare batch-to-batch consistency when the hold-time validation studies were only performed on one batch to validate a particular stage of the manufacturing process. Therefore, further validation data are requested to support the proposed hold-times of the intermediate products at different stages of the manufacturing process. The post-approval commitment to provide the data is acceptable.

The validation program for Vyxeos manufacturing process, which is a non-standard process, consisted of qualification of the aseptic filling process at the manufacturing site and validation studies on manufacturing unit operations. A prospective validation study has been performed initially on three commercial scale batches of Vyxeos. One batch failed release testing for one parameter. Following the OOS results some corrective and preventive actions was implemented. A fourth batch was successfully included in the formal validation study. Concerns over the out-of-specifications have been adequately discussed and justified. The relevant specification control limits have been amended accordingly.

Each batch was manufactured in the same manufacturing facility, using the same process and the same equipment as the commercial process.

In conclusion, it has been demonstrated that the manufacturing process is sufficiently robust to provide assurance that finished product of consistent quality, complying with the specification, is produced.

## Product specification

The finished product release and shelf life specifications, include appropriate tests and limits for appearance of Lyophilized Cake and  Post-Reconstitution Suspension (visual), reconstitution time, water content of the Lyophilized Cake (Ph. Eur.), pH of the reconstituted suspension (Ph. Eur.), particle size (Ph. Eur.), Osmolality (Ph. Eur.), Particulate Matter (Ph. Eur.), identification of cytarabine and daunorubicin (HPLC, UV), cytarabine and daunorubicin assay (HPLC), cytarabine and daunorubicin % encapsulation (HPLC),  cytarabine and daunorubicin impurities (HPLC), cytarabine and daunorubicin content uniformity (Ph. Eur.), DSPC assay (HPLC), DSPG-Na assay (HPLC), cholesterol assay (HPLC), Lipid impurities (HPLC), copper assay (atomic absorption), residual solvents (GC), endotoxin (Ph. Eur.), sterility (Ph. Eur.) and  in-vitro release.

Data from eight commercial-scale batches, along with data from twelve process development batches of lyophilised finished product form the basis for the justification of specifications for Vyxeos. Batches that were rejected during development were not used for specification setting. The proposed commercial IVR acceptance criteria are based primarily on the commercial scale batches manufactured at the proposed manufacturing site.

A risk assessment was conducted for Vyxeos finished product to identify potential elemental impurities that may be present in the finished product in accordance with ICH Q3D Elemental Impurities in Drug Products. In addition to the elemental impurities risk assessment, Vyxeos finished product was tested for levels of heavy metals via Inductively Coupled Plasma Mass Spectrometry (ICP-MS).  Based on the outcome of the risk assessment appropriate control strategy is put in place.

The finished product is released on the market following traditional final product release testing. The procedures for analytical methods used are provided. Most of them are compendial and for these methods verification reports were provided. The non-compendial analytical methods were validated according to current ICH guidance. Satisfactory information regarding the reference standards used in the routine analysis of finished product has been presented.

<div style=\"page-break-after: always\"></div>

Batch analysis data from commercial-scale batches of lyophilised finished product manufactured to date for use in Phase 3 clinical studies, registration stability studies process validation and commercial batches have been presented. These batches were manufactured at the commercial manufacturing site. In addition, batch analysis data of batches of frozen liquid product, as well as one batch of liquid formulation of Vyxeos, used in Phase I and II development have also been presented as supportive data.

All product batches were tested using the methods, and released against the specifications, in place at the time of test. The results show that the finished product can be manufactured with consistent quality and meeting its specifications.

## Stability of the product

Nine batches of Vyxeos, manufactured at the commercial manufacturing facility according to the commercial manufacturing process, have been placed on stability under long term (2 - 8 ° C) and accelerated conditions (25 ° C/60 % RH) according to the ICH guidelines. All stability batches were of commercial scale and kept in the proposed container closure system. Results are available for up to 42 months stored in long term and up to 24 months at accelerated conditions.

All test vials were stored upright in the container closure system and analysed based on the following parameters: appearance (lyophilised, and post-reconstitution); reconstitution time; cytarabine (identification, assay, % encapsulation and impurities); daunorubicin (identification, assay, % encapsulation and impurities); DSPC/DSPG/cholesterol assay; lipid impurities; pH; liposome particle size; in vitro release of cytarabine and daunorubicin; particulate matter and osmolality.

There was no change in appearance of the lyophilised plug or the reconstituted dispersion through 42 months. There were essentially no changes in any of the following: cytarabine and daunorubicin assays, impurities, and encapsulation, lipid assays, pH, osmolality, copper assay, triethanolamine assay, residual water content, particulate matter, endotoxins or sterility, in-vitro release rate.  There is a slight trend for the total daunorubicin impurities to increase through 42 months but remains well within the specification limit. However out-of-specification (OOS) results were observed for the in vitro drug release and mean particle size of the liposome, both of which are critical parameters for providing quality assurance of the finished product. OOS results were sufficiently justified. Nevertheless, only for three batches were there no OOS were observed for up to 12 months stability testing under all long-term (5 ± 3 °C), accelerated (25 ºC/60% RH) and stress conditions (30 ºC/65% RH or 40 °C/75 % RH).

In view of the limited number of batches that showed full compliance with the finished product specifications, the proposed shelf-life of 48 months is not acceptable; a shelf-life of 24 months can be considered acceptable provided that the Applicant commits to place two additional finished product batches, manufactured using the currently  proposed  ASs  sources,  manufacturing  process  and  controls,  on  stability.  Updated  stability  data should be provided annually until 24 months real time data is available for both batches.

The updated 18-month stability data for the one batch and 9-month long term stability data for a second batch confirms compliance with the proposed finished product specifications for up to the study period of 18and 9- months, respectively.  No significant differences for the tested parameters have been observed for these two batches during stability, which is satisfactory.

Furthermore, stress testing (i.e. photo-stability under ICH photostability conditions, temperature cycling) was also performed to study the effect of heat and light on Vyxeos. The stability of Vyxeos post reconstitution has also been studied in accordance with ICH Q1A guidance. Samples were analysed against the stability

<div style=\"page-break-after: always\"></div>

specifications in place at the time of testing. The photostability studies demonstrated that Vyxeos vials should not be exposed to intense light for prolonged periods of time and that the secondary packaging can be considered to provide sufficient protection against light-induced product degradation. Chemical and physical in-use stability has been demonstrated for 4 hours at 2°C to 8°C for the econstituted suspension in the vial and for the diluted infusion solution (SmPC section 6.3).

Short-term stability studies of lyophilised Vyxeos exposed to low and cycling temperatures were also performed. The results demonstrated the product is sensitive to light under ICH photostability conditions, and sensitive to elevated temperatures but not sensitive to temperature cycling within the tested range.

Overall the stability results based on the real-time stability results, a shelf-life of 24 months at storage conditions of 5°C ± 3°C for Vyxeos in the commercial container closure configuration is considered acceptable. According to results from the photostability study and following ICH requirements Vyxeos is sensitive to light. Therefore, the finished product should be protected from prolonged exposure to intense light and kept in the secondary packaging until use.

## Adventitious agents

Cholesterol is the only animal derived excipient used in the manufacture of Vyxeos. It is supplied under guarantee from the manufacturer that the source and/or processing used to obtain the cholesterol is in compliance with the \" Note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products, EMA/410/01 Rev. 3 \". A certificate of suitability from the European Directorate for the Quality of Medicines and Health Care has been provided.

All other excipients/components, including the other lipids, are manufactured from raw materials of plant, petroleum or chemical origin.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The source of both active substances has been changed during development and new manufacturers were identified as alternate commercial suppliers for cytarabine and daunorubicin. The comparability of the ASs has been discussed in detail and the quality of the ASs sourced from the different manufacturers is considered comparable. A satisfactory comparability investigation followed by the second process performance qualification for the finished product manufactured with active substances from the new suppliers was performed. Some issues with a number of development finished product batches not meeting all criteria have been investigated and satisfactory corrective actions and justifications have been provided. The suitability of the in vitro release assay which is one of the critical controls for Vyxeos has been successfully demonstrated. Overall, the results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

<div style=\"page-break-after: always\"></div>

## 2.2.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

1. The daunorubicin ASMF Holder should provide by 31 st  July 2018, as post-approval commitment, evidence that the Ph. Eur. monograph recommendation that the production process of daunorubicin hydrochloride should be designed to eliminate or minimise the presence of histamine is met.
2. All IPC control limits should be reviewed after manufacturing of 26 commercial batches of the finished product.
3. Further satisfactory validation data from two batches are required to support the proposed hold-times relating to the non-standard processing steps.
4. Two additional finished product batches, manufactured using the currently proposed active substance sources, manufacturing process and controls, should be placed on stability.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Single dose toxicity studies conducted with Vyxeos comprised a non-GLP single ascending dose study, in dogs, and two GLP-compliant single dose studies followed by a 14-day observation period, in rats and dogs.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

## In vitro assessment of cytarabine:daunorubicin combinations for synergy

Synergism with respect to cytotoxicity was more evident at higher cytarabine:daunorubicin molar ratios than one, and antagonist cytotoxic effects were observed in a larger proportion of cells at ratios lower than one. (Study FR-051212TH). A molar ratio of 5:1 cytarabine:daunorubicin showed the greatest degree of synergy while minimizing the degree of antagonism in a majority of tumour cell lines.

## Anti-tumour efficacy of Vyxeos against P388 Murine Lymphocytic Leukaemia in BDF-1 Mice (Study SR050705)

In Study SR050705, CPX-351, non-liposomal (free) cytarabine and daunorubicin, and the free drug cocktail (cytarabine:daunorubicin) were administered intravenously on Days 1, 4, 7 at the MTD and at dose-matched levels in the P388 murine lymphocytic leukaemia model.

With increasing dosage of daunorubicin, %ILS values increased, whereas cytarabine showed minimal dose dependence in the dosage range of 400 to 1000 mg/kg. Administration of the free drug cocktail at the MTD of 600:9 mg/kg cytarabine:daunorubicin was moderately effective with an MST of 29.5 days and %ILS of 293.3%, while treatment with higher doses of the free drug cocktail was not tolerated. Overall, the antitumour activity of CPX-351 administered at 12.5:5 mg/kg (in the first experiment) was approximately 3-fold greater than the activity of the free drug (cytarabine, 1000 mg/kg) or the free drug cocktail administered at the MTD.

<div style=\"page-break-after: always\"></div>

## Anti-tumour Efficacy of Vyxeos against WEHI-3B Murine Myelomonocytic leukaemia cells implanted in CD-1 nude mice (Study SR190805)

Administration of free cytarabine:daunorubicin cocktail at doses ≥ MTD of 600:9 mg/kg was associated with high toxicity compared with animals treated with 12:5.3 mg/kg . Mice treated with  had a longer MST and larger %ILS than ratio-matched free drug cocktail at matched doses and at the MTD.

## Anti-tumour efficacy of Vyxeos in the CCRF-CEM Human Acute T-Lymphoblastic Leukaemia Xenograft Model: Dose-Matched and at MTD Levels (Study SR250805)

Vyxeos and the 5:1 molar ratio-matched non-liposomal free drug cocktail (cytarabine:daunorubicin) were administered at dose-matched and at MTD levels in SCID/Rag2M mice implanted with CCRF-CEM human acute T-lymphoblastic leukaemia cells. Vyxeos had potent and dose-dependent anti-tumour activity against CCRF-CEM human acute T-lymphoblastic leukaemia. Maximum anti-tumour effect occurred at a dose of 12.5:5 mg/kg with 5/5 animals surviving until the end of the study.

## Anti-tumour efficacy of Vyxeos in the CCRF-CEM Human Acute T-Lymphoblastic Leukaemia Xenograft Model: Ratio-Matched and Dose-Pushed Levels (Study SR060905)

Vyxeos and non-liposomal free drug cocktail (cytarabine:daunorubicin) were administered at ratio-matched and dose-pushed levels to SCID/Rag2M mice.  Vyxeos had potent and dose-dependent anti-tumour activity against CCRF-CEM human acute T-lymphoblastic leukaemia. Maximum effect occurred at a dose of 10:4.4 mg/kg (MST and %ILS values of 79.5 days and 134% respectively with a p-value of 0.0008). Administration of Vyxeos at the highest dose of 12:5.3 mg/kg was not tolerated and was associated with significant mortality and adverse effects.

Vyxeos efficacy was also compared with the free drug cocktail administered at ratio-matched and dosepushed levels. Treatment with the ratio-matched free cocktail at 25:11 mg/kg was associated with significant body weight loss, high toxicity scores, and marked adverse events. Dose escalation of the dose-pushed free drug cocktail to 600:9 mg/kg resulted in unacceptable bodyweight loss and toxicity.  Vyxeos at 6:2.64 mg/kg and at 10:4.4 mg/kg had respectively a longer MST and a higher %ILS than dose-pushed free drug cocktail at the MTD of 300:4.5 mg/kg (respectively 59.5 day MST and 75% ILS for Vyxeos at 6:2.64 mg/kg and 79.5 day MST and 134% ILS for Vyxeos at 10:4.4 mg/kg compared  to a 53.5 day MST and 57% for the free drug cocktail at 300:4.5 mg/kg with a respective p-value of 0.066 and 0.0123.

## Anti-tumour Efficacy of Vyxeos in the HL-60B Human Acute Promyelocytic Leukaemia Xenograft Model (Study SR160905)

In Study SR160905, Vyxeos and non-liposomal free drug cocktail (cytarabine:daunorubicin) were administered to SCID/[CB17SC-M] mice implanted with HL-60B human acute promyelocytic leukaemia cells. The dose regimen consisted of IV injections on Days 8, 11, and 14 after implantation of HL-60B leukaemia cells.

Vyxeos exhibited dose-dependent anti-tumour activity against HL-60B human acute promyelocytic leukaemia xenografts, producing a maximum effect at the highest dose of 5:2 mg/kg (MST and %ILS values of 43.0 days and 43% respectively with a p-value of 0.0006). Treatment with a lower dose of Vyxeos at 2.5:1 mg/kg was less effective (MST and %ILS values of 35.0 days and 17%, respectively with a p-value of 0.006). No animals survived to Day 45 in either of the Vyxeos-treated groups. However, comparison of survival time between Vyxeos groups treated at 5:2 mg/kg and 2.5:1 mg/kg with that of control saline-treated group demonstrated statistically significant anti-tumour activity for both Vyxeos doses at p=0.0006 and p=0.006, respectively.

<div style=\"page-break-after: always\"></div>

Treatment of mice with Vyxeos at 5:2 mg/kg compared to animals treated with the ratio-matched free cocktail at the same dose resulted in a longer MST (43 days compared to 33 days) and % ILS (43% compared to10%). Dose escalation of the ratio-matched free drug cocktail to the MTD level of 10:4 mg/kg did not result in a survival benefit, with the MST value remaining comparable to that of controls.

The survival effect of Vyxeos at 5:2 mg/kg resulted in a longer MST and higher %ILS than mice treated with the ratio-matched free drug cocktail at matched dose of 5:2 mg/kg (43.0 days MST and 43% ILS for Vyxeos at 5:2 mg/kg compared to a 33.0 days MST and 10% ILS for the ratio-matched free drug cocktail at matched dose of 5:2 mg/kg) and at the MTD of 10:4 mg/kg (43.0 days MST and 43% ILS for Vyxeos at 5:2 mg/kg compared to a 27.0 days MST and -10% ILS for the ratio-matched free drug cocktail at matched dose of 10:4 mg/kg) with p-values at 0.0007 and 0.0012, respectively. CPX-35l anti-tumour activity was also greater than the dose-pushed free drug cocktail (a ratio of 200:3; p=0.0009).

## Anti-tumour Efficacy of Vyxeos Compared with Individual Liposomal Agents Against P388 Murine Lymphocytic Leukaemia Cells Implanted in BDF-1 Mice (Study SR250505)

Study SR250505 was a compilation of data from 2 individual experiments (NC003CT312 and NC003CT325) in the IP-implanted P388 murine lymphocytic leukaemia model. The dose regimen consisted of multiple IV injections administered Q3Dx3 on Days 1, 4, and 7, beginning 1 day after tumour cell implantation. After a 60-day period, surviving animals were re-inoculated to rule out the possibility of an immunological tumour rejection.

Animals in group treated with the high dose of Vyxeos (10:5 mg/kg) survived for 60 days, representing a &gt;7fold increase over the control (saline) median survival time. The studies showed that Vyxeos had potent antitumour activity against P388 syngeneic murine lymphocytic leukaemia. The anti-tumour activity of Vyxeos was shown to be dose-dependent, producing the greatest effect at a dosage level of 10:5 mg/kg. Vyxeos dose-dependent anti-tumour effect was consistent with animal survival at Day 60. Treatment of mice with Vyxeos at 10:5 mg/kg resulted in a longer MST and higher %ILS than individual liposomal drugs administered at dose-matched levels that produced a relatively moderate activity (&gt;60 days MST and &gt;675%

ILS for Vyxeos at 10:5 mg/kg compared to a 22 days MTS and 175% ILS for Liposomal Cytarabine at 10 mg/kg and a 16 day MST and 100% ILS for Liposomal Daunorubicin at 5 mg/kg with a p-value &lt;0.0001).

Surviving mice re-inoculated with P388 tumour cells had an MST of 8 days, identical to that of saline-control mice.

## Anti-tumour Efficacy of Vyxeos Compared with Free Drug Cocktail and Individual Liposomal Agents Against L1210 Murine Lymphocytic Leukaemia Cells Implanted in BDF-1 Mice (Study SR220705)

In Study SR220705, Vyxeos, and individual liposomal cytarabine and liposomal daunorubicin were administered at dose-matched and/or MTD levels in BDF-1 mice implanted with L1210 murine lymphocytic cells. The dose regimen consisted of multiple IV injections administered Q3Dx3 on Days 1, 4, and 7, beginning 1 day after tumour cell implantation. Vyxeos had potent and dose-dependent anti-tumour activity against Ll210 syngeneic murine lymphocytic leukaemia cells. A robust anti-tumour effect was observed at the highest dose of Vyxeos used in this study (12.5:5 mg/kg) (MST and %ILS values of &gt;64 days and &gt;814% respectively with a p-value of 0.0009). The Vyxeos dose-dependent anti-tumour effect was consistent with the survival rate.

Mice treated with Vyxeos had a longer MST and higher %ILS than those treated with the ratio-matched free drug cocktail at both the matched dose level as well as at the MTD (&gt;64 days MST and &gt;814% ILS for Vyxeos at 12.5:5 mg/kg compared to a 12 day MST and 71% ILS for the free cocktail administered at the

<div style=\"page-break-after: always\"></div>

same dose (12.5:5 mg/kg )with a p-value of 0.0012). Furthermore, all mice treated with the 12.5:5 mg/kg dose of Vyxeos survived until the end of the study (9-fold increase in MST vs. saline control), whereas none of the mice treated with the free drug cocktail at the same ratio survived until Day 64.

Mice treated with Vyxeos had a longer MST and higher %ILS than mice treated with individual liposomal drugs administered at the MTD (&gt;64 days MST and &gt;814% ILS for Vyxeos at 12.5:5 mg/kg compared to a 43.5 day MTS and 521% ILS for Liposomal Cytarabine at 15 mg/kg and a 19 day MST and 171% ILS for Liposomal Daunorubicin at 10 mg/kg with a respective p-value of 0.0566 and 0.0005). Likewise, the antitumour efficacy of Vyxeos over the individual liposomal drugs was also reflected by an increased incidence of survival at Day 64.

## Anti-tumour Efficacy of Vyxeos Compared with Individual Liposomal Agents Following a Delayed Q3Dx3 IV Administration Against P388 Murine Lymphocytic Leukaemia in BDF-1 Mice (Study SR221105)

In Study SR221105 Vyxeos, liposomal daunorubicin, and liposomal cytarabine were administered at dosematched and MTD levels to BDF-1 mice implanted with P388 syngeneic murine lymphocytic leukaemia cells. The dose regimen consisted of multiple IV injections administered on Days 4, 7, and 10, beginning 4 days after IP inoculation of P388 leukaemia cells.

Vyxeos had potent and dose-dependent anti-tumour activity against the P388 murine lymphocytic leukaemia which correlated with survival at Day 64. Mice treated with Vyxeos had a longer MST and higher %ILS than the individual liposomal drugs administered at dose-matched levels and at their MTD (38 days MST and 443% ILS for Vyxeos at 10:4.4 mg/kg compared to a 20.0 day MTS and 186 % ILS for Liposomal Cytarabine at 10 mg/kg and a 10 day MST and 43% ILS for Liposomal Daunorubicin at 4.4 mg/kg with a respective pvalue of 0.0006 and 0.0012).

## Anti-tumour Efficacy of Vyxeos Compared with Individual Liposomal Agents Against WEHI-3B Murine Myelomonocytic Leukaemia Cells Implanted in CD-1 Nude Mice (Study SR011205)

In Study SR011205, Vyxeos, liposomal daunorubicin, and liposomal cytarabine were administered at dosematched and MTD levels to CD-1 nude mice implanted with WEHI-3B murine myelomonocytic leukaemia cells. The dose regimen consisted of multiple IV injections administered on Days 1, 4, and 7, beginning 1 day after IP inoculation of tumour cells.  Vyxeos had potent and dose-dependent anti-tumour activity against the WEHI-3B murine myelomonocytic leukaemia, producing a maximum effect at a Vyxeosdose of 12:5: 3 mg/kg (MST and %ILS values of &gt;102 days and &gt;343% respectively with a p-value of 0.0008). The dose-dependent anti-tumour effect of Vyxeos was consistent with an increase in survival. Mice treated with the mid- and high dose of Vyxeos demonstrated a &gt;5-fold increase in MST compared with the control (saline).

Mice treated with Vyxeos had a longer MST and higher %ILS than mice treated with the individual liposomal drugs administered at dose-matched levels in WEHI-3B tumour-bearing mice (&gt;102 days MST and &gt;343% ILS for Vyxeos at 12:5.3 mg/kg compared to a 24.5 day MTS and 7.0 % ILS for Liposomal Cytarabine at 12 mg/kg and a 38.5 day MST and 67% ILS for Liposomal Daunorubicin at 5.3 mg/kg with a respective p-value of 0.0018 and 0.1006). The anti-tumour effect was consistent with an increased incidence of survival at Day 102.

## Anti-tumour Efficacy of Liposomal Cytarabine:Daunorubicin at Different Drug to Drug Molar Ratios: Optimal Drug Ratio Identification in P388 Xenografts (Study SR090905)

In study SR090905 three liposomal cytarabine:daunorubicin formulations at various fixed drug:drug molar ratios were compared with Vyxeos. Therapeutic treatment consisted of IV injections on Days 1, 4, 7 after IP tumour cell implantation. In a P388 murine lymphocytic leukaemia model, anti-tumour activity of Vyxeos

<div style=\"page-break-after: always\"></div>

(5:1 molar ratio) was dose dependent producing maximum effect at the highest dose tested correlating with the survival at Day 63 (p=0.001 vs. control). Vyxeos at 10:4 mg/kg (0.8 MTD) resulted in a comparable antitumour activity to that of liposomal cytarabine:daunorubicin administered at 11.6:1 molar ratio administered at 15:3 mg/kg (MTD). Mice treated with Vyxeos (5:1) had a longer MST and higher %ILS than formulations at 3:1 or 1:1 molar ratio administered at their respective MTD (&gt;63 days MST and 563% ILS for Vyxeos (5:1 molar ratio) compared to a 47.0 day MTS and 395 % ILS for formulation at 3:1 molar ratio  and a 44.0 day MST and 358% ILS for ILS for formulation at 1:1 molar ratio with a respective p-value of 0.1895 and 0.0563).

## Secondary pharmacodynamic studies

Following IV bolus doses of Vyxeos or a non-liposomal cocktail of cytarabine and daunorubicin (Study CT832), bone marrow exposures to cytarabine and daunorubicin were higher and more sustained with Vyxeos than with the non-liposomal formulations, half-lives in bone marrow for cytarabine and daunorubicin with Vyxeos were at least twice as long as those in plasma suggesting bone marrow as the site of retention for Vyxeos.

A Rag2 CCRF-CEM xenograft model was used to assess distribution to bone marrow in Study SR150105. Following a full course (Q3Dx3) of treatment with either Vyxeos or free drug cocktail, peak bone marrow levels of cytarabine or daunorubicin ranged from 2- to 14-fold higher in Vyxeos treated mice than in free drug-treated mice. Concomitantly, the bone marrow AUC values for both drugs were higher for Vyxeos treated mice than those treated with the free drug cocktail.

Off-target activity of Vyxeos on normal bone marrow cell lines was evaluated in study SR150105. Vyxeos was less cytotoxic in normal bone marrow cells. Intracellular accumulation of cytarabine and daunorubicin were 9 and 2 times higher in CCRF-CEM cells than in normal bone marrow cells. Similarly, the uptake of liposomal lipid in CCRF-CEM cells was 2 times greater than that in normal bone marrow cells.

The time-dependent intracellular accumulation of daunorubicin from Vyxeos liposomes was examined using fluorescence microscopy. In CCRF-CEM cells and chronic myelogenous leukemia cells, daunorubicin was observed to accumulate within the nucleus, and fluorescently labeled lipid in the Vyxeos liposomes was visible on the plasma membrane, surrounding the nucleus and throughout the cytoplasm. Concomitantly, plasma membrane-associated liposomes decreased over time.

## Safety pharmacology programme

No safety pharmacology studies have been submitted (see discussion on non- clinical aspects).

## Pharmacodynamic drug interactions

No pharmacodynamic drug interaction studies have been submitted (see discussion on non- clinical aspects).

## 2.3.3. Pharmacokinetics

Validated bioanalytical methods based on high-performance liquid chromatography and tandem mass spectrometry (LC/MS/MS) were used to measure plasma concentrations of cytarabine and AraU, daunorubicin and daunorubicinol in rats and dogs in GLP toxicology studies.

<div style=\"page-break-after: always\"></div>

For the non-GLP studies, qualified methods based on high-performance liquid chromatography with ultraviolet light, fluorescence, or mass spectrometry (LC/UV, LC/fluorescence, and LC/MS, respectively) were used to measure concentrations of total and free cytarabine and daunorubicin in plasma and bone marrow.

The general PK of cytarabine and daunorubicin associated with Vyxeos was evaluated in mice, rats, and dogs and the results are displayed in Table 1.

Table 1 PK parameters for cytarabine and daunorubicin in mice, rats, and dogs

Mouse data are from single-dose study CT832. CPX-351 was dosed at 12 units/kg; non-liposomal formulations were dosed at 600mg/kg for cytarabine and 9 mg/kg for daunorubicin.

|                   | Mice a   | Mice a   | Rats b   | Rats b   | Dogs c   | Dogs c   |
|-------------------|----------|----------|----------|----------|----------|----------|
| PKParameter       | CPX-351  | NL       | CPX-351  | NL       | CPX-351  | NL       |
| Cytarabine        |          |          |          |          |          |          |
| Dose (mg/kg)      | 12       | 600      | 5        | NA       | 2        | 2        |
| AUClast (μg/mL·h) | 2233     | 399      | 1438     | NA       | 380      | 3.29     |
| DN-AUC            | 186      | 0.665    | 288      | NA       | 190      | 1.64     |
| tlast (h)         | 38       | 4        | 48       | NA       | 48       | 4        |
| CL (mL/h/kg)      | 5.24     | 1503     | 3.49     | NA       | 5.26     | 587      |
| Vss(mL/kg)        | 48.1     | 592      | 29.4     | NA       | 49.4     | 693      |
| Terminal ty (h)   | 6.58     | 0.35     | 6.94     | NA       | 5.55     | 0.86     |
|                   | Mice a   | Mice a   | Rats b   | Rats b   | Dogs c   | Dogs c   |
| PKParameter       | CPX-351  | NL       | CPX-351  | NL       | CPX-351  | NL       |
| Daunorubicin      |          |          |          |          |          |          |
| Dose (mg/kg)      | 5.3      | 9        | 2.2      | 5        | 0.88     | 1        |
| AUClast (μg/mL·h) | 872      | 1.001    | 546      | 3.60     | 195      | 0.076    |
| DN-AUC            | 165      | 0.111    | 248      | 0.72     | 222      | 0.076    |
| tlas (h)          | 38       | 4        | 48       | NA       | 24       | NA       |
| CL (mL/h/kg)      | 6.0      | 6869     | 4.15     | 1424     | 4.49     | 12633    |
| Vss (mL/kg)       | 49.2     | 18253    | 37.8     | 50836    | 29.8     | 261810   |
| Terminal t (h)    | 5.74     | 1.99     | 6.46     | 25.4     | 4.59     | 21.8     |

Rat data are from study 1005-0361; mean data from males and females on Day 1. CPX-351 was dosed at 5 mg/kg. Data for non-liposomal daunorubicin were obtained from literature at 5 mg/kg (Zhang et al. 2014).

Dog data are from study1005-0372; mean data from males and females on Day 1. Both CPX-351 and non-liposomal cytarabine were dosed at 2 mg/kg. Data for non-liposomal daunorubicin were obtained from literature at 1 mg/kg (Oosterbaan et al. 1984).

Note: PK parameters are shown for single-dose intravenous administration.

CL=clearance; NL=non-liposomal; PK=pharmacokinetic; ty-half-life; Vss=volume of distribution at steady state;

DN-AUC=dose-normalized AUC, calculated by AUC/dose.

Cytarabine and daunorubicin tissue distributions were evaluated in two studies in which the 14C-labeled drugs were administered as components of Vyxeos or as non-liposomal formulations (Studies XBL14628 and XBL13687). The results are displayed in Table 2.

<div style=\"page-break-after: always\"></div>

Table 2 Tissue-to-Plasma AUClast Ratios for 14C-Cytarabine and 14C-Daunorubicin in Rats (Studies XBL14628  and XBL13687)

<!-- image -->

|                      | Tissue-to-Plasma AUCiast Ratio   | Tissue-to-Plasma AUCiast Ratio   | Tissue-to-Plasma AUCiast Ratio   | Tissue-to-Plasma AUCiast Ratio   |
|----------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                      | CPX-351                          | CPX-351                          | Non-liposomal                    | Non-liposomal                    |
| Tissue               | Cytarabine                       | Daunorubicin                     | Cytarabine                       | Daunorubicin                     |
| Plasma               | 1.00                             | 1.00                             | 1.00                             | 1.00                             |
| Spleen               | 0.44                             | 3.28                             | 1.50                             | 131.46                           |
| Adrenal cortex       | 0.24                             | 0.57                             | 1.15                             | 90.87                            |
| Adrenal gland        | 0.26                             | 0.64                             | 1.13                             | 91.87                            |
| Adrenal medulla      | 0.39                             | 1.06                             | 1.17                             | 102.54                           |
| Urinary bladder wall | 0.29                             | 0.07                             | 1054.5                           | 17.62                            |
| Bone marrow          | 0.21                             | 0.97                             | 0.47                             | 66.08                            |
| Lung                 | 0.21                             | 0.35                             | 1.15                             | 36.65                            |
| Kidney               | 0.15                             | 0.39                             | 2.81                             | 49.61                            |
| Kidney cortex        | 0.14                             | 0.37                             | 2.15                             | 45.55                            |
| Kidney medulla       | 0.16                             | 0.42                             | 4.23                             | 57.41                            |
| Heart                | 0.12                             | 0.31                             | 1.31                             | 29.30                            |
| Liver                | 0.11                             | 0.54                             | 1.14                             | 27.43                            |
| Lymph node           | 0.09                             | 0.73                             | 1.27                             | 70.16                            |
| Thymus               | 0.05                             | 0.27                             | 2.74                             | 50.39                            |
| Pancreas             | 0.04                             | 0.23                             | 1.24                             | 113.35                           |
| Pituitary gland      | 0.04                             | 0.25                             | 1.09                             | 120.91                           |
| Esophagus wall       | 0.03                             | 0.09                             | 1.90                             | 20.70                            |
| Stomach wall         | 0.03                             | 0.14                             | 1.22                             | 11.44                            |
| Brain (whole)        | 0.01                             | 0.01                             | 0.28                             | 0.95                             |

AUClast=area under the curve up to the last measurable concentration

Study CT832 assessed bone marrow targeting in in female CD-1 nude mice. The purpose was to determine the bone marrow uptake profiles of cytarabine and daunorubicin associated with administration of Vyxeos and non-liposomal formulations (cytarabine and daunorubicin in saline). The mice received an IV bolus dose of Vyxeos at 12 units/kg or a combination of 600 mg/kg cytarabine and 9 mg/kg daunorubicin as the nonliposomal formulations. Following administration of Vyxeos, both cytarabine and daunorubicin showed sustained retention in bone marrow; time of the maximum concentration (tmax) was 1 and 2 hours for cytarabine and daunorubicin, respectively, and levels of cytarabine and daunorubicin decreased very gradually and were still detectable at 24 hours post-dose. Following administration of the non-liposomal formulations, both cytarabine and daunorubicin distributed rapidly into bone marrow; tmax was 0.25 and 0.5 hours for cytarabine and daunorubicin, respectively. Levels of cytarabine decreased quickly and were below the limit of detection at 4 hours post-dose. Levels of daunorubicin remained relatively constant through 24 hours post-dose.

Bone marrow exposures to cytarabine and daunorubicin were higher and more sustained with Vyxeos than with the non-liposomal formulations. Dose-normalised AUCs were more than 2-times higher with Vyxeos administration, suggesting greater efficiency in delivering cytarabine and daunorubicin to the bone marrow.

<div style=\"page-break-after: always\"></div>

The t½ values were more than 2-times longer with Vyxeos. In addition, the t½ values for cytarabine and daunorubicin in bone marrow with Vyxeos were at least twice as long as the t½ in plasma. The cytarabine:daunorubicin molar ratio in bone marrow was maintained close to the desired synergistic ratio of 5:1 (range: 2:1 to 6:1) for the first 24 hours. In contrast, the molar ratio of cytarabine:daunorubicin with the non-liposomal formulations changed rapidly over the first 4 hours post-dose, reflecting no control of the desired molar ratio in bone marrow.

A single-dose metabolism study was performed in rats to determine the metabolite profile of 14Cdaunorubicin associated with administration of Vyxeos and a non-liposomal presentation (daunorubicin in saline) in plasma, urine, faeces, and bile. Parent daunorubicin was the only prominent circulating entity across the two formulations, accounting for approximately 91% of the total circulating radioactivity for Vyxeos and approximately 78% for the non-liposomal formulation. In the Vyxeos treatment, the only other radioactive component that accounted for at least ~3% of the plasma AUC for total radioactivity was daunorubicinol, which amounted to approximately 4% to 5%. The daunorubicinol metabolite:parent ratio based on plasma AUC was approximately 0.05 for Vyxeos.

A single-dose vivo metabolism study was performed in rats to determine the metabolite profile of 14Ccytarabine associated with administration of Vyxeos and a non-liposomal presentation (cytarabine in saline) in plasma, urine, feces, and bile. Plasma profiling showed that parent cytarabine was the only prominent circulating entity across the two formulations, accounting for approximately 97% of the total circulating radioactivity for Vyxeos and approximately 86% for the non-liposomal formulation. The only other radioactive component that accounted for at least ~1% of the plasma AUC for total radioactivity was AraU, which amounted to approximately 0.6% to 0.9% with Vyxeos and approximately 8% for the non-liposomal formulation.

Single-dose 14C mass balance and biliary excretion studies were performed in both intact and bile ductcannulated male and female Sprague-Dawley rats (Studies XBL14629 and XBL13700). The results are displayed in Table 3 and Table 4.

Table 3 Excretion of 14C-Cytarabine with Administration of Vyxeos or Non-Liposomal Formulation in Rats (Study XBL14629)

|                  | PercentofAdministeredDose(0-96hours)   | PercentofAdministeredDose(0-96hours)   | PercentofAdministeredDose(0-96hours)   | PercentofAdministeredDose(0-96hours)   | PercentofAdministeredDose(0-96hours)   |
|------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Group            | Bile                                   | Urine                                  | Feces                                  | Cage Rinse/Wash                        | Total                                  |
| CPX-351,BDC,Mean | 0.40                                   | 83.61                                  | 0.80                                   | 11.61                                  | 96.42                                  |
| NL,BDC.Male      | 0.66                                   | 90.18                                  | 0.88                                   | 8.47                                   | 100.19                                 |

NOTE: Values are means (n=7 for Vyxeos; n=3 for NL).

BDC=bile duct-cannulated; NL=non-liposomal formulation in saline.

Table 4 Excretion of 14C-Daunorubicin with Administration of Vyxeos or Non-Liposomal Formulation in Rats (Study XBL13700)

|                     | PercentofAdministeredDose   | PercentofAdministeredDose   | PercentofAdministeredDose   | PercentofAdministeredDose   | PercentofAdministeredDose   | PercentofAdministeredDose   |
|---------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Group               | Bile                        | Urine                       | Feces                       | Cage Rinse/Wash             | Carcass                     | Total                       |
| CPX-351,Intact.Mean | ND                          | 9.32                        | 76.14                       | 2.56                        | 2.28                        | 90.30                       |
| CPX-351,BDC.Mean    | 45.52                       | 6.76                        | 3.08                        | 1.32                        | ND                          | 56.69                       |
| NL,BDC,Male         | 61.57                       | 20.44                       | 4.93                        | 2.09                        | ND                          | 89.03                       |

a Excretion was determined over 336 hours after dosing; values are means (n=8). b Excretion was determined over 96 hours after dosing; values are means (n=7 for Vyxeos; n=4 for NL).

BDC=bile duct-cannulated; ND=not determined; NL=non-liposomal formulation in saline.

<div style=\"page-break-after: always\"></div>

## 2.3.4. Toxicology

## Single dose toxicity

An overview of the single-dose toxicity studies is displayed in Table 5.

## Table 5 Single-Dose Toxicity studies

| Species/ Strain      | ROA (Vehicle/ Formulation)                    | Dose Ratio Cytarabine: Daunorubicin (mg/kg)                                  | No. per Sex per Group   | Observed Max. Nonlethal Dose (Cytarabine: Daunorubicin [mg/kg])   | Approx. Lethal Dose (mg/kg)   | Noteworthy Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Study No.   |
|----------------------|-----------------------------------------------|------------------------------------------------------------------------------|-------------------------|-------------------------------------------------------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Rat/ Sprague- Dawley | IV 60-minute infusion (liposomal formulation) | 0:0 (saline) 5: 2.2 10: 4.4 15: 6.6 20: 8.8                                  | N=10/dose 5M/5F         | 20:8.8                                                            | NA                            | No mortality, drug-related clinical signs, changes in body weight, coagulation, clinical chemistry, or urinalysis Comparedwithsaline control values, a dose-dependent trend was observed in plasma copper levels collected on Day 15, but the trend was not statistically significant. Slight tomoderatedecreasein WBC, RBC and lymphocytes in 15:6.6 and 20:8.8 mg/kg doses Drug-related increase in spleen and liver extramedullary hematopoiesis                                                                                                                                                                                                                                                                                                                                                                                  | 1004-3331   |
| Dog/ Beagle          | IV 60-minute infusion (liposomal formulation) | Single ascending dosegiven once each week at: 1: 0.44 2: 0.88 3:1.32 4: 1.76 | N=1F                    | 4:1.76                                                            | NA                            | Decreased food consumption and activity after 3:1.32 mg/kg dose. No clinical signs after 4:1.76 mg/kg dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 3004-3322   |
| Dog/ Beagle          | IV 60-minute infusion (liposomal formulation) | 0:0 (saline) 0:0 (vehicle) 1.5: 0.66 3.0: 1.32 6.0: 2.64                     | N=2/dose, 1M/1F         | 1.5: 0.66                                                         | 3.0-6.0                       | Poor condition led to premature termination of animalsin the 6.0:2.64 mg/kg dosing group and the female in the 3.0:1.32 mg/kg dosing group between days 8-10. The 3.0:1.32 and 6.0:2.64 mg/kg groups displayed decreased food consumption and body weight, retching, vomiting, diarrhea, loss of activity, dehydration, and pale gums. Blood samples for copper concentration analysiswere collected once prior to treatment and on Days 2 and 15 (or earlier in pre-terminal sacrificed animals). Compared to predose, blood copper concentrations on Day 2 were elevated. Animalsterminatedearlyhad marked lymphoid hypocellularity, spleen atrophy,glandularnecrosis, GI tract hemorrhage, decreased WBC, and decreased platelets. No treatment-related gross or microscopic findings in vehicle or 1.5:0.66 mg/kg dosing groups. | 1004-3342   |

<div style=\"page-break-after: always\"></div>

## Repeat dose toxicity

## A 2-Cycle IV Infusion Toxicity Study followed by a 28-Day Recovery Period in Sprague-Dawley Rats (Study 1005-0361)

The purpose of this study was to evaluate the toxicity and toxicokinetic profile of Vyxeos when administered as 2 cycles (for a total of 3 doses/cycle) and to assess the reversibility of any test article-related effects following a 28-day recovery period. Test article or saline control was administered to 10 animals/sex (main study group) by IV infusion for a period of 1 hour at a dose rate of 20 mL/kg/h, as 2 cycles, on Days 1, 3 and 5, and on Days 22, 24 and 26. The control (Group 1) and high-dose (Group 4) groups included 5 additional rats per sex to serve as recovery groups.

Mortality and poor condition leading to preterminal sacrifice, which were considered related to the test article, occurred at mid and high dose levels of Vyxeos. In Group 3 (mid dose), 8 of 10 male rats and 7 of 10 female rats died or were sacrificed early between Days 3 and 33; in Group 4 (high dose) all rats died or were sacrificed early between Days 8 and 16. Clinical signs preceding death included decreased grooming, decreased activity, dehydration, laboured respiration, and changes in the consistency/colour of faeces. The underlying histopathological changes that lead to the unscheduled sacrifices or preterminal deaths were mostly due to marked or severe hematopoietic hypocellularity of the bone marrow of the sternum and femur, as well as marked or severe lymphoid hypocellularity/atrophy of the spleen and thymus. There was also glandular and cryptal epithelium necrosis of the large and small intestinal mucosa. Other treatment-related changes, such as mild to marked haemorrhage in different tissues (testes, epididymis, adrenals, heart) and minimal to marked bacterial deposits in tissues such as the lungs, kidneys, bone marrow, and heart were considered secondary to the cytotoxic effects on the bone marrow.

When compared with the control animals, there were no apparent drug-related clinical signs in Group 2 (low dose) and the 4 unscheduled terminations (1 male and 3 females) of this group were considered to be related to surgical catheterization and not test-article related. Drug-related reductions in body weight gain were noted in Group 2 (low dose) and surviving Group 3 (mid dose) animals, concomitant with reductions in food consumption. There were no ophthalmoscopy, coagulation, clinical chemistry, or urinalysis effects related to the administration of Vyxeos. Compared with controls, no neurologic effects of Vyxeos were evident in Group 2 (low dose) rats; interpretation of neurologic assessment of rats in Group 3 (mid dose) was complicated by the poor clinical condition of the few remaining animals in that group and no definitive conclusion could be drawn. When compared with mean control values obtained on Day 34 (7 days after the last dose), a moderate drug-related reduction in WBC counts was noted in Group 2 (low dose). In addition, slight drugrelated decreases in RBCs and associated parameters, including platelet counts, were also noted. Among the 5 surviving Group 3 (mid dose) rats, 4 animals showed marked reductions in white and RBCs, platelets, haemoglobin, and reticulocytes.

When compared to control values, dose-related reductions in absolute and relative thymic and spleen weight, and prostate (for males only) were noted in Vyxeos -treated animals. A dose-related increase in absolute and relative adrenal weight was noted in Vyxeos -treated animals.

Minimal to severe drug- and dose-related histological changes included hematopoietic hypocellularity of sternal and/or femoral bone marrow, lymphoid hypocellularity/atrophy of the spleen and/or thymus, and lymphoid hypocellularity/atrophy with or without sinusoidal erythrocytosis/hemorrhage of various lymph nodes.

<div style=\"page-break-after: always\"></div>

## A 2-Cycle IV Infusion Toxicity Study in Beagle Dogs followed by a 28-Day Recovery Period (Study 10050372)

The purpose of this study was to evaluate the toxicity and toxicokinetic profile of Vyxeos when administered as 2 cycles (for a total of 3 doses/cycle) and to assess the reversibility of any test article-related effects following a 28-day recovery period. The test and control articles were administered by IV infusion (except as noted for Group 6 where the commercial formation of daunorubicin HCl was given as a slow IV bolus). Infusions were delivered over a 1-hour period at a dose rate of 20 mL/kg/h as 1 or 2 cycles. The first cycle was administered on Days 1, 3, and 5 to animals of all groups. The second cycle was administered on Days 22, 24, and 26 to Groups 1 (control), 2 (vehicle), 3 (low dose), and 6 (comparative control). Due to the number of deaths and/or preterminal sacrifices in the high-dose Group 5 animals, the remaining animals in this group were sacrificed on Day 11. Subsequently, an additional haematology investigation was performed on all remaining animals prior to the start of the second cycle of dosing. After evaluation, the second cycle of dosing was not administered to surviving Group 4 (mid dose) animals. The surviving Group 4 animals were re-assigned as recovery animals to replace the animals from Group 5 (high dose) that were sacrificed early.

No significant electrocardiography findings were noted. Following the first dosing cycle, all dogs in the high dose Vyxeos group (Group 5) were either found dead (2 males) or were sacrificed due to poor condition between Days 7 and 10. Two dogs in the mid-dose group (Group 4, 1 male and 1 female) were sacrificed in poor condition on Day 12. The probable cause of death in the dogs found dead and the main underlying affliction of those that underwent unscheduled sacrifice was considered to be severe bone marrow hypocellularity and/or moderate to severe enteric (duodenum, jejunum, ileum, cecum, colon, and rectum) cryptal/glandular necrosis and lymphoid atrophy of gut-associated lymphoid tissue.

Decreases in WBCs were evident in animals in Groups 3 (low dose) and 6 (comparative control) at Day 33 [6 days after the last dose of Vyxeos or the non-liposomal free drugs]. These reductions were the result of marked decreases in absolute and relative neutrophil, monocyte, and eosinophil counts. In addition, mild to moderate decreases in hemoglobin, hematocrit, and platelet counts were noted in Groups 3 and 6. Group 4 (mid dose) animals, having received only 1 cycle of drug treatment, showed mean haematology values similar to those of the control (Group 1) on Day 33 (with the exception of RDW and HDW). Following the 22day recovery period (Day 56), the haematological values for Group 4 animals were comparable to those of control animals, including RDW and HDW.

Drug-related severe hematopoietic hypocellularity of sternal and/or femoral bone marrow was observed in all animals in the mid- and high-dose groups (Groups 4 and 5; 2 and 3 units/kg, respectively) that were sacrificed early. In addition mild to severe cryptal necrosis of the small intestinal mucosa (with or without cryptal epithelial hyperplasia or hypertrophy, cryptal dilation, villous atrophy, GALT lymphoid atrophy and mucosal hemorrhage) as well as marked to severe glandular necrosis of the large intestinal mucosa were noted in these animals. Moderate to severe splenic lymphoid necrosis and/or atrophy of the white pulp, moderate to marked thymic lymphoid cortical hypocellularity, and mild to marked lymphoid atrophy of the mandibular, mediastinal, mesenteric, or tracheobronchial lymph nodes were also present in the animals sacrificed early. Following the recovery period, there were no drug-related histopathological changes noted in the surviving dogs in the mid-dose group (Group 4; 2 units/kg) with the exception of 1 dog showing moderate splenic lymphoid necrosis.

The plasma toxicokinetics of liposome-encapsulated cytarabine and daunorubicin (Vyxeos) and their respective metabolites, uracil arabinoside and daunorubicinol, were evaluated and confirmed a dosedependent increase in exposure to the test article.

<div style=\"page-break-after: always\"></div>

## Genotoxicity

No genotoxicity studies of were submitted with Vyxeos (see discussion on non-clinical aspects).

Cytarabine was genotoxic in cultures of normal proliferating human lymphocytes during late G2-prophase, i.e. , when cells performed post-replication DNA repair. The frequency of chromosomal aberrations during metaphase increased with increasing drug concentration. The genotoxic damage was associated with a block in cell cycle progression at the G2 checkpoint, however, this block was consistently overridden before DNA repair was complete (checkpoint adaptation). Due to the inhibitory effects of cytarabine on post-replication DNA repair processes, activation of the G2 checkpoint blockade promotes the development of genomic instability instead of preventing it (4).

In mutagenicity studies, the effects of Ara-C on the chromosomes of human leukocytes were tested (5). AraC (10-5 M) induced chromosome aberrations in human leukocytes and the effects consisted of gaps and open breaks.

In an in vitro transformation study, exponentially growing HF (secondary Syrian Golden hamster fetal) cells and H43 (rat) cells were exposed to various doses of cytarabine for 2 to 24 hours (6). Transformed effects were induced by various doses (10-3 to 10-7 M) of Ara-C.

The effect of Ara-C was tested for the induction of micronuclei in mouse bone marrow erythrocytes (7). Ara-C was clastogenic at 12.5 mg/kg IP and 25 mg/kg PO.

The cytogenetic effects of Ara-C were studied in in vivo and In vitro test systems (8). Male mice received either single or daily x5 IP doses of Ara-C at 0, 160, 440, 660, and 870 μg. Animals were sacrificed at different time intervals after single and multiple doses. Ara-C exhibited a strong mitodepressive effect in mouse bone marrow cells. The effect was more intense in the multiple-dose than single-dose treatment. Cytarabine caused a dose-dependent increase in structural abnormalities, polyploidy, and SCEs with both schedules. Ara-C caused sperm-head abnormalities after single- and multiple-dose administration. In vitro , Ara-C induced dose-dependent structural abnormalities in human leukocytes and in SCE analysis a significant effect was noted for all doses from 24-72 hour exposure.

## Carcinogenicity

No carcinogenicity studies of were submitted with Vyxeos (see discussion on non-clinical aspects).

Published literature suggests that cytarabine is not carcinogenic in rats (9)(10).

Berger conducted a long-term study of carcinogenic effect of Ara-C in Sprague-Dawley rats. Rats received either daily IP doses of 5 and 25 mg/kg or pulse doses of 500 mg/kg x 3/week for 72 weeks. Ara-C did not reduce the life-expectancy of the animals. Overall tumor incidence (malignant/benign) was slightly higher in male rats treated with 25 mg/kg/day x 5 (38%), 5 mg/kg/day x 5 (35%) and 500 mg/kg x 3/week (87%) and female rats treated with 500 mg/kg x3/week (50%) than control.

Weisburger tested mice and rats given IP doses of 125 and 250 mg/kg Ara-C 3 times a week for 6 months and observed for 1 year. Forty-eight of 50 female rats survived 18 months. Eighteen of these 49 (38%) rats had tumors and 6/18 tumors were malignant (10 breast, 3 pituitary, 2 adrenal). If the level of significance is computed for control vs treated rats with mammary tumors, its p-value (0.156) is not significant (Fisher's exact test). Thirteen of 49 male rats that survived had tumors and only 3/13 were malignant. Only 10/50 female and 13/50 male mice survived 18 months after IP doses of 62 and 125 mg/kg Ara-C. Tumor incidences were 2/10 (20%) in female mice and 6/13 (46%) in male mice. However, tumor incidence is not

<div style=\"page-break-after: always\"></div>

an appropriate parameter for assessing carcinogenicity. There is no basis for concluding Ara-C is carcinogenic under the conditions of this experiment.

The IARC Working Group (IARC 2000) conducted a carcinogenic evaluation of cytostatics (antineoplastic medicinal products), including daunorubicin, and classified daunorubicin under Group 2B - Drugs which are possibly carcinogenic to humans (generally, limited human evidence, but absence of animal evidence).

Published literature reports that daunorubicin may be carcinogenic. It can cause renal and mammary tumors in rats (11).

Multiple mammary tumors, mostly adenocarcinomas, were observed in 64% of female Sprague-Dawley rats administered a single IV dose of 10 mg/kg daunorubicin. The mean induction time in females was 80 days. Single mammary tumors, also mostly adenocarcinomas, were observed on average 91 days after injection in 37% of the males (12).

In another study in female Sprague-Dawley rats, a single IV injection of 10 mg/kg daunorubicin resulted in the development of mammary tumors in 11 of 24 (46%) of the animals within 8 months after injection. Tissue distribution studies found that the liver, kidney, heart, and intestines had higher daunorubicin concentrations than mammary tissue in the first 24 hours after injection. A comparison of the in vitro metabolism of daunorubicin in mammary tissue and hepatocytes demonstrated approximately 70% of the daunorubicin was metabolised in 90 minutes by hepatocyte homogenates, whereas no metabolism was seen with mammary tissue homogenates. In addition, daunorubicin injected directly into rat mammary gland was neither metabolised nor released into the systemic circulation. These results suggest that retention of daunorubicin in the mammary tissue may explain the preferential induction of mammary tumors in rats intravenously administered daunorubicin (13).

## Reproduction Toxicity

No reproductive and developmental toxicity studies were submitted with Vyxeos (see discussion on nonclinical aspects).

## Toxicokinetic data

An overview of toxicokinetic data from repeat dose studies is presented in Table 6.

## Table 6 Toxicokinetic data from repeat dose studies

| Cytarabine + daunorubicin dose level (mg/kg)                                    | Samplin g day                                                                   | Animal AUC 0-t (ng.h/ml) (M/F)                                                  | Animal AUC 0-t (ng.h/ml) (M/F)                                                  | Animal C max (ng/ml) (M/F)                                                      | Animal C max (ng/ml) (M/F)                                                      |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Cytarabine + daunorubicin dose level (mg/kg)                                    | Samplin g day                                                                   | Cytarabine                                                                      | Daunorubicin                                                                    | Cytarabine                                                                      | Daunorubicin                                                                    |
| Two-cycle repeated dose toxicity study in Sprague-Dawley rats (Study 1005-0361) | Two-cycle repeated dose toxicity study in Sprague-Dawley rats (Study 1005-0361) | Two-cycle repeated dose toxicity study in Sprague-Dawley rats (Study 1005-0361) | Two-cycle repeated dose toxicity study in Sprague-Dawley rats (Study 1005-0361) | Two-cycle repeated dose toxicity study in Sprague-Dawley rats (Study 1005-0361) | Two-cycle repeated dose toxicity study in Sprague-Dawley rats (Study 1005-0361) |
| 5 + 2.2                                                                         | 1                                                                               | 1598082 /278387                                                                 | 444989 / 646256                                                                 | 107317 /103533                                                                  | 46480 / 45867                                                                   |
| (low dose)                                                                      | 5                                                                               | 1555565 / 1153976                                                               | 1313338 541134                                                                  | 107867 / 99150                                                                  | 42200 / 44720                                                                   |
| 10 + 4.4                                                                        | 1                                                                               | 3135371 / 3099705                                                               | 1348911 /1386307                                                                | 212833 / 215667                                                                 | 91160 / 92080                                                                   |
| (mid dose)                                                                      | 5                                                                               | 3963012 / 3178525                                                               | 1569630 /1218737                                                                | 203333 /185667                                                                  | 87200 / 77467                                                                   |
| Two-cycle repeated dose toxicity study in Beagle dogs (Study 1005-0372)         | Two-cycle repeated dose toxicity study in Beagle dogs (Study 1005-0372)         | Two-cycle repeated dose toxicity study in Beagle dogs (Study 1005-0372)         | Two-cycle repeated dose toxicity study in Beagle dogs (Study 1005-0372)         | Two-cycle repeated dose toxicity study in Beagle dogs (Study 1005-0372)         | Two-cycle repeated dose toxicity study in Beagle dogs (Study 1005-0372)         |

<div style=\"page-break-after: always\"></div>

| 1 + 044 (low dose)    |   1 | 132589 / 151259   | 72553 / 79546   | 13600 / 12933   | 9017 / 9013   |
|-----------------------|-----|-------------------|-----------------|-----------------|---------------|
| 1 + 044 (low dose)    |   5 | 108907 / 121993   | 59938 / 66837   | 12300 / 12900   | 7987 / 8867   |
| 2 + 0.88 (mid dose)   |   1 | 364713 / 395024   | 178378 /211504  | 28100 / 26500   | 17933 / 20200 |
| 2 + 0.88 (mid dose)   |   5 | 455831 / 435680   | 188908 /203138  | 26233 / 24700   | 16367 / 18200 |
| 2 + 0.88 (comparator) |   1 | 3018 / 3557       | BLQ*            | 1710 / 2150     | BLQ           |
| 2 + 0.88 (comparator) |   5 | 3022 / 3093       | BLQ             | 1730 / 1780     | BLQ           |
| 3 + 1.32 (high dose)  |   1 | 531756 /698313    | 304374 /400135  | 37133 / 40867   | 26667 / 30000 |
| 3 + 1.32 (high dose)  |   5 | 911629 / 902906   | 430334 /457412  | 45867 / 39500   | 27833 / 28067 |

## Local Tolerance

No studies on local tolerance were submitted with Vyxeos (see discussion on non-clinical aspects).

## Other toxicity studies

## Toxicological evaluation of copper as an excipient of Vyxeos

Vyxeos contains copper gluconate, which plays a role in the retention of daunorubicin inside the liposome. The amount of copper gluconate in the to-be-marketed formulation of Vyxeos is 5 mg/mL for the reconstituted product, of which approximately 14% is copper. The maximum exposure to copper in patients under the currently proposed dosing regimen is 42.0 mg per induction dose and 27.3 mg per consolidation dose. A patient would theoretically have 319 mg maximum lifetime exposure to copper (5 total induction doses [100 units/m 2 ] and 4 total consolidation doses [65 units/m 2 ]). A lifetime exposure of 319 mg copper exceeds safe doses reported in the literature for either oral or parenteral administration of copper.

Whole blood concentrations of copper were measured in several single- and repeat-dose nonclinical toxicology studies with the to-be-marketed Vyxeos formulation. In all cases, copper was administered as a component of Vyxeos. In single dose Study 1004-331, copper was administered at 0.5 to 2 mg/kg and blood samples for copper determinations were collected approximately 14 days after administration of the single dose. In repeat-dose Study 1005-0361, copper was administered at 0.5 to 1.5 mg/kg, and blood samples were collected approximately 7 or 28 days after the last dose for all animals except in instances of early termination. Whole blood copper concentrations increased relative to baseline in a dose-dependent manner. In the repeat-dose study, copper concentrations remained higher than baseline for 24 hours from 7 to 9 days after the last dose of Vyxeos administration; the highest copper level was observed in an animal that was sacrificed on Day 3, and corresponded to about 8 times the baseline concentration. Whole blood concentrations of copper concentrations returned to baseline several days to a few weeks after the last dose.

Dogs also received copper as a component of Vyxeos. In single dose Study 1004-3342, copper was administered at 0.2 to 0.8 mg/kg and blood samples for copper determinations were collected predose and approximately 2 and 15 days after administration of the single dose. In repeat-dose Study 1005-0372, copper was administered at 0.1 to 0.3 mg/kg, and blood samples were collected approximately 1 or 3 weeks after the last dose for all animals except in instances of early termination. On Day 2 of the single dose study, whole blood copper concentrations were increased relative to baseline in a dose-dependent manner; at the

<div style=\"page-break-after: always\"></div>

highest dose level of 0.8 mg/kg, copper concentrations were 6 times higher than baseline. In both studies, copper concentrations returned to baseline within 8 to 15 days after the last dose.

Copper levels in plasma, tissues, urine, and feces were used for mass balance calculations. Twelve days after single dose administration of Vyxeos in female rats, the total copper levels indicated that 2% of the total copper was associated with plasma and tissues and 85% was associated with feces and urine.

## Toxicological evaluation of cobalt as an elemental impurity in Vyxeos drug product

Administration of Vyxeos induction and consolidation doses may result in exposure to approximately 4.2 and 2.7 μg/day cobalt, respectively, leading to an absolute maximum total exposure of approximate 31.8 μg cobalt for any patient over a lifetime (i.e., 5 induction and 4 consolidation doses). Potential exposure to the 4.2 μg/day exogenous cobalt can transiently exceed the ICH Q3D guideline parenteral PDE threshold (5 μg/day).

The acute oral rat no observed effect level of 175-mg/kg and the 90-day oral rat no observed adverse effect level of 3-mg/kg/day results in a &gt; 70,000-fold and 1251-fold safety margin, respectively. There is a 2571fold safety margin at the clinical dose of 150 mg/day cobalt (approximately 1 mg/kg/day) that resulted in polycythemia following short-term (22 days) ingestion. The safety margin calculations were based on the most conservative estimate of bioavailability (18%) relative to the approximate 4.2-μg daily dose of cobalt that a patient could be exposed to following administration of a 60-mL induction dose.

Peak blood cobalt concentrations as high as 0.117 μg/mL were not associated with clinically significant changes in haematological, thyroid, cardiac, or neurological parameters in healthy individuals following oral administration for 90 days. Theoretical maximum concentrations would be 0.0009 μg/mL, assuming 100% bioavailability of the approximate 4.2 μg daily dose of cobalt, given a 4800-mL human blood volume. This result in a 130-fold safety margin for the 4.2-μg/day cobalt dose administered during a Vyxeos induction dose.

## 2.3.5. Ecotoxicity/environmental risk assessment

## Screening for Persistence, Bioaccumulation, and Toxicity

The octanol-water partition coefficient (log P) of cytarabine, was determined by the Shake Flask Method (Liboiron, 2017). The log P of cytarabine at 21°C, determined for 3 different water:octanol ratios from 0.5 to 2 using the shake flask method, was determined to be -2.02 ± 0.04. This result is comparable to the calculated log P estimate of -2.27 for cytarabine. For daunorubicin, the experimental value of log P reported in the literature is 1.83 (EPA, 2017), compared with the estimated value of 1.79. The experimental log P values for the drug substances cytarabine, -2.02, and daunorubicin, 1.83, are below 4.5; therefore, further screening is not necessary for persistence, bioaccumulation, and toxicity.

## Calculation of the Predicted Environmental Concentration

The PECSURFACEWATER value is not above 0.01 µg/L for both drug substances, therefore, the phase II environmental-fate and effect analysis is not required.

<div style=\"page-break-after: always\"></div>

## 2.3.6. Discussion on non-clinical aspects

Vyxeos is a liposomal formulation of a fixed combination (5:1 molar ratio) of the antineoplastic drugs cytarabine and daunorubicin hydrochloride. Vyxeos was designed to enhance the anti-tumour efficacy of cytarabine and daunorubicin combination therapy by encapsulating both compounds within a drug carrier that maintains the synergistic 5:1 molar ratio for extended times after injection. The 5:1 molar ratio of cytarabine:daunorubicin HCl has been shown to  demonstrate the most optimal synergy against tumour cells synergy against tumour cells in vitro whereas reduced synergy or antagonism was observed at other ratios. Superiority of Vyxeos over free cytarabine:daunorubicin HCl cocktail treatment in anti-leukaemic efficacy was observed in a number of animal leukaemia models. In addition, Vyxeos liposomes were shown to be able to maintain the 5:1 molar ratio of cytarabine:daunorubicin HCl in plasma for an extended period of time compared to the free drug cocktail. Furthermore, within bone marrow that contained both normal and leukaemic cells, Vyxeos was shown to be preferentially taken up by the leukaemic cell population, however, the mechanism whereby this occurs is currently unknown.

Consistent with ICH S9, no stand-alone safety pharmacology studies were conducted with Vyxeos. Safety pharmacology parameters were included as part of the repeat-dose toxicology studies in rat and dog. Although the safety pharmacology assessment was confounded by several toxicities, no unexpected CNS or CVS safety signals were evident. Overall, the safety pharmacology assessment did not identify toxicities other than those already well known for cytarabine and daunorubicin. In view of the known toxicities of both compounds, further non-clinical testing is not warranted.

No stand-alone nonclinical pharmacodynamic drug interactions studies have been conducted with Vyxeos. The risks of pharmacodynamic drug interactions are expected to be similar to those described in the SmPCs and literature of the referenced medicinal products (DepoCyte and DaunoXome) and, by inference, the respective active ingredients, cytarabine and daunorubicin.

The PK studies were performed in mice, rats, and dogs and involved investigations of single- and repeat-dose PK, tissue distribution, metabolism, and excretion of Vyxeos following IV administration. The nonclinical species, strains, drug doses, and routes of administration were comparable with those used in the nonclinical pharmacology and toxicology programmes. The same liquid formulation used in the pharmacology and toxicology studies was also used in the nonclinical PK studies.

Cytarabine:daunorubicin molar ratios in animal plasma were maintained near the desired 5:1 molar ratio for at least 24 hours after IV administration. This was attributed to high retention of the drug cargo within the liposomes. In vivo release from Vyxeos liposomes is deduced to be very slow, because only a very small fraction (&lt;1%) of the total drug concentration in the circulation exists as free drug.

Due to high retention of drug cargo within Vyxeos liposomes, when cytarabine and daunorubicin are administered to animals as components of Vyxeos, the liposomes appear to govern their tissue distribution and rates of elimination therefore whilst the non-liposomal drugs have markedly different CL, V, and t½, Vyxeos causes these PK parameters to converge. High and sustained plasma concentrations are achieved with Vyxeos because CL is approximately 100-times lower than those of the non-liposomal drugs. The volume of distribution is approximately the same as the blood volume, because the liposomes are mostly confined to the vascular space.

Upon repeat-dose administration of Vyxeos in animals, there were no major deviations from dose proportionality or time linearity for cytarabine or daunorubicin. Very good allometric relationships indicate that excretion, metabolism, and distribution data in animals are likely to translate directly to humans.

<div style=\"page-break-after: always\"></div>

Tissue distribution data for cytarabine and daunorubicin suggested that Vyxeos liposomes are slowly taken up by the mononuclear phagocyte system (MPS) in several tissues, particularly spleen. Intracellular accumulation of Vyxeos is higher within leukaemic than normal bone marrow cells (9.5-fold higher for cytarabine; 2.2-fold higher for daunorubicin), indicating selective targeting.  After internalization by leukaemia cells, Vyxeos liposomes undergo degradation, releasing the drug cargo within the intracellular environment and enabling the drugs to exert their antineoplastic activity. There were different patterns of tissue distribution for 14C-cytarabine and 14C-daunorubicin associated with Vyxeos versus the non-liposomal formulations.

The major metabolism and biotransformation pathways in humans are similar to those in animals and qualitatively similar for Vyxeos versus non-liposomal drugs the only difference being that the rates of excretion are slower with Vyxeos.The presence of the major human metabolites (AraU and daunorubicinol) in rats and dogs suggested suitability of these animal models to predict Vyxeos safety in humans.

The toxicology profile of Vyxeos is sufficiently characterised based on the data and information generated in the Vyxeos toxicology studies and is comparable with the known toxicological effects of cytarabine and daunorubicin. No unexpected or novel toxicities were noted for Vyxeos, beyond those reported for cytarabine or daunorubicin.

Repeat-dose toxicity of Vyxeos was tested in two-cycle intravenous infusion toxicity studies with 28 day recovery periods conducted in rats and dogs. Adverse effects of Vyxeos occurred at all tested dose levels (low to null safety margins as based on systemic exposures) and were generally consistent with those known for non-liposomal daunorubicin and/or cytarabine, comprising mainly findings of gastrointestinal and hematological toxicity. Although central nervous system (CNS) and cardiovascular system parameters were included in these studies, given the observed morbidity and mortality, there was insufficient information to arrive at an integrated assessment of safety pharmacology of Vyxeos. Vyxeos contains daunorubicin, which is known for its profound cardiotoxicity potential, and cytarabine, which is known to be associated with CNS toxicities(SmPC, section 5.3).

Carcinogenicity, mutagenicity, and reproductive toxicity studies have not been conducted with Vyxeos(SmPC, section 5.3). This is acceptable since cytarabine and daunorubicin are well known compounds and their toxicological properties are well characterise and described in the SmPC.

A high incidence of mammary tumours was observed about 120 days after a single intravenous dose of daunorubicin in rats (at about 1.7 times the human dose on a mg/m 2  basis). Daunorubicin was mutagenic in in vitro tests (Ames assay, V79 hamster cell assay), and clastogenic in vitro (CCRF CEM human lymphoblasts) and in vivo (SCE assay in mouse bone marrow) tests (SmPC, section 5.3).

Cytarabine was mutagenic in in vitro tests and was clastogenic in vitro (chromosome aberrations and SCE in human leukocytes) and in vivo (chromosome aberrations and SCE assay in rodent bone marrow, mouse micronucleus assay). Cytarabine caused the transformation of hamster embryo cells and rat H43 cells in vitro (SmPC, section 5.3).

Cytarabine was clastogenic to meiotic cells (SmPC, section 5.3).

Both cytarabine and daunorubicin, tested separately, showed teratogenic and embryotoxic effects in animal studies. Furthermore, daunorubicin caused testicular atrophy and total aplasia of spermatocytes in the seminiferous tubules in dogs and cytarabine, sperm-head abnormalities in mice. A single dose of cytarabine in rats, administered on day 14 of gestation, reduced prenatal and postnatal brain size and caused permanent impairment of learning ability (SmPC, section 5.3).

<div style=\"page-break-after: always\"></div>

Based on findings in animals, male fertility may be compromised by treatment with Vyxeos (SmPC, section 4.6).

Each vial contains 100 mg of copper gluconate, which corresponds to 14 mg of elemental copper. Vyxeos should only be used in patients with a history of Wilson's disease or other copper-related disorder if the benefits outweigh the risks. Vyxeos should be discontinued in patients with signs or symptoms of acute copper toxicity (SmPC, section 4.4).

The amounts of cobalt that patients will receive following the therapeutic administration of Vyxeos, is unlikely to pose an unacceptable risk to the intended patient population.

While cytarabine is not a carcinogen, daunorubicin is a possible carcinogen, hence, Vyxeos may be associated with a carcinogenic potential. Both daunorubicin and cytarabine are genotoxic, therefore, Vyxeos may be associated with a genotoxic risk (SmPC, section 5.3).

Environmental risk assessment has shown that Vyxeos is not anticipated to have the potential to be persistent, bioaccumulative, or toxic to the environment (SmPC, section 5.3).

## 2.3.7. Conclusion on the non-clinical aspects

Overall, the non-clinical documentation submitted was considered adequate. The relevant information has been included in the SmPC (sections 4.4, 4.6, 5.1, 5.3).

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

Table 7 Clinical studies in the clinical development program of Vyxeos

| Study Number, Status   | Type of Study       | Phase; Study Design                                                | Primary Objective(s)                                                                                                                                          | Number and Age (mean [range]) of Subjects                                                    | Treatment;Routeof Administration,Dose,and DurationofTreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------|---------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CLTR0305-101 Complete  | Safety and PK       | Phase 1; OL, single-arm, dose escalation                           | To determine the recommended Phase 2 dose of CPX-351 (defined as MTD in protocol) that can be given to subjects with advanced hematologic malignancies        | 31 male subjects and 17 female subjects with confirmed AML, ALL or MDS; 60 (23 to 81)        | CPX-351, IV (90 min infusion) Dose escalation by cohort: Cohort 1: 3 units/m2 Cohort 2: 6 units/m2 Cohort 3: 12 units/m2 Cohort 4: 24 units/m2 Cohort 5: 32 units/m Cohort 6: 43 units/m2 Cohort 7: 57 units/m2 Cohort 8: 76 units/m2 Cohort 9: 101 units/m2 Cohort 10: 134 units/m                                                                                                                                                                                                                                                                                                                             |
| Study Number, Status   | Type of Study       | Phase; Study Design                                                | Primary Objective(s)                                                                                                                                          | Number and Age(mean [range]) of Subjects                                                     | Treatment;Route of Administration,Dose,and Duration of Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| CLTR0308-204 Complete  | Safety and Efficacy | Phase 2b OL, Parallel- arm, Rand, MC, Standard- therapy controlled | To estimate the rate of response and confirm the safety of CPX-351 compared to 7 + 3 as first line therapy in elderly patients with standard or high risk AML | 78 male subjects and 48 female subjects with newly diagnosed or secondary AML; 68 (60 to 77) | CPX-351, IV (90 min infusion) IInduction: 100 units/m2/day, Days 1, 3 and 5 2nd Induction: 100 units/m'/day, Days 1 and 3 Consolidation(upto2courses): 100 units/m/day, Days 1 and 3 7 + 3. IV (control) Ist Induction: Cytarabine 100 mg/m2/day, 7-day continuous infusion Daunorubicin 40-60 mg/m2/day, Days 1, 2 and 3 2nd Induction: Cytarabine 100 mg/m2/day, 5-day continuous infusion Daunorubicin 40-60 mg/m2/day, Days 1 and 2 Consolidation(upto2courses): (Investigator's choice) Recommended: Cytarabine 100-200 mg/m2/day for 5-7 days ± anthracycline or Cytarabine 1.0-1.5 g/m2/day for 4-6 days |

<div style=\"page-break-after: always\"></div>

| Study Number, Status   | Type of Study            | Phase; Study Design                                               | Primary Objective(s)                                                                                                                                 | Number and Age (mean [range]) of Subjects                                                                                                                             | Treatment;Route of Administration,Dose,and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------|--------------------------|-------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CLTR0308-205 Complete  | Safety and Efficacy      | Phase 2b OL, Parallel- arm, Rand, MC                              | To estimate the efficacy of CPX-351 when compared to intensive salvage therapy in patients with AML in first relapse.                                | 57 male subjects and 68 female subjects with pathologically confirmed relapsed AML; 50 (20 to 66)                                                                     | Duration of Treatment CPX-351, IV (90 min infusion) I\"t Induction: 100 units/m2/day, Days 1, 3 and 5 2nd Induction: 100 units/m2/day, Days 1 and 3 Consolidation (up to 2 courses): 100 units/m2/day, Days 1 and 3 Salvage Therapy (control) (Investigator's choice of intensive salvage therapy included:) 1\"t Inductiona Mitoxantrone /Etoposide based regimens such as \"MEC\" 7+3 Cytarabine ± anthracycline ± additional agents: 2nd Induction Second inductions were administered according to local practice. Consolidation (up to 2 courses) Investigators chose an appropriate consolidation regimen according to local practice. |
| CLTR0310-206 Complete  | Safety, Efficacy, and PK | Phase 2 OL, Single-arm, MC                                        | To assess the effects of CPX-351 on cardiac repolarization following the first induction cycle as determined by QTeF                                 | 14 male subjects and 12 female subjects with pathological confirmation of AML with high cytogenetic risk, secondary AML, refractory AML or ALL, or MDS; 65 (37 to 80) | CPX-351. IV (90 min infusion) I\"t Induction: 100 units/m2/day, Days 1, 3 and 5 2nd Induction: 100 units/m2/day, Days 1 and 3 Consolidation (up to 4 courses): 65 units/m2/day, Days 1 and 3                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Study Number, Status   | Type of Study            | Phase; Study Design                                               | Primary Objective(s)                                                                                                                                 | Number and Age (mean [range]) of Subjects                                                                                                                             | Treatment;Route of Administration,Dose, and DurationofTreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| CLTR0310-301 Ongoing   | Safety, Efficacy and PK  | Phase 3 OL, parallel- arm, Rand, MC, standard- therapy controlled | To confirm the efficacy of CPX-351 compared with 7 + 3 as first line therapy in elderly patients (60 to 75 years old) with high risk (secondary) AML | 190 male subjects and 119 female subjects with newly diagnosed AML; 68 (60 to 75)                                                                                     | CPX-351. IV (90 min infusion) 1t Induction: 100 units/m2/day, Days 1, 3 and 5 2nd Induction: 100 units/m2/day, Days 1 and 3 Consolidation (up to 2 courses): 65 units/m2/day, Days 1 and 3 7 + 3 / 5 + 2.IV (control) It Induction: Cytarabine 100 mg/m2/day, 7-day continuous infusion  Daunorubicin 60 mg/m2/day, Days 1, 2 and 3 2nd Induction: Cytarabine 100 mg/m2/day, 5-day continuous infusion Daunorubicin 60 mg/m2/day, Days 1 and 2 Consolidation (up to 2 courses): Cytarabine 100 mg/m2/day, 5-day continuous infusion Daunorubicin 60 mg/m2/day, Days 1 and 2                                                              |

Abbreviations: AML = acute myeloid leukemia; AE = adverse event; ALL = acute lymphocytic leukemia; CI= continuous infusion; D= days; IV = intravenous; MC = multicenter; MDS = myelodysplastic syndrome; OL = open-label; PK = pharmacokinetic; QTcF = QT interval with Fridericia's correction; Rand = randomised;

a In Study 205, the decision of which salvage therapy to prescribe was up to the investigator. Recommended dosing regimens were as follows: 1st induction : High Dose Ara-C ± Anthracycline: Cytarabine: 6-36 g/m2 Total Dose (eg, 3 g/m2 x 12

<div style=\"page-break-after: always\"></div>

doses; 1.5 g/m2 continuous infusion x 4 days; 2 g/m2 Q12h x 8 doses); '7 + 3': Cytarabine: 100- 200 mg/m2 CI x 7 days; Daunorubicin: 45 to 60 mg/m2 days 1-3 or equivalent; Mitoxantrone / Etoposide based regimens such as 'MEC': Mitoxantrone 8 mg/m2/day IV + Etoposide 100 mg/m2/day IV + Cytarabine 1000 mg/m2/day IV on days 1-5.

## 2.4.2. Pharmacokinetics

Data on clinical pharmacokinetics are provided from three clinical studies as indicated in Table 9.

Table 8 Tabular summary of clinical pharmacology studies

One subject was excluded due to missing/erroneous sampling date and/or time records.

| Clinical Study   | Title                                                                                                                                                                                                         | Formulation   | Induction Dose Nunber of Subjects with PK Data)                                                                                                                                    | PK Samples                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study101         | Phase1StudyofCPX-351 Liposome Injection in Subjects with Advanced Hematologic Malignancies                                                                                                                    | Liquid        | 3units/m² (n=1) 6 units/m² (n=1) 12 units/m² (n=2) 24 units/m² (n=3) 32 units/m² (n=3) 43 units/m² (n=4) 57 units/m²(n=3) 76 units/m² (n=3) 101 units/m² (n=13) 134 units/m² (n=6) | Plasma samples were collected at the following times (relative to the start of the infusion) during the first induction: Day 1: Prior to dosing, during the infusion at 45 min (or the mid-point of the infusion) and 90 min (or at EO1), then at 2, 4, 6, 8, 12 and 24 h relative to the SO1. Day 3: prior to dosing, during the infusion at 45 and 90 min. Day 5: Prior to dosing, during the infusion at 45 min (or the mid-point of the infusion) and 90 min (or at the EOI), then at 2,4, 6, 8, 12, 24,48, 72, 96, and 168 h relative to the SOI |
| Study 206        | An Open Label Phase 2 Pharmacokinetic and Pharmacodynamic AssessmentofthePotential forQTcProlongation Following First Induction Treatment with CPX-351 Liposome Injection in Acute Leukemias and MDS Subjects | Lyophilized   | 100 units/m²(n=26)                                                                                                                                                                 | The following plasma samples were collected after the first induction. Day l: pre-dose, 45 min, 1.5, 2, 4, 6, 8, and 24 h after S0I on Day 1 Day 5: pre-dose,45 min, 1.5,2,4,6,8, 24, 28,48,72,96, 168, 216, 336, and 384 h after the S0I on Day 5                                                                                                                                                                                                                                                                                                    |
| Study 301        | Phase 3, Multicenter, Randomized,Trial of CPX-351 Liposome Injection versus Cytarabine and Daunorubicin in Subjects 60- 75 years of Age with Untreated High Risk (Secondary) AML                              | Lyophilized   | 100 units/m² (n=132)                                                                                                                                                               | Subjects randomized to CPX-351 had samples drawn for population PK. Five plasma samples per subject were taken during the first induction, all times were relative to the start of Day 1 infusion. CPX-351 subjects were randomized to one of two PK sampling schedules: Schedule 1 Day 1: 45 min, 3 h, 8 h, Day 3 prior to dosing (48 h (+/- 6 h)) and on Day 7 (168 h (+/- 6 h)) or Schetdule 2: Day 1: EO1, 2 h, 6 h, Day 5 prior to dosing (96 h (+/- 6 h)) and on Day 7 (168 h (+/- 6 h))                                                        |

AML, acute myeloid leukemia; EOI, end of infusion; h, hours; MDS, myelodysplasia syndrome; min, minutes; QTc, interval between the start ofQ wave to the end of the T wave.

## 2.4.3. Methods

The bioanalytical methods for cytarabine, daunorubicin and their respective metabolites were based on liquid chromatography with tandem mass spectrometry (LC-MS/MS) among the studies.

## Absorption

Vyxeos is administered intravenously, therefore absorption is not applicable. The plasma PK of total daunorubicin following administration of Vyxeos is presented in Table 10.

<div style=\"page-break-after: always\"></div>

Table 9 Plasma PK of Total Daunorubicin Following Administration of Vyxeos

| Clinical Study   | CPX-351 Dose (units/m²)   | PK Interval   | No. Subjects   | Cmax (μg/mL)             | AUC4sh (μg.h/mL)      | t1/2 (h)                 | CL (L/h)                    | Vss (L)                   |
|------------------|---------------------------|---------------|----------------|--------------------------|-----------------------|--------------------------|-----------------------------|---------------------------|
| Study 101        | 3                         | Day 1         | 1              | 6.94                     | 216                   | 28.2                     | 0.0177                      | 0.727                     |
| Study 101        |                           | Day 5         | 1              | 3.77                     | 113                   | 31.1                     | 0.0497                      | 2.17                      |
| Study 101        | 6                         | Day 1         | 1              | 2.23                     | 28.7                  | 9.67                     | 0.346                       | 4.58                      |
| Study 101        |                           | Day 5         | 1              | 2.11                     | 29.6                  | 9.54                     | 0.346                       | 4.37                      |
| Study 101        | 12                        | Day 1         | 2              | 5.88 (13.9%)             | 131 (73.8%)           | 17.3 (103.7%)            | 0.204 (79.3%)               | 3.2 (30.4%)               |
| Study 101        |                           | Day 5         | 2              | 7.89 (54.0%)             | 192 (121.7%)          | 23.3 (126.8%)            | 0.4 (114.5%)                | 3.48 (68.4%)              |
| Study 101        | 24                        | Day 1         | 3              | 12.9 (43.5%)             | 330 (33.4%)           | 38.8 (43.1%)             | 0.101 (60.4%)               | 4.72 (25.4%)              |
| Study 101        |                           | Day 5         | 3              | 14.7 (36.7%)             | 433 (50.7%)           | 31.9 (8.7%)              | 0.13 (42.4%)                | 6.62 (39.6%)              |
| Study 101        | 32                        | Day 1         | 3              | 16.6 (24.1%)             | 482 (28%)             | 40.7 (26.9%)             | 0.0817 (53.6%)              | 4.38 (31.1%)              |
| Study 101        |                           | Day 5         | 3              | 25.3 (29.8%)             | 742 (26.3%)           | 35.1 (11.1%)             | 0.089 (28.9%)               | 4.69 (34.1%)              |
| Study 101        | 43                        | Day 1         | 4              | 20.0 (2.8%)              | 575 (24.2%)           | 54.6 (79.4%)             | 0.074 (54.2%)               | 4.16 (12.9%)              |
| Study 101        |                           | Day 5         | 3              | 31.7 (16.2%)             | 984 (43.9%)           | 35.8 (20.6%)             | 0.0871 (46.0%)              | 3.92 (21.7%)              |
| Study 101        | 57                        | Day 1         | 3              | 20.3 (13.7%)             | 601 (14.3%)           | 63.6 (83.9%)             | 0.07 (38.7%)                | 5.31 (31%)                |
| Study 101        |                           | Day 5         | 3              | 33.9 (3.0%)              | 1082 (8.2%)           | 37.2 (18.0%)             | 0.0863 (17.1%)              | 4.83 (21.1%)              |
| Study 101        | 76                        | Day 1         | 3              | 29.1 (35%)               | 813 (59.3%)           | 43.3 (98.9%)             | 0.218 (107.9%)              | 7.31 (47%)                |
| Study 101        |                           | Day 5         | 3              | 39.9 (54.1%)             | 1102 (62.3%)          | 28.4 (30.5%)             | 0.236 (82.0%)               | 9.58 (67.9%)              |
| Study 101        | 101                       | Day 1         | 13             | 42.6 (19.6%)             | 1158 (33.2%)          | 42.5 (62.2%)             | 0.119 (56.8%)               | 5.48 (36.9%)              |
| Study 101        |                           | Day 5         | 13             | 64.6 (36.0%)             | 1851 (50.5%)          | 36.9 (66.4%)             | 0.131 (41.2%)               | 5.88 (38.3%)              |
| Study 101        | 134                       | Day 1         | 6              | 62.6 (15%)               | 1896 (15.0%)          | 52.2 (44.6%)             | 0.0677 (50.9%)              | 4.36 (27.6%)              |
| Study 101        |                           | Day 5         | 6              | 89.1 (4.8%)              | 2973 (13.8%)          | 46.0 (35.2%)             | 0.0809 (14.1%)              | 5.36 (46.3%)              |
| Study 206        | 100                       | Day 1         | 26             | 46.0 (27.3%)             | 1110 (31.0%)          | NA                       | NA                          | NA                        |
| Study 206        |                           | Day 5         | 26             | 62.2 (33.7%)             | 1900 (44.3%)          | 40.4 (24.2%)             | 0.131 (60.2%)               | 7.11 (49.2%)              |
| Study 101        | 3                         | Day 1         |                | 3.30                     | 91.5                  | 16.2                     | 0.0234                      | 0.553                     |
| Study 101        |                           | Day 5         | 1              | 1.06                     | 24.0                  | 12.9                     | 0.103                       | 2.09                      |
| Study 101        | 6                         | Day 1         | 1              | 1.15                     | 14.8                  | 8.69                     | 0.295                       | 3.54                      |
| Study 101        |                           | Day 5         | 1              | 1.03                     | 15.9                  | 8.27                     | 0.283                       | 3.31                      |
| Study 101        | 12                        | Day 1         | 2              | 2.92 (20.8%)             | 61.4 (73.1%)          | 13.0 (78.8%)             | 0.195 (67.2%)               | 2.64 (19.1%)              |
| Study 101        |                           | Day 5         | 2              | 3.83 (39.5%)             | 74.0 (109.9%)         | 14.2 (114.8%)            | 0.305 (99.2%)               | 2.56 (60.2%)              |
| Study 101        | 24                        | Day 1         | 3              | 6.50 (38.1%)             | 135 (21.4%)           | 19.3 (19.3%)             | 0.135 (27.4%)               | 3.49 (21.1%)              |
| Study 101        |                           | Day 5         | 3              | 6.41 (24.6%)             | 151 (30.5%)           | 20.6 (24.6%)             | 0.15 (32.8%)                | 4.8 (33.3%)               |
| Study 101        | 32                        | Day 1         | 3              | 8.54 (15.8%)             | 230 (16.4%)           | 17.9 (38.8%)             | 0.0939 (17.5%)              | 2.97 (25.1%)              |
| Study 101        |                           | Day 5         | 3              | 9.06 (25.2%)             | 257 (35.1%)           | 20.3 (28%)               | 0.118 (39.7%)               | 7.35 (64%)                |
| Study 101        | 43                        | Day 1         | 4              | 11.2 (20.4%)             | 288 (35.8%)           | 24.2 (43.6%)             | 0.0984(54.6%)               | 2.79 (15.8%)              |
| Study 101        |                           | Day 5         | 3              | 14.8 (27.2%)             | 395 (46.3%)           | 26.7 (58.7%)             | 0.102 (60.3%)               | 4.21 (39.7%)              |
| Study 101        | 57                        | Day 1 Day 5   | 3 3            | 14.3 (8.7%) 17.6 (10.5%) | 377 (5.3%) 474 (1.9%) | 32.4 (33.7%) 35.0 (8.2%) | 0.0706 (13.6%) 0.0878 (27%) | 3.19 (35.1%) 3.59 (21.9%) |
| Study 101        | 76                        | Day 1         |                | 18.2 (33%)               | 446 (42.7%)           | 16.8 (43.2%)             | 0.172 (53.5%)               | 3.67 (35.2%)              |
| Study 101        |                           |               | 3              |                          |                       |                          |                             |                           |
| Study 101        |                           | Day 5         | 3              | 20.6 (45%)               | 444 (47.7%)           | 19 (8.9%)                | 0.206 (53.1%)               | 5 (42%)                   |
| Study 101        | 101                       | Day 1         | 13             | 24.8 (18.3%)             | 553 (27.6%)           | 22.1 (31.2%)             | 0.133 (31%)                 | 3.82 (32.7%)              |
| Study 101        |                           | Day 5         | 13             | 30.2 (20.5%)             | 667 (31.4%)           | 25.2 (46.1%)             | 0.143 (32.8%)               | 4.55 (36.5%)              |
|                  | 134                       | Day 1         | 6              | 37.8 (14.5%)             | 954 (12.7%)           | 26.2 (21.6%)             | 0.0816 (20.9%)              | 3.01 (36.8%)              |
| Study 206        | 100                       | Day 1         | 26             | 23.1 (28.5%)             | 499 (28.9%)           | NA                       | 0.0879 (10%) NA             | 4.06 (34.7%) NA           |
|                  |                           | Day 5         | 6              | 44.7 (5.8%)              | 1204 (17.3%)          | 37.0 (31.5%)             |                             | 6.64 (36.8)               |
|                  |                           | Day 5         | 26             | 26.0 (32.7)              | 637 (38.4%)           | 31.5 (28.5%)             | 0.163 (53.3%)               |                           |

AUC4sh, area under the curve from t = 0 to 48 h postdose; Cmax, maximum observed concentration; t12, terminal elimination half-life; CL, clearance; Vs, steady-state volume of distribution; NR, not reported. NA, not available

NOTES: Values reported as mean (%CV). Values may differ from clinical study reports due to rounding.

<div style=\"page-break-after: always\"></div>

## Distribution

The volume of distribution (%CV) for daunorubicin is 6.6 L (36.8%) and cytarabine is 7.1 L (49.2%). Plasma protein binding was not evaluated (SmPC, section 5.2).

## Elimination

Based on published data, cytarabine to Ara-U and daunorubicin to daunorubicinol are important systemic metabolism pathways in humans, and Ara-U and daunorubicinol are major human metabolites. To assess these pathways with Vyxeos, data on the plasma PK of Ara-U and daunorubicinol were obtained from 13 - 26 patients who received Vyxeos at 100 units/m 2  on Days 1, 3, and 5 in Study 206. Plasma concentration-time profiles show that plasma concentrations of the metabolites were considerably lower than those of the parent drugs (~40-60% for daunorubicinol:daunorubicin and ~80% for AraU:cytarabine.

Figure 3). Median Tmax of Ara-U and daunorubicinol after the Day 5 dose were 8.0 h and 26.2 h, respectively, i.e. substantially later than Tmax of the parent drugs. The mean AUClast metabolite/parent ratio was 3.22% for Ara-U/cytarabine and 1.79% for daunorubicinol/daunorubicin. These ratios are lower than the ratios typically reported for the non-liposomal products, ~40-60% for daunorubicinol:daunorubicin and ~80% for AraU:cytarabine.

Figure 3 Mean Plasma Concentration-Time Curves and Exposure Parameters for Total Cytarabine and Daunorubicin and their Major Metabolites on Day 5 (Study 206)

|                 | Mean Exposure Parameter   | Mean Exposure Parameter   | Mean Exposure Parameter   |
|-----------------|---------------------------|---------------------------|---------------------------|
|                 | N                         | Cmax (μg/mL)              | AUC48h (μg.h/mL)          |
| ODaunorubicin   | 26                        | 26.0                      | 637                       |
| △Daunorubicinol | 26                        | 0.147                     | 6.24                      |

AraU, 1-β-d-arabinofuranosyluracil; AUC4sh, area under the curve from t = 0 to 48 hours postdose; Cmax maximum observed concentration; N,sample size

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4 Plasma PK Parameters for Cytarabine and Daunorubicin when Administered as Vyxeos or as Non-liposomal Formulations

| PK Parameter   | CPX-351    | CPX-351      | Non-liposomal   | Non-liposomal   |
|----------------|------------|--------------|-----------------|-----------------|
|                | Cytarabine | Daunorubicin | Cytarabine      | Daunorubicin    |
| V (L)          | 7.11       | 6.64         | 138a            | 1364*           |
| CL (L/h)       | 0.131      | 0.163        | 272a            | 129 a           |
| t1/2 (h)       | 40.4       | 31.5         | 1-3 b           | 18.5 c          |

NOTES: Values reported are means.

V, volume of distribution; CL, clearance; ti1/2, terminal half-life

Total urinary recovery over one dosing interval for cytarabine plus Ara-U averaged 70.7% (33.8%). The mean renal clearance of cytarabine was 0.00167 (0.00102) L/h and of Ara-U was 3.81 (2.02) L/h (Table 11).

Table 10 Urinary excretion parameters for cytarabine and Ara-U

|           | Cytarabine   | Cytarabine                     | Cytarabine            | AraU    | AraU                                   | AraU                  | Total                 |
|-----------|--------------|--------------------------------|-----------------------|---------|----------------------------------------|-----------------------|-----------------------|
| Statistic | Ae (mg)      | Cumulative %Dose Recovered (%) | Renal Clearance (L/h) | Ae (mg) | Cumulative %Dose Recovered (% of Dose) | Renal Clearance (L/h) | Percent Recovered (%) |
| N         | 6            | 6                              | 6                     | 6       | 6                                      | 6                     | 6                     |
| Mean      | 2.22         | 1.11                           | 0.00167               | 136     | 69.6                                   | 3.81                  | 70.7                  |
| SD        | 0.748        | 0.354                          | 0.00102               | 56.6    | 33.9                                   | 2.02                  | 33.8                  |
| CV%       | 33.6         | 31.7                           | 60.9                  | 41.6    | 48.7                                   | 52.9                  | 47.8                  |
| Geo Mean  | 2.11         | 1.06                           | 0.00140               | 128     | 64.2                                   | 3.38                  | 65.4                  |
| GeoCV%    | 38.6         | 35.9                           | 75.7                  | 38.5    | 44.1                                   | 58.8                  | 43.1                  |
| Median    | 2.23         | 1.15                           | 0.00168               | 112     | 53.1                                   | 3.67                  | 45.0                  |
| Min       | 1.11         | 0.576                          | 0.000581              | 92.5    | 43.9                                   | 1.88                  | 54.5                  |
| Max       | 3.35         | 1.67                           | 0.00334               | 237     | 132                                    | 6.92                  | 133                   |

Ae = Amount Excreted in mg.

Total urinary recovery over one dosing interval for daunorubicin plus daunorubicinol averaged 9.00% (3.21%). The mean renal clearance of daunorubicin was 0.00610 (0.00284) L/h and of daunorubicinol was 1.13 (0.738) L/h (Table 12).

Table 11 Urinary excretion parameters for daunorubicin and daunorubicinol

|           | Daunorubicin   | Daunorubicin         | Daunorubicin          | Daunorubicinol   | Daunorubicinol       | Daunorubicinol        | Total                 |
|-----------|----------------|----------------------|-----------------------|------------------|----------------------|-----------------------|-----------------------|
| Statistic | Ae (mg)        | % Dose Recovered (%) | Renal Clearance (L/h) | Ae (mg)          | % Dose Recovered (%) | Renal Clearance (L/h) | Percent Recovered (%) |
| N         | 6              | 6                    | 6                     | 6                | 6                    | 6                     | 6                     |
| Mean      | 2.77           | 3.19                 | 0.00610               | 5.00             | 5.80                 | 1.13                  | 9.00                  |
| SD        | 0.756          | 0.912                | 0.00284               | 1.79             | 2.49                 | 0.738                 | 3.21                  |
| CV%       | 27.3           | 28.6                 | 46.5                  | 35.8             | 42.9                 | 65.3                  | 35.7                  |
| Geo Mean  | 2.70           | 3.09                 | 0.00554               | 4.78             | 5.46                 | 0.936                 | 8.60                  |
| GeoCV%    | 25.8           | 27.8                 | 51.4                  | 32.1             | 37.9                 | 77.2                  | 32.6                  |
| Median    | 2.39           | 2.82                 | 0.00565               | 4.61             | 5.24                 | 0.913                 | 6.03                  |
| Min       | 2.14           | 2.40                 | 0.00330               | 3.55             | 3.63                 | 0.388                 | 7.88                  |
| Max       | 4.00           | 4.35                 | 0.00967               | 8.42             | 10.6                 | 2.24                  | 15.0                  |

Ae =Amount Excreted in mg

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

Table 12 Cytarabine PK parameters Vyxeos Dose (3 - 134 units/m 2 ) for Days 1 and 5

* Note - Due to limited sample size Group 1-3 (i.e., 3, 6, and 12 units/m2 CPX-351) were excluded from statistical comparisons.

| Dose (units/m²) and Day   | Cmax (ng/ml)   |   Tmax (he) | AUCo-last AUCo-tau (ng*hr/mL)   | AUCo-inf AUCo-tau (ng*hr/mL)   |   t1/2 (hr) |   Vz (mL/m²) |   Vss (mL/m2) |   CL (mL/hr/m) | Cmax/Dose [(ng/mL) /(mg/kg)]   | AUCc-Dose AUCo-m/Dose [(ng*hr/mL) /(mg/kg)]   |   AUCoin/Dose AUCo-taw/Dose [(ng*hr/mL) /(mg/kg)] |
|---------------------------|----------------|-------------|---------------------------------|--------------------------------|-------------|--------------|---------------|----------------|--------------------------------|-----------------------------------------------|---------------------------------------------------|
| 24 Day 1                  | 12897          |       3.83  | 330179                          | 599560                         |      38.8   |     2397     |      2367     |         50.4   | 537                            | 13757                                         |                                         24982     |
| 24 Day 5                  | 14733          |       2.33  | 432519                          | 432519                         |      31.9   |     2880     |      3267     |         64     | 614                            | 18022                                         |                                         18022     |
| 32 Day 1                  | 16600          |       2     | 481688                          | 888748                         |      40.7   |     2232     |      2213     |         41     | 519                            | 15053                                         |                                         27773     |
| 32 Day 5                  | 25333          |       3.17  | 741802                          | 741802                         |      35.1   |     2319     |      2364     |         45     | 792                            | 23181                                         |                                         23181     |
| 43 Day 1                  | 19975          |       1.75  | 575294                          | 1392494                        |      54.6   |     2457     |      2452     |         44     | 465                            | 13379                                         |                                         32384     |
| 43 Day 5                  | 31700          |       3     | 983820                          | 983820                         |      35.8   |     2515     |      2263     |         50.5   | 737                            | 22880                                         |                                         22880     |
| 57 Day 1                  | 20267          |       6     | 601127                          | 1631171                        |      63.6   |     3067     |      3220     |         46     | 356                            | 10546                                         |                                         28617     |
| 57 Day 5                  | 33933          |       4.5   | 1081929                         | 1081929                        |      37.2   |     2868     |      2977     |         52.9   | 595                            | 18981                                         |                                         18981     |
| 76 Day 1                  | 29133          |       2.33  | 813020                          | 1693635                        |      43.3   |     3269     |      3206     |        105     | 383                            | 10698                                         |                                         22285     |
| 76 Day 5                  | 39900          |       5.83  | 1101673                         | 1101673                        |      28.4   |     4290     |      4364     |        111     | 525                            | 14496                                         |                                         14496     |
| 101 Day 1                 | 42577          |       2.42  | 1158444                         | 2276888                        |      42.5   |     2750     |      2739     |         62.5   | 422                            | 11470                                         |                                         22543     |
| 101 Day 5                 | 64608          |       3.02  | 1851089                         | 1851089                        |      36.9   |     2876     |      2925     |         67.3   | 640                            | 18328                                         |                                         18328     |
| 134 Day 1                 | 62567          |       2.42  | 1896454                         | 4216357                        |      52.2   |     2398     |      2389     |         37.1   | 467                            | 14153                                         |                                         31465     |
| 134 Day 5                 | 89117          |       2.58  | 2972656                         | 2972656                        |      46     |     2939     |      2896     |         45.9   | 665                            | 22184                                         |                                         22184     |
| p:Treatment               | <0.001         |       0.657 | <0.001                          | <0.001                         |       0.834 |        0.875 |         0.707 |          0.618 | 0.378                          | 0.460                                         |                                             0.618 |
| p: Day                    | <0.001         |       0.834 | <0.001                          | 0.004                          |       0.117 |        0.25  |         0.039 |          0.004 | <0.001                         | <0.001                                        |                                             0.004 |
| p:Interaction             | 0.547          |       0.57  | 0.633                           | 0.986                          |       0.996 |        0.94  |         0.4   |          0.986 | 0.547                          | 0.633                                         |                                             0.986 |

## Table 13 Daunorubicin PK parameters Vyxeos Dose (3 - 134 units/m 2 ) for Days 1 and 5

| Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   | Table 8.Statistical Comparison*of DaunorubicinPharmacokineticParametersbetweenDay1 and Day 5 Following Administration of 3, 6, 12, 24, 32, 43, 57, 76, 101, and 134 units/m² CPX-351 Every 48 Hours by Intravenous Infusion over 90 Minutes to Patients with Advanced Hematologic Malignancies   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dose (units/m²) and Day                                                                                                                                                                                                                                                                          | Cmax (ng/ml)                                                                                                                                                                                                                                                                                     | Tmax (he)                                                                                                                                                                                                                                                                                        | AUCo-last AUCo-tau (ng*hr/mL)                                                                                                                                                                                                                                                                    | AUCo-inf AUCo-tau (ng*hr/mL)                                                                                                                                                                                                                                                                     | t1/2 (hr)                                                                                                                                                                                                                                                                                        | Vz (mL/m²)                                                                                                                                                                                                                                                                                       | Vss (mL/m²)                                                                                                                                                                                                                                                                                      | CL (mL/hr/m)                                                                                                                                                                                                                                                                                     | Cmax/Dose [(ng/mL) /(mg/kg)]                                                                                                                                                                                                                                                                     | AUCox/Dose AUCo-m/Dose [(ng*hr/mL) /(mg/kg)]                                                                                                                                                                                                                                                     | AUCo-n/Dose AUCo-Dose [(ng*hr/mL) /(mg/kg)]                                                                                                                                                                                                                                                      |
| 24 Day 1                                                                                                                                                                                                                                                                                         | 6503                                                                                                                                                                                                                                                                                             | 3.83                                                                                                                                                                                                                                                                                             | 135013                                                                                                                                                                                                                                                                                           | 165360                                                                                                                                                                                                                                                                                           | 19.3                                                                                                                                                                                                                                                                                             | 1835                                                                                                                                                                                                                                                                                             | 1753                                                                                                                                                                                                                                                                                             | 67.2                                                                                                                                                                                                                                                                                             | 614                                                                                                                                                                                                                                                                                              | 12737                                                                                                                                                                                                                                                                                            | 15600                                                                                                                                                                                                                                                                                            |
| 24 Day 5                                                                                                                                                                                                                                                                                         | 6410                                                                                                                                                                                                                                                                                             | 1.67                                                                                                                                                                                                                                                                                             | 151297                                                                                                                                                                                                                                                                                           | 151297                                                                                                                                                                                                                                                                                           | 20.6                                                                                                                                                                                                                                                                                             | 2274                                                                                                                                                                                                                                                                                             | 2374                                                                                                                                                                                                                                                                                             | 74.2                                                                                                                                                                                                                                                                                             | 605                                                                                                                                                                                                                                                                                              | 14273                                                                                                                                                                                                                                                                                            | 14273                                                                                                                                                                                                                                                                                            |
| 32 Day 1                                                                                                                                                                                                                                                                                         | 8543                                                                                                                                                                                                                                                                                             | 2.67                                                                                                                                                                                                                                                                                             | 229618                                                                                                                                                                                                                                                                                           | 298098                                                                                                                                                                                                                                                                                           | 17.9                                                                                                                                                                                                                                                                                             | 1195                                                                                                                                                                                                                                                                                             | 1506                                                                                                                                                                                                                                                                                             | 47.7                                                                                                                                                                                                                                                                                             | 606                                                                                                                                                                                                                                                                                              | 16285                                                                                                                                                                                                                                                                                            | 21142                                                                                                                                                                                                                                                                                            |
| 32 Day 5                                                                                                                                                                                                                                                                                         | 9057                                                                                                                                                                                                                                                                                             | 1.83                                                                                                                                                                                                                                                                                             | 257151                                                                                                                                                                                                                                                                                           | 257151                                                                                                                                                                                                                                                                                           | 20.3                                                                                                                                                                                                                                                                                             | 1725                                                                                                                                                                                                                                                                                             | 3734                                                                                                                                                                                                                                                                                             | 59.4                                                                                                                                                                                                                                                                                             | 642                                                                                                                                                                                                                                                                                              | 18238                                                                                                                                                                                                                                                                                            | 18238                                                                                                                                                                                                                                                                                            |
| 43 Day 1                                                                                                                                                                                                                                                                                         | 11248                                                                                                                                                                                                                                                                                            | 1.88                                                                                                                                                                                                                                                                                             | 287905                                                                                                                                                                                                                                                                                           | 411360                                                                                                                                                                                                                                                                                           | 24.2                                                                                                                                                                                                                                                                                             | 1687                                                                                                                                                                                                                                                                                             | 1639                                                                                                                                                                                                                                                                                             | 58.3                                                                                                                                                                                                                                                                                             | 595                                                                                                                                                                                                                                                                                              | 15233                                                                                                                                                                                                                                                                                            | 21765                                                                                                                                                                                                                                                                                            |
| 43 Day 5                                                                                                                                                                                                                                                                                         | 14833                                                                                                                                                                                                                                                                                            | 2.33                                                                                                                                                                                                                                                                                             | 395338                                                                                                                                                                                                                                                                                           | 395338                                                                                                                                                                                                                                                                                           | 26.7                                                                                                                                                                                                                                                                                             | 1775                                                                                                                                                                                                                                                                                             | 2437                                                                                                                                                                                                                                                                                             | 58.8                                                                                                                                                                                                                                                                                             | 785                                                                                                                                                                                                                                                                                              | 20917                                                                                                                                                                                                                                                                                            | 20917                                                                                                                                                                                                                                                                                            |
| 57 Day 1                                                                                                                                                                                                                                                                                         | 14333                                                                                                                                                                                                                                                                                            | 2.67                                                                                                                                                                                                                                                                                             | 376944                                                                                                                                                                                                                                                                                           | 590219                                                                                                                                                                                                                                                                                           | 32.4                                                                                                                                                                                                                                                                                             | 1949                                                                                                                                                                                                                                                                                             | 1894                                                                                                                                                                                                                                                                                             | 44.3                                                                                                                                                                                                                                                                                             | 571                                                                                                                                                                                                                                                                                              | 15018                                                                                                                                                                                                                                                                                            | 23515                                                                                                                                                                                                                                                                                            |
| 57 Day 5                                                                                                                                                                                                                                                                                         | 17633                                                                                                                                                                                                                                                                                            | 2.5                                                                                                                                                                                                                                                                                              | 473848                                                                                                                                                                                                                                                                                           | 473848                                                                                                                                                                                                                                                                                           | 35                                                                                                                                                                                                                                                                                               | 2671                                                                                                                                                                                                                                                                                             | 2188                                                                                                                                                                                                                                                                                             | 53                                                                                                                                                                                                                                                                                               | 703                                                                                                                                                                                                                                                                                              | 18878                                                                                                                                                                                                                                                                                            | 18878                                                                                                                                                                                                                                                                                            |
| 76 Day 1                                                                                                                                                                                                                                                                                         | 18200                                                                                                                                                                                                                                                                                            | 2.5                                                                                                                                                                                                                                                                                              | 446045                                                                                                                                                                                                                                                                                           | 534360                                                                                                                                                                                                                                                                                           | 16.8                                                                                                                                                                                                                                                                                             | 1641                                                                                                                                                                                                                                                                                             | 1596                                                                                                                                                                                                                                                                                             | 79                                                                                                                                                                                                                                                                                               | 545                                                                                                                                                                                                                                                                                              | 13355                                                                                                                                                                                                                                                                                            | 15999                                                                                                                                                                                                                                                                                            |
| 76 Day 5                                                                                                                                                                                                                                                                                         | 20567                                                                                                                                                                                                                                                                                            | 1.67                                                                                                                                                                                                                                                                                             | 444427                                                                                                                                                                                                                                                                                           | 444427                                                                                                                                                                                                                                                                                           | 19                                                                                                                                                                                                                                                                                               | 2611                                                                                                                                                                                                                                                                                             | 2217                                                                                                                                                                                                                                                                                             | 94.8                                                                                                                                                                                                                                                                                             | 616                                                                                                                                                                                                                                                                                              | 13306                                                                                                                                                                                                                                                                                            | 13306                                                                                                                                                                                                                                                                                            |
| 101 Day 1                                                                                                                                                                                                                                                                                        | 24831                                                                                                                                                                                                                                                                                            | 2.19                                                                                                                                                                                                                                                                                             | 552527                                                                                                                                                                                                                                                                                           | 725034                                                                                                                                                                                                                                                                                           | 22.1                                                                                                                                                                                                                                                                                             | 1997                                                                                                                                                                                                                                                                                             | 1912                                                                                                                                                                                                                                                                                             | 68.4                                                                                                                                                                                                                                                                                             | 559                                                                                                                                                                                                                                                                                              | 12444                                                                                                                                                                                                                                                                                            | 16330                                                                                                                                                                                                                                                                                            |
| 101 Day 5                                                                                                                                                                                                                                                                                        | 30185                                                                                                                                                                                                                                                                                            | 1.87                                                                                                                                                                                                                                                                                             | 666640                                                                                                                                                                                                                                                                                           | 666640                                                                                                                                                                                                                                                                                           | 25.2                                                                                                                                                                                                                                                                                             | 2413                                                                                                                                                                                                                                                                                             | 2269                                                                                                                                                                                                                                                                                             | 72.9                                                                                                                                                                                                                                                                                             | 680                                                                                                                                                                                                                                                                                              | 15014                                                                                                                                                                                                                                                                                            | 15014                                                                                                                                                                                                                                                                                            |
| 134 Day 1                                                                                                                                                                                                                                                                                        | 37750                                                                                                                                                                                                                                                                                            | 2.13                                                                                                                                                                                                                                                                                             | 953673                                                                                                                                                                                                                                                                                           | 1316510                                                                                                                                                                                                                                                                                          | 26.2                                                                                                                                                                                                                                                                                             | 1700                                                                                                                                                                                                                                                                                             | 1634                                                                                                                                                                                                                                                                                             | 45.8                                                                                                                                                                                                                                                                                             | 640                                                                                                                                                                                                                                                                                              | 16164                                                                                                                                                                                                                                                                                            | 22314                                                                                                                                                                                                                                                                                            |
| 134 Day 5                                                                                                                                                                                                                                                                                        | 44733                                                                                                                                                                                                                                                                                            | 2.33                                                                                                                                                                                                                                                                                             | 1204275                                                                                                                                                                                                                                                                                          | 1204275                                                                                                                                                                                                                                                                                          | 37                                                                                                                                                                                                                                                                                               | 2575                                                                                                                                                                                                                                                                                             | 2205                                                                                                                                                                                                                                                                                             | 50.2                                                                                                                                                                                                                                                                                             | 758                                                                                                                                                                                                                                                                                              | 20411                                                                                                                                                                                                                                                                                            | 20411                                                                                                                                                                                                                                                                                            |
| p: Treatment                                                                                                                                                                                                                                                                                     | <0.001                                                                                                                                                                                                                                                                                           | 0.673                                                                                                                                                                                                                                                                                            | <0.001                                                                                                                                                                                                                                                                                           | <0.001                                                                                                                                                                                                                                                                                           | 0.080                                                                                                                                                                                                                                                                                            | 0.082                                                                                                                                                                                                                                                                                            | 0.901                                                                                                                                                                                                                                                                                            | 0.222                                                                                                                                                                                                                                                                                            | 0.707                                                                                                                                                                                                                                                                                            | 0.247                                                                                                                                                                                                                                                                                            | 0.222                                                                                                                                                                                                                                                                                            |
| p: Day                                                                                                                                                                                                                                                                                           | 0.001                                                                                                                                                                                                                                                                                            | 0.044                                                                                                                                                                                                                                                                                            | 0.002                                                                                                                                                                                                                                                                                            | 0.004                                                                                                                                                                                                                                                                                            | 0.093                                                                                                                                                                                                                                                                                            | 0.001                                                                                                                                                                                                                                                                                            | <0.001                                                                                                                                                                                                                                                                                           | 0.004                                                                                                                                                                                                                                                                                            | 0.001                                                                                                                                                                                                                                                                                            | 0.002                                                                                                                                                                                                                                                                                            | 0.004                                                                                                                                                                                                                                                                                            |
| p:Interaction                                                                                                                                                                                                                                                                                    | 0.580                                                                                                                                                                                                                                                                                            | 0.835                                                                                                                                                                                                                                                                                            | 0.644                                                                                                                                                                                                                                                                                            | 0.947                                                                                                                                                                                                                                                                                            | 0.865                                                                                                                                                                                                                                                                                            | 0.696                                                                                                                                                                                                                                                                                            | 0.225                                                                                                                                                                                                                                                                                            | 0.947                                                                                                                                                                                                                                                                                            | 0.580                                                                                                                                                                                                                                                                                            | 0.644                                                                                                                                                                                                                                                                                            | 0.947                                                                                                                                                                                                                                                                                            |

* Note - Due to limited sample size Group 1-3 (i.e., 3, 6, and 12 units/m² ( CPX-351) were excluded from statistical comparisons.

<div style=\"page-break-after: always\"></div>

Figure 5 Mean cytarabine:daunorubicin molar ratio vs. Time on Days 1 and 5

<!-- image -->

NOTES:Ratios were computed by comparing total concentrations of cytarabine:daunorubicin (in molar units) at each PK sample time for individual subjects; the reported ranges correspond to lowest to highest mean ratios from 0.75 to 24 hours afterthestartoftheinfusion

N, sample size

## Special populations

Table 14 Subjects participating in population PK assessments from study 301, by age category

|                                               | Age 65 to 74 n / N (%)   | Age 75 to 84 n / N (%)   | Age 85+ n / N (%)   |
|-----------------------------------------------|--------------------------|--------------------------|---------------------|
| Subjects participating in PK Trials (N = 131) | 90/131 (68.7)            | 9/131 (6.9)              | 0/131 (0)           |

Based on the covariate analyses, age, sex, race, body weight, body mass index, and white blood cell count do not appear to account for significant sources of variability in PK parameters for total cytarabine or daunorubicin.

Descriptive statistics for cytarabine AUC from time 0 to 48 h after the Day 5 dose (AUCτ) across renal impairment and bilirubin categories in the analysis population are summarised in Table 16.

<div style=\"page-break-after: always\"></div>

Table 15 Descriptive statistics of AUCτ for cytarabine among renal impairment and bilirubin categories

|                | AUCtau (ng·h/mL)                                 | AUCtau (ng·h/mL)                                 | AUCtau (ng·h/mL)                                 | AUCtau (ng·h/mL)     | AUCtau (ng·h/mL)     |
|----------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------|----------------------|
| Statistics     | RenalImpairmentCategories (Creatinine Clearance) | RenalImpairmentCategories (Creatinine Clearance) | RenalImpairmentCategories (Creatinine Clearance) | Bilirubin Categories | Bilirubin Categories |
|                | Normal ( 90 mL/min)                              | Mild (60 -89 mL/min)                             | Moderate (30 - 59 mL/min)                        | <1.2 mg/dL           | 1.2 -3 mg/dL         |
| N              | 69                                               | 63                                               | 24                                               | 141                  | 15                   |
| ArithmeticMean | 1760000                                          | 2000000                                          | 2140000                                          | 1940000              | 1650000              |
| SD             | 896000                                           | 986000                                           | 865000                                           | 949000               | 697000               |
| CV%            | 50.8                                             | 48.9                                             | 40.5                                             | 48.9                 | 42.2                 |
| Geometric Mean | 1520000                                          | 1730000                                          | 1960000                                          | 1680000              | 1510000              |
| Geometric CV%  | 65.4                                             | 66.0                                             | 46.3                                             | 65.1                 | 46.7                 |
| Median         | 1630000                                          | 1820000                                          | 2280000                                          | 1820000              | 1390000              |
| Minimum        | 202000                                           | 197000                                           | 907000                                           | 197000               | 543400               |
| Maximum        | 4300000                                          | 5020000                                          | 3920000                                          | 5020000              | 3030000              |
| Lower 95% CI   | 1550000                                          | 1760000                                          | 1790000                                          | 1790000              | 1300000              |
| Upper 95% CI   | 1970000                                          | 2240000                                          | 2480000                                          | 2100000              | 2000000              |

The analysis population consisted of all subjects in the PK population who were treated with 100 units/m2 CPX-351 on Days 1, 3 and 5. This corresponded to subjects in the PK population who were enrolled in studies CLTR0310206andCLTR0310-301.

AUCtau: AUC from time 0 to 48 hours after the Day 5 dose, CI: confidence interval, CV% coefficient of variability, N: number of subjects,SD:Standard deviation.

Descriptive statistics for daunorubicin AUC from time 0 to 48 h after the Day 5 dose (AUC0-τ) across renal impairment and bilirubin categories in the analysis population are summarised in Table 17.

Table 16 Descriptive statistics of AUCτ for daunorubicin among renal impairment and bilirubin categories

|                | AUCtau (ng·h/mL)                                  | AUCtau (ng·h/mL)                                  | AUCtau (ng·h/mL)                                  | AUCtau (ng·h/mL)     | AUCtau (ng·h/mL)     |
|----------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|----------------------|----------------------|
| Statistics     | Renal Impairment Categories (CreatinineClearance) | Renal Impairment Categories (CreatinineClearance) | Renal Impairment Categories (CreatinineClearance) | Bilirubin Categories | Bilirubin Categories |
|                | Normal (90 mL/min)                                | Mild (60 - 89 mL/min)                             | Moderate (30 - 59 mL/min)                         | <1.2 mg/dL           | 1.2 - 3 mg/dL        |
| N              | 69                                                | 63                                                | 24                                                | 141                  | 15                   |
| ArithmeticMean | 584000                                            | 655000                                            | 684000                                            | 635000               | 562000               |
| SD             | 256000                                            | 249000                                            | 225000                                            | 255000               | 201000               |
| CV%            | 43.8                                              | 38.1                                              | 32.9                                              | 40.1                 | 35.9                 |
| GeometricMean  | 527000                                            | 604000                                            | 647000                                            | 580000               | 528000               |
| GeometricCV%   | 50.8                                              | 44.6                                              | 36.2                                              | 47.7                 | 38.2                 |
| Median         | 531000                                            | 643000                                            | 723000                                            | 596000               | 531000               |
| Minimum        | 123000                                            | 188000                                            | 370000                                            | 123000               | 240000               |
| Maximum        | 1220000                                           | 1160000                                           | 1073000                                           | 1220000              | 975000               |
| Lower 95% CI   | 524000                                            | 593000                                            | 595000                                            | 593000               | 460000               |
| Upper 95% CI   | 644000                                            | 716000                                            | 774000                                            | 677000               | 663000               |

The analysis population consisted of all subjects in the PK population who were treated with 100 units/m² CPX-351 on Days 1, 3 and 5. This corresponded to subjects in the PK population who were enrolled in studies CLTR0310206andCLTR0310-301.

AUCtau: AUC from time 0 to 48 hours after the Day 5 dose, CI: confidence interval, CV% coefficient of variability. N: number of subjects, SD: Standard deviation.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic interaction studies

No in vitro or in vivo studies on pharmacokinetic drug interactions have been submitted.

## Pharmacokinetics using human biomaterials

N/A

## 2.4.4. Pharmacodynamics

## Mechanism of action

No clinical pharmacodynamic studies were submitted.

## Primary and Secondary pharmacology

No primary pharmacology studies were submitted.

The effect of Vyxeos on cardiac repolarization was determined following the first induction (100 units/m 2 on Days 1, 3 and 5) in Study 206. ECG intervals at selected time points were obtained as the averages from triplicate recordings for all time points. Each ECG was interpreted using digital, on-screen software allowing the placement of electronic markers at the beginning and end of each ECG interval. The primary endpoint was to assess the mean change between time-matched measurements of Fridericia's corrected QT-interval (QTcF) following the first induction dose of Vyxeos. Bazett's corrected QT-interval (QTcB) was also tested for comparison.

A total of 26 patients were enrolled in the study. Twenty-four patients had ECG and PK data; however, not all patients had data at all time-points reducing the number available for comparisons. The largest change from baseline, upper limit of the one-sided 95% CI of the ΔQTcF was 12.3 msecs at 4 hours post-SOI (start of infusion) on Day 1 (mean ± SD, 8.0 ± 11.69 msecs). At 3 hours post-SOI, the UB 95% CI was 10.7 msecs (mean ± SD, 5.3 ± 15.17 msecs), but it was not statistically significant. No other change from baseline 95% CI crossed was greater than 10 msecs (Figure 6). No patients had QTcF changes from baseline greater than 60 msecs and no QTcF values were greater than 500 msecs.

<div style=\"page-break-after: always\"></div>

Figure 6 Mean (90% CI) change from baseline and placebo in QTcF duration by time point

<!-- image -->

Abbreviations: CI = confidence interval; ECG = electrocardiogram; QTcF = Fridericia's corrected QT-interval. Note that the upper limit of the 2-sided 90% CI is the same quantity as the upper limit for a 1-sided 95% CI.

Results of analyses using QTcB were comparable to those using QTcF (data not shown).

## 2.4.5. Discussion on clinical pharmacology

The pharmacokinetics of daunorubicin and cytarabine administered as Vyxeos were investigated in adult patients who received a dose of daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered as a 90minute intravenous infusion on days 1, 3, and 5. The pharmacokinetics of each medicinal product was based on total plasma concentrations (i.e., encapsulated plus unencapsulated medicinal product). Following the dose administered on day 5, the mean (% coefficient of variation [CV]) maximum plasma concentrations (Cmax) for daunorubicin was 26.0 (32.7%) mcg/mL and cytarabine was 62.2 (33.7%) mcg/mL. The mean (%CV) area under the curve (AUC) during one dosing interval for daunorubicin was 637 (38.4%) mcg.h/mL and cytarabine was 1900 (44.3%) mcg.h/mL (SmPC, section 5.2).

When daunorubicin and cytarabine are administered as components of Vyxeos, the liposomes appear to govern their tissue distribution and rates of elimination; therefore, while the non-liposomal medicinal products have markedly different clearance (CL), volume of distribution (V), and terminal half-life (t1/2) Vyxeos causes these pharmacokinetic parameters to converge (SmPC, section 5.2).

The accumulation ratio was 1.3 for daunorubicin and 1.4 for cytarabine. There was no evidence of timedependent kinetics or major departures from dose proportionality over the range of 1.3 mg/3 mg per m 2  to 59 mg/134 mg per m 2  (0.03 to 1.3 times the approved recommended dosage) (SmPC, section 5.2).

Age, sex, race, body weight, body mass index, and white blood cell count do not have a clinically important effect on the exposure of total daunorubicin or cytarabine after adjusting dose by body surface area(SmPC, section 5.2).

<div style=\"page-break-after: always\"></div>

Insufficient pharmacokinetic data were collected in paediatric patients to draw conclusions (SmPC, section 5.2).

The pharmacokinetics of Vyxeos in patients aged &gt; 85 years has not yet been evaluated. No data are available(SmPC, section 5.2).

The pharmacokinetics of total daunorubicin and cytarabine were not altered in patients with bilirubin ≤ 50 µmol/L. The pharmacokinetics in patients with bilirubin greater than 50 µmol/L is unknown(SmPC, section 5.2).

Based on a population pharmacokinetic analysis using data from clinical studies in patients, no significant difference in clearance of daunorubicin or cytarabine was observed in patients with pre-existing mild to moderate renal impairment (30 mL/min ≤ creatinine clearance [CrCL] ≤ 59 mL/min for moderate, and 60 mL/min ≤ creatinine clearance [CrCL] ≤ 89 mL/min for mild)) compared to patients with baseline normal renal function (CrCL ≥ 90 mL/min). The potential effects of severe renal impairment (CrCL 15 mL/min to 29 mL/min, C-G) and end stage renal disease on the pharmacokinetics of daunorubicin and cytarabine administered as Vyxeos are unknown (SmPC, section 5.2).

Vyxeos can be considered an optimised liposomal formulation of the standard 7+3 daunorubicin and cytarabine combination chemotherapy with the advantage of a synergy anti-tumour activity between cytarabine and anthracycline and the delivery of these two anti-neoplastic substances at a high cargo to the target leukaemic bone marrow.

Anthracyclines are considered to be among the most active drugs in AML treatment but their use have been limited by the cumulative dose related cardiac toxicity. Vyxeos is associated with a lower cumulative dose of daunorubicin compared to 7+3 and there is no evidence of having a meaningful clinical effect on cardiac repolarization. However, long term safety data would still be needed to confirm any advantage with regards to cardiac toxicity, of no concern for this submission given the proposed patient population has very poor prognosis. Concurrent use of cardiotoxic agents may increase the risk of cardiotoxicity. Use of Vyxeos in patients who have previously received doxorubicin increases the risk of cardiotoxicity. Vyxeos should not be administered in combination with other cardiotoxic agents unless the patient's cardiac function is closely monitored (SmPC, section 4.5).

No interaction studies have been performed with Vyxeos. The delivery of daunorubicin and cytarabine in the Vyxeos liposomal formulation is anticipated to reduce the possibility of interactions, because systemic freedrug concentrations of daunorubicin and cytarabine are much lower than when administered as the non-liposomal formulation (SmPC, section 4.5).

Hepatotoxic medicinal products may impair liver function and increase the toxicity. Since daunorubicin is metabolised by the liver, changes in hepatic function induced by concomitant therapies may affect metabolism, pharmacokinetics, therapeutic efficacy, and/or the toxicity of Vyxeos. Monitor hepatic function more frequently when Vyxeos is coadministered with hepatotoxic agents (SmPC, section 4.5).

## 2.4.6. Conclusions on clinical pharmacology

The PK of Vyxeos has been reasonably well investigated. The relevant information has been included in the SmPC (sections 5.2).

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

## 2.5.1. Dose response study

## Study CLTR0310-101

This was a Phase 1, single arm, dose escalation study in subjects &gt; 18 years with AML (multiply relapsed, refractory, or with first CR duration of ≤ 6 months), acute lymphocytic leukemia (ALL), or high risk MDS.

The primary objective was to determine the recommended Phase 2 dose of Vyxeos (defined as maximum tolerated dose [MTD]) that could be given to patients with advanced hematologic malignancies. Secondary objectives were to evaluate the safety and dose limiting toxicities, PK parameters, and assess preliminary efficacy.

Subjects were to receive up to 2 inductions and 1 consolidation. Vyxeos was administered by 90 minute IV infusions on Days 1, 3, and 5 for each induction and on Days 1 and 3 for each consolidation. Dose escalation was initiated at 3 units/m 2  and a 2-phase accelerated dose escalation schedule was employed with early escalation by dose doubling and late escalation by 33% increments. Dose expansion occurred at the declared MTD. At every dose level subjects were monitored for signs of antileukemic activity.

A total of 48 subjects were enrolled in the study, received at least 1 dose, and comprised the safety population. Two subjects were excluded from the efficacy evaluable analysis set (N = 46). The majority of subjects (60.4%) terminated treatment due to progressive disease or lack of response; 7 subjects (14.6%) completed the study. Two subjects discontinued the study due to AEs.

Most subjects were male (64.6%), white (85.4%) and the mean (SD) age was 59.1 (15.34) years. Most subjects (89.6%) had AML; 3 subjects had ALL, and 2 subjects had MDS. At enrolment, the mean (SD) time since diagnosis was 11.4 (7.93) months.

A total of 48 subjects were exposed to Vyxeos at doses from 3 units/m 2  to 134 units/m 2 . Subjects had 1 to 10 exposures and cumulative dose of 9 to 804 units/m 2 . Most subjects (26/48, 54%) were treated at the higher dose levels (ie, 101 and 134 units/m2). Vyxeos at a dose of 134 units/m 2  was administered to 6 adults, and dose-limiting toxicities were observed in 3 subjects (hypertensive crisis, reduced left ventricular ejection fraction in the clinical context of sepsis, and prolonged cytopenia).

Therefore, the MTD in this study and the dose recommended for Phase 2 was 101 units/m 2  administered by a 90 minute IV infusion on Days 1, 3, and 5 for each induction course and on Days 1 and 3 for each consolidation course in subjects able to tolerate intensive chemotherapy.

<div style=\"page-break-after: always\"></div>

Table 11. Actual Administered Dose Levels and Number of Patients

| Dose   | Dose             | Dose             | Dose               | PatientsEntered   | PatientsEntered   |
|--------|------------------|------------------|--------------------|-------------------|-------------------|
| Level  | CPX-351 units/m² | Cytarabine mg/m² | Daunorubicin mg/m² | Escalation Phase  | Extension Phase   |
| 1      | 3                | 3                | 1.32               | 1                 |                   |
| 2      | 6                | 6                | 2.64               | 1                 |                   |
| 3      | 12               | 12               | 5.28               | 2                 |                   |
| 4      | 24               | 24               | 10.6               | 4                 |                   |
| 5      | 32               | 32               | 14.08              | 4                 |                   |
| 6      | 43               | 43               | 18.92              | 4                 |                   |
| 7      | 57               | 57               | 25.08              | 3                 |                   |
| 8      | 76               | 76               | 33.44              | 3                 |                   |
| 9      | 101              | 101              | 44.44              | 6                 | 14                |
| 10     | 134              | 134              | 58.96              | 6                 |                   |

The key efficacy findings were that responses were achieved in multiple subjects, most with prior exposure to cytarabine and daunorubicin. No clinical responses were observed in any patient receiving less than 32 units/m 2 of CPX 351. Neither of the two patients with high-risk MDS responded.

Forty-three patients with AML were treated and 41 patients completed one induction course of therapy. Two patients received only two of the planned three doses before adverse events led to treatment discontinuation. Ten of 43 AML patients cleared their leukaemias, including one patient with multiple relapses who achieved complete responses with incomplete platelet recovery (CRp) after treatment at 32 units/m 2  following two induction courses.

Complete responses (CR) were achieved after single induction course at dose level as low as 43 units/m 2 . At the MTD dose level, aplasia was observed in 13 of 20 patients leading to 5 CR, 4 of which lasted longer than 6 months (including two consolidated with stem cell transplant). There were 7 CR among 22 AML patients receiving Vyxeos as first salvage, 1 CR and 1 CRp among the 11 patients given second salvage, and 1 CR among the 10 treated with third or greater salvage. Among the first salvage patients there were 5 patients with primary induction failure (PIF) 1 of whom achieved CR.

Not unexpectedly, Vyxeos showed substantially greater anti-leukemic efficacy among younger first relapse patients, with 4 of 7 (57.1%) patients aged 18-60 achieving CR compared with only 2 of 11 (18.2%) patients older than 60. Among the 18 first relapse patients, CR was achieved in 6, and of these patients the remission achieved following Vyxeos was longer than the initial remission in 2 patients (12 vs 16+ months in patient 03-018 at the 101 units/m 2  dose level, and 2 vs 5.4 months in patient 03-006 at the 32 units/m 2 dose level).

DLTs in this study were hypertensive crisis, prolonged cytopenia and congestive heart failure.

The cardiotoxic potential of daunorubicin has been appreciated for at least two decades and cardiac toxicity is a well-known side effect of anthracycline therapy, so it is unsurprising that this was observed as a DLT. The predominant AEs in this study are related to myelosuppression and its consequences, infections with opportunistic organisms during the myelosupressed period. At the recommended Phase 2 dose, 101units/m 2 , there does not seem to be an unusual predisposition to observe the classic cardiovascular consequences of anthracycline exposure, which are largely related to cumulative doses. Cardiac events were observed, including one patient treated at the Phase 2 recommended dose.

The declared MTD in this study and the dose recommended for Phase 2 was 101 units/m 2  administered by a 90 minute IV infusion on Days 1, 3, and 5 for each induction course and on Days 1 and 3 for each consolidation course in patients able to tolerate intensive chemotherapy.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Main study

## Study CLTR0310-301

## Methods

This was a phase III, multicentre, randomised, trial of Vyxeos (cytarabine: daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60 -75 years of age with untreated high risk (secondary) AML study.

## Study Participants

## Inclusion criteria

- Age 60 to 75 years at the time of diagnosis of AML.
- Pathological diagnosis of AML according to WHO criteria (at least 20% blasts in peripheral blood or bone marrow).
- Documentation of antecedent hematologic disorder: t-AML: prior cytotoxic or radiation therapy for an unrelated disease; MDSAML: MDS prior to diagnosis of AML;  CMMoLAML: CMMoL prior to diagnosis of AML; de novoAML with FISH or cytogenetic changes linked to MDS per WHO criteria.
- ECOG performance status of 0-2.
- Laboratory values: serum creatinine &lt; 2.0 mg/mL.; serum total bilirubin &lt; 2.0 mg/dL; serum ALT or AST &lt; 3 times the upper limit of normal.
- Cardiac ejection fraction ≥ 50% by ECHO or MUGA.
- Subjects with second malignancies in remission were eligible if there was clinical evidence of disease stability for ≥ 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies at screening. Subjects on long-term non-chemotherapy treatment such as hormonal therapy were eligible.

## Exclusion criteria

- Except for CMMoL, history of MPN (essential thrombocytosis or polycythemia vera, or idiopathic myelofibrosis) prior to the diagnosis of AML, or combined MDS/MPN
- Acute promyelocytic leukemia [t(15;17)] or favourable cytogenetics, including t(8;21) or inv 16 if known at the time of randomization
- Active central nervous system (CNS) leukemia.
- Active (uncontrolled, metastatic) second malignancies.
- Prior treatment for induction therapy of AML; only hydroxyurea was permitted for control of blood counts. For example, a subject with MDS that changes HMA dose and schedule after the diagnosis of AML was excluded. AML-type therapy, such as cytarabine alone (&gt; 1g/m 2 /day) or cytarabine plus an anthracycline as well as prior HSCT were also excluded.
- Administration of any therapy for MDS must have been completed by 2 weeks before the first study treatment; in the event of rapidly proliferative disease, the use of hydroxyurea was permitted until 24

<div style=\"page-break-after: always\"></div>

hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to grade 1 or less prior to start of treatment.

- Any major surgery or radiation therapy in 4 weeks.
- Prior cumulative anthracycline exposure of greater than 368 mg/m 2  daunorubicin (or equivalent).
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent obtaining informed consent.
- Myocardial impairment of any cause (e.g., cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging).
- Active or uncontrolled infection; subjects with an infection receiving treatment could be entered into the study provided the subject was afebrile and hemodynamically stable for ≥ 72 hours.
- Current evidence of invasive fungal infection (blood or tissue culture); subjects with recent fungal infection must have had subsequent negative cultures to be eligible; known HIV (new testing not required) or evidence of active hepatitis B or C infection (with rising transaminase values).
- Hypersensitivity to cytarabine, daunorubicin or liposomal products.
- History of Wilson's disease or other copper-metabolism disorder.

## Treatments

The study comprised 2 phases: a Treatment Phase and a Follow-up Phase.

Figure 7 Study Design (Study CLTR0310-301)

<!-- image -->

<div style=\"page-break-after: always\"></div>

For the treatment phase subjects were to receive up to 2 inductions and up to 2 consolidations with either Vyxeos or cytarabine and daunorubicin given as a 7+3. The number of inductions and consolidations received depended on response confirmed by bone marrow assessment.

The follow-up phase began 30 days after the completion of the last induction or consolidation course, and was to last until death or 5 years after randomization.

The initial induction course began within 24 hours of randomization.

Each unit of Vyxeos contained 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes.

## First induction :

- Vyxeos: 100 units/m 2 by 90-minute IV infusion on Days 1, 3, 5
- 7+3: cytarabine 100 mg/m 2 /day on Days 1 through 7 by continuous infusion daunorubicin 60 mg/m 2 /day on Days 1, 2, and 3

## Second induction :

- Vyxeos   100 units/m 2  by 90-minute IV infusion on Days 1 and 3
- 5+2: cytarabine 100 mg/m 2 /day on Days 1 through 5 by continuous infusion daunorubicin 60 mg/m 2 /day on Days 1 and 2

## Consolidation :

- Vyxeos   65 units/m 2  by 90-minute IV infusion on Days 1 and 3
- 5+2: cytarabine 100 mg/m 2 /day on Days 1 through 5 by continuous infusion

daunorubicin 60 mg/m 2 /day on Days 1 and 2

Doses in both treatment groups could be delayed due to toxicities or hypersensitivity reactions. Any doses missed or delayed due to these events were administered as soon as the subject recovered from the event.

Post remission therapy with bone marrow transplant was permitted either in place of or after postremission chemotherapy and was administered according to local practice.

## Permitted Therapies

- Premedication for nausea and vomiting per institutional policy
- Subjects were not routinely pre-medicated for hypersensitivity or for potential infusion-related reactions prior to the first infusion of the first treatment course. If a subject developed a hypersensitivity reaction, then the subject should have been pre-medicated at all subsequent infusions.
- Prophylactic use of anti-infectives was highly recommended during the period of neutropenia until the absolute neutrophil count (ANC) returned to 500/μL or greater. The choice of anti-infectives was determined according to institutional protocol.
- Growth factors were allowed according to institutional protocol

<div style=\"page-break-after: always\"></div>

## Objectives

The primary objective was to confirm the efficacy of Vyxeos compared with 7+3 as first line therapy in elderly patients (60 to 75 years old) with high risk (secondary) AML.

The secondary objectives were to confirm the safety of Vyxeos and improvement in the rate of leukemia-free state, post induction response, remission duration, event-free survival, and overall best response rate. It also included assessment of serum copper elevations, population pharmacokinetics of Vyxeos and pharmacoeconomic.

## Outcomes/endpoints

The primary endpoint was overall survival (OS) defined as the time from randomisation to death from any cause.

## Secondary

- Event-free-survival (EFS): time from randomization until the date of induction treatment failure (persistent disease), relapse from CR or CRi or death from any cause, whichever came first.

- Response: subjects who achieved CR or CRi during the treatment phase.

- Best response: subjects who completed the induction(s) with a response of CRi but were upgraded to CR during or after consolidation

- Remission duration: time from the date of achievement of a remission (CR or CRi) until the date of relapse or death from any cause. For subjects whose best response was upgraded from CRi to CR, the remission duration for CR+CRi analyses were calculated from the date of CRi to the date of relapse or death.

- Morphologic Leukemia-free State: bone marrow blasts &lt; 5% and the absence of Auer rods and/or extramedullary disease. All randomised subjects with at least 1 evaluable post-randomization bone marrow assessment performed on or after Day 14 after the last induction were assessed for MLFS.

- The number and percentage of subjects transferred for HSCT after induction
- Medical resource use to identify costs associated with planned and any unplanned treatment/support.

## Criteria used for assessment of response:

· CR: bone marrow blasts &lt; 5%; absence of blasts with Auer rods; absence of extramedullary disease; ANC &gt; 1.0 x 10 9 /L (1000/μL); platelet count &gt; 100 x 10 9 /L (100,000/μL); independence from red cell transfusions.

· CRi: all the CR criteria except for residual neutropenia (&lt; 1.0 x 109/L [1000/μL]) or thrombocytopenia (&lt; 100 x 109/L [100,000/μL]).

Subject's response to induction was made on the first day when all criteria for CR or treatment failure were met. Response was assessed locally and decisions about starting post-remission chemotherapy or referral for transplant were made per local institutional standards prior to independent review of response. An independent hematopathologist evaluated response assessments by reviewing bone marrow reports, data on peripheral blood and transfusion reports. The responses reported in this study are those confirmed by the independent hematopathologist.

<div style=\"page-break-after: always\"></div>

The independent confirmation of induction response was completed earlier than assessment of overall survival or other secondary endpoints. To minimise the potential for bias, the analysis of induction response with independent confirmation was prospectively incorporated as a final analysis into the study protocol and was initiated only after subjects had completed randomization and all study treatments.

In addition, molecular mutation data for CEBPA, FLT3, and NPM1 were obtained via a central or local laboratory prior to the primary endpoint analysis.

## Sample size

The study was designed to enrol 300 subjects so that a minimum of 270 subjects would be evaluable for the primary endpoint. It was anticipated that up to 10% of subjects would be ineligible or withdraw consent. All sample size and power justifications were based on evaluable subjects only.

Assuming a median OS of 0.526 years in the 7+3 treatment group, 236 deaths were required for final analysis of OS with 93.7% power and a 1-sided significance level ( α = 0.025) to detect a hazard ratio of 0.635 between the 2 treatment groups.

This study was designed to have 93.7% power for the primary endpoint to ensure that a sensitivity analysis of OS, which would censor subjects at the start of transplant, was powered at 90% for the same hazard ratio (0.635).

## Randomisation

At registration, patients were randomised to receive Vyxeos (Study Arm A) or cytarabine + daunorubicin (7+3 regimen) (Study Arm B) in a 1:1 ratio.

Randomization was stratified according to Age (60-69 vs 70-75) and AML type (t-AML vs MDS AML with prior treatment with hypomethylating agents vs MDS AML without prior treatment with hypomethylating agents, vs de novo AML with karyotype characteristic of MDS vs CMMoL AML).

## Blinding (masking)

This was an open label study.

## Statistical methods

## Analysis populations:

- Intent-to-Treat (ITT): all randomised subjects who were assigned to a treatment group. It constituted the primary efficacy population.
- Safety population: all subjects who received at least 1 dose of a study medication
- Per protocol population (PP): subjects who were a subset of the ITT population, met all inclusion/exclusion criteria, received at least 1 dose of a study medication, and have their AML diagnosis and type confirmed by an independent pathologist. The analysis of transfer to HSCT was performed on this study population.

<div style=\"page-break-after: always\"></div>

- Morphologic leukemia-free state (MLFS): subjects who were a subset of the PP population and had at least 1 evaluable post-randomization bone marrow assessment performed on or after Day 14 after the last induction.

## Analyses:

Primary analysis: OS (ITT population). Subjects who did not die at last follow-up were censored on the date they were last known to be alive. Subjects were to be followed for up to 5 years.

Sensitivity analyses: because of potential imbalances in use of HSCT, a sensitivity analysis was performed after censoring subjects at the start of HSCT, so that survival potentially attributable to HSCT could be removed.

Subgroup analyses on time to event endpoints (remission duration and EFS) to assess whether the treatment effect differs according to the stratification factors.

Exploratory analyses to determine which prognostic factors had a significant effect on the primary and secondary endpoints. The prognostic factors used were: sex, ECOG performance status, karyotype, white blood cell (WBC) category, platelet category, hemoglobin category, bone marrow blast count, and FLT3 mutation.

## Method of analysis

A stratified log-rank test was used to compare the Vyxeos and 7+3 treatment groups. In addition, the distribution of overall survival was estimated in each treatment group with the Kaplan-Meier methodology. The hazard ratio and overall survival at different time points, along with corresponding confidence intervals, were reported. Exploratory multivariate analyses were performed to assess the treatment effect adjusting for key prognostic factors using the Cox proportional hazard regression model.

## Timing of analysis

The pre-planned analysis of induction response (CR+CRi) was performed after all subjects had been enrolled and completed induction and consolidation treatments. This analysis was reviewed by the DSMB to allow decisions for initiating other clinical studies of Vyxeos. The use of response information did not bias the conduct of the study because all subjects were randomised, had completed all study treatments, and had been followed long enough to recover from hematopoietic effects of treatment and because the remaining data to be collected on each subject consisted only of relapse and survival information. These analyses did not affect the conduct of the trial or the alpha of the primary endpoint. All other analyses were performed after the endpoint for the primary analysis had occurred. The analysis for the primary endpoint was performed after 236 deaths had occurred. The number of deaths was based on the alternative hypothesis.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Figure 8 Disposition of subjects (ITT population-Study CLTR0310-301)

<!-- image -->

## Recruitment

## Conduct of the study

## Protocol amendments

The initial protocol (Version 1.0) was issued on 22 May 2012. It was subsequently amended 4 times: on 12 March 2013 (Version 2.0), 17 September 2013 (Version 2.1, never issued, changes incorporated in Version 2.2), 9 October 2013 (Version 2.2), and 4 November 2013 (Version 2.3).

Protocol amendments of clinical relevance were (Amendment version 2.0): Increased the sample size to 300 to provide greater power. Consequently, the analysis of the primary endpoint was to be performed after 236

<div style=\"page-break-after: always\"></div>

deaths occurred;  The mandatory second induction should occur only if it was safe to do so; Added an optional consolidation schedule (intermediate dose cytarabine, 1.5 g/m 2 twice daily on days 1, 3 and 5) for subjects that had exceeded 500 mg/m 2  lifetime exposure to daunorubicin or its equivalent; The assessment of early deaths was changed so that the assessment by the DSMB was conducted after the first 75 subjects had been evaluated for induction mortality

## Protocol compliance

A total of 9 subjects (4 in the Vyxeos and 5 in the control) violated at least 1 of the inclusion criteria and 17 subjects (5 in the Vyxeos and 12 in the control) failed at least 1 exclusion criterion.  A total of 9 protocol deviations were categorised as major deviations, 4 subjects in the Vyxeos and 5 in the control. In the Vyxeos arm two subjects had a delay of 1 week after randomization before they received the investigational product, a site delayed reporting an SAE for 1 subject who died, and 1 subject received 100 units/m 2 instead of 65 units/m 2 for consolidation. In the control, 2 subjects were assigned the wrong AML subtype, 1 subject received idarubicin instead of daunorubicin for 1 treatment course, 1 subject had a delay in receiving daunorubicin, and 1 subject failed to sign the consent form for Amendment 2.

## Baseline data

The baseline demographics and disease characteristics are presented in Table 18.

Table 17 Baseline demographics and disease characteristics (ITT population-Study CLTR0310301)

|                                    | CPX-351 N=153   | 7+3 N =156   |
|------------------------------------|-----------------|--------------|
| Age,year's,median (range)          | 68 (60, 75)     | 68 (60, 75)  |
| 60 to 69, n (%)                    | 96 (63)         | 102 (65)     |
| 70 to 75,n (%)                     | 57 (37)         | 54 (35)      |
| Sex, n (%)                         |                 |              |
| Male                               | 94 (61)         | 96 (62)      |
| Female                             | 59 (39)         | 60 (38)      |
| Race, n (%)                        |                 |              |
| American Indian or Alaska Native   | 1 (1)           | 0            |
| Asian                              | 6 (4)           | 2 (1)        |
| Black                              | 7 (5)           | 6 (4)        |
| White                              | 128 (84)        | 139 (89)     |
| Other                              | 11 (7)          | 8 (5)        |
| Multiple                           | 0               | 1 (1)        |
| ECOG Performance Group, n (%)      |                 |              |
| PS 0                               | 37 (24)         | 45 (29)      |
| PS 1                               | 101 (66)        | 89 (57)      |
| PS 2                               | 15 (10)         | 22 (14)      |
| Extra medullary disease, n (%)     | 5 (3)           | 5 (3)        |
| AMIL subtype, n (%)                |                 |              |
| CIMIMol toAML                      | 11 (7)          | 12 (8)       |
| De NovoAML                         | 41 (27)         | 37 (24)      |
| MDSwithHMAtoAML                    | 50 (33)         | 55 (35)      |
| MDSwithoutHMAtoAML                 | 21 (14)         | 19 (12)      |
| tAML                               | 30 (20)         | 33 (21)      |
| GeneticMutations,n(%)              |                 |              |
| FLT3positivemutation               | 22 (14)         | 21 (14)      |
| NPM1 positive mutation             | 13 (9)          | 12 (8)       |
| CEBPAmutated                       | 12 (8)          | 5 (3)        |
| Cytogenetic risk assessment, n (%) |                 |              |
| Better-risk                        | 7 (5)           | 5 (3)        |
| Intermediate-risk                  | 64 (45)         | 58 (40)      |
| Poor-risk                          | 72 (50)         | 83 (57)      |

Abbreviations:AML= acutemyeloid leukemia;CMMoL=chronicmyelomonocyticleukemia;ECOG=East Coast Oncology Group; MDS = myelodysplastic syndrome; HMA = hypomethylating agents; PS =performance status; tAML = therapy-related AML.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 18 Summary of the number of subjects in each analysis population (Study CLTR0310-301)

| AnalysisPopulation              | NumberofSubjects   | NumberofSubjects   |
|---------------------------------|--------------------|--------------------|
|                                 | CPX-351            | 7+3                |
| LLI                             | 153                | 156                |
| Safety                          | 153                | 151                |
| PerProtocol                     | 145                | 135                |
| IMorphologicLeukemia- freeState | 126                | 119                |

## Outcomes and estimation

## Primary endpoint: Overall survival

The results of the primary endpoint OS are presented in Table 20 and Figure 9.

Table 19 Primary Endpoint Analysis: Overall Survival (ITT Analysis Population-Study CLTR0310301)

|                                         | CPX-351 (N=153)   | 7+3 (N=156)     |
|-----------------------------------------|-------------------|-----------------|
| Survived                                | 49 (32.0)         | 24 (15.4)       |
| Median SurvivalinMonths （95% Conf.Int.) | 9.56(6.60，11.86)  | 5.95(4.99,7.75) |
| Hazard Ratio(95% Conf.Int.)             | 0.69(0.52，0.90)   |                 |
| p-value (1-sided)                       | 0.003             |                 |

```
Note:P-valuefromstratifiedlog-ranktest Note:Hazard ratio are calculated with the 7+3 arm as the reference group.
```

Figure 9 Kaplan-Meier Curve for overall survival (ITT population- Study CLTR0310-301)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses

In a sensitivity analysis that censored OS data at HSCT in the ITT population, a Kaplan-Meier analysis showed that subjects in the Vyxeos treatment group had median survival 7.75 months compared to 5.55 months with those in the 7+3 treatment group (HR=0.81, for log rank test, 1-sided p = 0.082, ).

Figure 10).

Figure 10 Kaplan-Meier Curve for overall survival, sensitivity analysis (ITT population-Study CLTR0310-301)

<!-- image -->

In the per protocol population when censored OS data at HSCT in the ITT population, subjects in the Vyxeos group had 7.75 months median survival compared with 5.55 months in the control arm (HR 0.81, for log rank test, 1-sided p = 0.082) (data not shown).

The results of the OS data in the ITT population by randomization strata are presented in Table 20 .

<div style=\"page-break-after: always\"></div>

Table 20 Overall Survival by randomization strata (ITT population-Study CLTR0310-301)

| RandomizationStrata                   |    | CPX-351           | 7+3   | 7+3                     | 7+3                     | Hazard Ratio (95% CI)   |
|---------------------------------------|----|-------------------|-------|-------------------------|-------------------------|-------------------------|
|                                       | n  | MedianOs (months) | n     | Median OS (months)      | HR (95% CI) P-value     |                         |
| Age (years)                           |    |                   |       |                         |                         |                         |
| 69-09                                 | 96 | 9.63              | 102   | 6.87                    | 0.68 (0.49, 0.95) 0.023 |                         |
| 70-75                                 | 57 | 8.87              | 54    | 5.62                    | 0.55 (0.36, 0.84) 0.005 |                         |
| AML Subtype                           |    |                   |       |                         |                         |                         |
| CMMoL -> AML                          | 11 | 9.33              | 12    | 2.28 0.37 (0.14, 0.95)  | 0.032                   |                         |
| De novo AML with MDS karyotype        | 41 | 10.09             | 37    | 7.36 0.71 ( 0.42, 1.20) | 0.201                   |                         |
| MDS->AML with prior HMA treatment     | 50 | 5.65              | 55    | 7.43                    | 0.98 (0.64, 1.51) 0.944 |                         |
| MDS ->AML without prior HMA treatment | 21 | 15.74             | 19    | 5.13                    | 0.46 (0.21, 0.97) 0.037 |                         |
| Therapy-relatedAML                    | 30 | 12.17             | 33    | 5.95                    | 0.48 (0.26, 0.86) 0.012 |                         |
|                                       |    |                   |       |                         |                         | 0.2 0.6 1.0 1.4 1.8     |

## Secondary endpoint-Induction Response

The results of the analysis of induction responses are displayed in Table 21.

.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 20 Proportion of subjects with a response (ITT population-Study CLTR0310-301)

| Endpoint (N=CPX-351, N= 7+3)   | CPX-351 n (%)   | 7+3 n(%)   | Odds Ratio (95% CI)                   |
|--------------------------------|-----------------|------------|---------------------------------------|
| CR+CRi                         | 73 (47.7)       | 52 (33.3)  | 1.77 (1.11, 2.81) p = 0.008 (1-sided) |
| CR                             | 57 (37.3)       | 40 (25.6)  | 1.69 (1.03, 2.78) p = 0.020 (1-sided) |
| CRi                            | 16 (10.5)       | 12 (7.7)   |                                       |
| No response                    | 80 (52.3)       | 104 (66.7) |                                       |
| Age (years) 60-69 (96, 102)    |                 |            |                                       |
| CR                             | 38 (39.6)       | 27 (26.5)  | 1.82 (1.00, 3.32)                     |
| CRi                            | 10 (10.4)       | 10 (9.8)   |                                       |
| 70-75 (57,54)                  |                 |            |                                       |
| CR                             | 19 (33.3)       | 13 (24.1)  | 1.58 (0.69, 3.62)                     |
| CRi                            | 6 (10.5)        | 2 (3.7)    |                                       |
| AML Subtype                    |                 |            |                                       |
| CMMoLAML (11, 12) CR           | 2 (18.2)        | 3 (25.0)   | 0.67 (0.09, 4.99)                     |
| CRi                            | 2 (18.2)        | 0          |                                       |
| de novoAML (41, 37)            |                 |            |                                       |
| CR                             | 19 (46.3)       | 10 (27.0)  | 2.33 (0.90, 6.03)                     |
| CRi                            | 4 (9.8)         | 2 (5.4)    |                                       |
| MDs AML with HMA (50, 55)      |                 |            |                                       |
| CR                             | 13 (26.0)       | 10 (18.2)  | 1.58 (0.62, 4.02)                     |
| CRi                            | 5 (10.0)        | 8 (14.5)   |                                       |
| MDsAML without HMA (21, 19)    |                 |            |                                       |
| CR                             | 12 (57.1)       | 7 (36.8)   | 2.29 (0.64, 8.15)                     |
| CRi                            | 2 (9.5)         | 0          |                                       |
| t-AML (30, 33)                 |                 |            |                                       |
| CR                             | 11 (36.7)       | 10 (30.3)  | 1.33 (0.47, 3.81)                     |
| CRi                            | 3 (10.0)        | 2 (6.1)    |                                       |

## Secondary endpoint-Best Response

No subjects in either the ITT or PP populations with a CRi response were upgraded to CR. Consequently no changes occurred in the proportions of subjects with a best response compared with the induction response.

## Secondary endpoint-EFS

The median EFS was 2.53 (95%CI: 2.07, 4.99) months for the Vyxeos and 1.31 (95%CI: 1.08 , 1.64) months for the 7+3 treatment arms (HR = 0.74, 1-sided, p = 0.011). A Kaplan-Meier Estimate for EFS is displayed in Figure 11.

<div style=\"page-break-after: always\"></div>

Figure 11 Kaplan-Meier Estimate for event free survival (ITT population-Study CLTR0310-301)

<!-- image -->

## Secondary endpoint- Remission Duration

Remission duration in the Vyxeos treatment arm was 6.93 months vs. 6.11 months in the 7+3 treatment arm (1-sided p = 0.147). In the per protocol population, remission duration 7.36 in the Vyxeos treatment arm compared with the 7+3 treatment arm vs. 5.95 months in the 7+3 treatment arm ( 1-sided p = 0.086) (data not shown).

## Secondary endpoint-Morphologic leukemia-free state

The proportion of subjects achieved a MLFS is displayed in Table 22.

Table 21 Proportion of subjects achieving MLFS (ITT Population-Study CLTR0310-301)

| Endpoint (N CPX-351,        | CPX-351      | 7+3        | Odds Ratio                 |
|-----------------------------|--------------|------------|----------------------------|
| N 7+3)                      | N= 126 n (%) | N=119 n(%) | (95% CI)                   |
| MLFS                        | 87 (69.0)    | 66 (55.5)  | 1.78 (1.05, 3.03) p =0.017 |
| Age (years)                 |              |            |                            |
| 60-69 (82, 77)              | 54 (65.9)    | 43 (55.8)  | 1.52 (0.80, 2.89)          |
| 70-75 (44, 42)              | 33 (75.0)    | 23 (54.8)  | 2.48 (0.99, 6.18)          |
| AML Subtype                 |              |            |                            |
| CMMoLAML (9, 8)             | 5 (55.6)     | 3 (37.5)   | 2.08 (0.30, 14.55)         |
| de novoAML (35, 31)         | 23 (65.7)    | 14 (45.2)  | 2.33 (0.86, 6.29)          |
| MDsAML with HMA (41, 45)    | 28 (68.3)    | 26 (57.8)  | 1.57 (0.65, 3.81)          |
| MDsAML without HMA (19, 14) | 14 (73.7)    | 11 (78.6)  | 0.76 (0.15, 3.92)          |
| t-AML (22, 21)              | 17 (77.3)    | 12 (57.1)  | 2.55 (0.68, 9.54)          |

## Secondary endpoint-Stem Cell Transplant

The proportion of subjects receiving stem cell transplant is displayed in Table 23.

<div style=\"page-break-after: always\"></div>

Table 22 Proportion of Subjects Receiving Stem Cell Transplant (ITT Population-Study CLTR0310301)

| Endpoint (N CPX-351, N 7+3)   | CPX-351 n (%)   | 7+3 n(%)   | Odds Ratio (95% CI)                   |
|-------------------------------|-----------------|------------|---------------------------------------|
| HSCT (153, 156)               | 52 (34.0)       | 39 (25.0)  | 1.54 (0.92, 2.56) p = 0.049 (1-sided) |
| Age (years) 60-69 (96, 102)   | 36 (37.5)       | 33 (32.4)  | 1.25 (0.70, 2.25)                     |
| 70-75 (57, 54)                | 16 (28.1)       | 6 (11.1)   | 3.12 (1.12, 8.72)                     |
| AML Subtype CMMoLAML          | 3 (27.3)        | 0          | Not evaluable                         |
| de novoAML                    | 17 (41.5)       | 11 (29.7)  | 1.67 (0.65, 4.28)                     |
| MDsAML with prior HMA         | 14 (28.0)       | 14 (25.5)  | 1.14 (0.48, 2.71)                     |
| MDsAML without prior          | 7 (33.3)        | 5 (26.3)   | 1.40 (0.36, 5.49)                     |
|                               | 11 (36.7)       |            | 1.54 (0.53, 4.49)                     |
| t-AML                         |                 | 9 (27.3)   |                                       |

In the ITT population, a greater proportion of subjects in the Vyxeos treatment group received a HSCT while in CR or CRi compared with control (54.8% vs. 46.2%, respectively).

Table 23 Transplant Rate (Study CLTR0310-301)

|                              | CPX-351 N =153                   | 7+3 N=156                        |
|------------------------------|----------------------------------|----------------------------------|
| CR, n (%)                    | 57 (37.3)                        | 40 (25.6)                        |
| Received Transplant          | 30 (52.6)                        | 19 (47.5)                        |
| No Transplant                | 27 (47.4)                        | 21 (52.5)                        |
| CRi, n (%)                   | 16 (10.5)                        | 12 (7.7)                         |
| Received Transplant          | 10 (62.5)                        | 5 (41.7)                         |
| No Transplant                | 6 (37.5)                         | 7 (58.3)                         |
| Transplant rate              | 52 (34.0)                        | 39 (25.0)                        |
| Odds ratio (95% CI) p-value? | 1.54 (0.92,2.56) 0.049 ²; 0.097b | 1.54 (0.92,2.56) 0.049 ²; 0.097b |

Abbreviations: CI = confidence interval.

² 1-sided p-value is from a comparison of rates between treatment arms and is based on the Mantel-Haenszel test stratifying by age and AML type.

2-sided p-value is from a comparison ofrates between treatment arms and is based on the Mantel-Haenszel test stratifying by age and AML type.

A Kaplan-Meier analysis of the 91 subjects who received a transplant landmarked at the time of  transplant showed that subjects in the Vyxeos group performed better than those in the control (HR=0.46, p = 0.009 [1-sided]). The median survival was not reached in the Vyxeos treatment group, whereas the median survival in the 7+3 treatment group was 10.25 months (data not shown).

## Ancillary analyses

Efficacy results for all endpoints stratified by AML subtype are displayed in Table 25.

<div style=\"page-break-after: always\"></div>

Table 24 Efficacy results by disease stratification factors (Study CLTR0310-301)

| AML Subtype              | AML Subtype        | AML Subtype        | AML Subtype       | AML Subtype       | AML Subtype          | AML Subtype          | AML Subtype             | AML Subtype             | AML Subtype       | AML Subtype       |
|--------------------------|--------------------|--------------------|-------------------|-------------------|----------------------|----------------------|-------------------------|-------------------------|-------------------|-------------------|
|                          | CMMoL AML          | CMMoL AML          | de novo AML       | de novo AML       | MDSAMLwith prior HMA | MDSAMLwith prior HMA | MDSAMLwithout prior HMA | MDSAMLwithout prior HMA | t-AML             | t-AML             |
|                          | CPX-351            | 7+3                | CPX-351           | 7+3               | CPX-351              | 7+3                  | CPX-351 N=21            | 7+3 N=19                | CPX-351 N=30      | 7+3               |
|                          | N=1l               | N=12               | N=41              | N=37              | N=50                 | N=55                 |                         |                         |                   | N=33              |
| Overall Survival         |                    |                    |                   |                   |                      |                      |                         |                         |                   |                   |
| Median Survival (months) | 9.33               | 2.28               | 10.09             | 7.36              | 5.65                 | 7.43                 | 15.74                   | 5.13                    | 12.17             | 5.95              |
| HR (95% CI)              | 0.37 (0.14, 0.95)  | 0.37 (0.14, 0.95)  | 0.71 (0.42, 1.20) |                   | 0.98 (0.64, 1.51     | 0.98 (0.64, 1.51     | 0.46 (0.21, 0.97)       | 0.46 (0.21, 0.97)       | 0.48 (0.26, 0.86) | 0.48 (0.26, 0.86) |
| CR                       |                    |                    |                   |                   |                      |                      |                         |                         |                   |                   |
| (%) u                    | 2 (18.2)           | 3 (25.0)           | 19 (46.3)         | 10 (27.0)         | 13 (26.0)            | 10 (18.2)            | 12 (57.1)               | 7 (36.8)                | 11 (36.7)         | 10 (30.3)         |
| OR (95% CI)              | 0.67 (0.09, 4.99   | 0.67 (0.09, 4.99   | 2.33 (0.90, 6.03) | 2.33 (0.90, 6.03) | 1.58 (0.62, 4.02)    | 1.58 (0.62, 4.02)    | 2.29 (0.64, 8.15)       | 2.29 (0.64, 8.15)       | 1.33 (0.47, 3.81) | 1.33 (0.47, 3.81) |
| CRi                      |                    |                    |                   |                   |                      |                      |                         |                         |                   |                   |
| (%) u                    | 2 (18.2)           | 0(0)               | 4 (9.8)           | 2 (5.4)           | 5 (10.0)             | 8 (14.5)             | 2 (9.5)                 | 0(0)                    | 3 (10.0)          | 2 (6.1)           |
| MLFS                     |                    |                    |                   |                   |                      |                      |                         |                         |                   |                   |
| n (%)                    | 5 (55.6)           | 3 (37.5)           | 23 (65.7)         | 14 (45.2)         | 28 (68.3)            | 26 (57.8)            | 14 (73.7)               | 11 (78.6)               | 17 (77.3)         | 12 (57.1)         |
| OR (95% CI)              | 2.08 (0.30, 14.55) | 2.08 (0.30, 14.55) | 2.33 (0.86, 6.29) | 2.33 (0.86, 6.29) | 1.57 (0.65, 3.81)    | 1.57 (0.65, 3.81)    | 0.76 (0.15, 3.92)       | 0.76 (0.15, 3.92)       | 2.55 (0.68, 9.54) | 2.55 (0.68, 9.54) |
| HSCT                     |                    |                    |                   |                   |                      |                      |                         |                         |                   |                   |
| n (%)                    | 3 (27.3)           | 0(0)               | 17 (41.5)         | 11 (29.7)         | 14 (28.0)            | 14 (25.5)            | 7(33.3)                 | 5 (26.3)                | 11 (36.7)         | 9 (27.3)          |
| OR (95% CI)              | Not Evaluable      | Not Evaluable      | 1.67 (0.65, 4.28) | 1.67 (0.65, 4.28) | 1.14 (0.48, 2.71)    | 1.14 (0.48, 2.71)    | 1.40 (0.36, 5.49)       | 1.40 (0.36, 5.49)       | 1.54 (0.53, 4.49) | 1.54 (0.53, 4.49) |

Abbreviations: CR = complete response; CRi = complete response with incomplete neutrophil or platelet recovery, HSCT = hematopoietic stem cell transplant; MLFS = morphologic leukemia free state; OR = odds ratio

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 20. Summary of efficacy for trial CLTR0310-301

| Title : A phase 3, multicenter, randomised, trial of Vyxeos(cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML.   | Title : A phase 3, multicenter, randomised, trial of Vyxeos(cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML.   | Title : A phase 3, multicenter, randomised, trial of Vyxeos(cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                      | CLTR0310-301                                                                                                                                                                                                          | CLTR0310-301                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                                | Randomised, open-label, parallel-arm, standard therapy-controlled                                                                                                                                                     | Randomised, open-label, parallel-arm, standard therapy-controlled                                                                                                                                                     |
| Design                                                                                                                                                                                                                | Duration of main phase:                                                                                                                                                                                               | treatment phase (168-224 days)                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                | Duration of Run-in phase:                                                                                                                                                                                             | not applicable                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                | Duration of Extension phase:                                                                                                                                                                                          | Follow-up phase: 30 days after the completion of the last induction or consolidation course, and was to last until death or 5 years after randomization.                                                              |
| Hypothesis                                                                                                                                                                                                            | Superiority                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                                                                     | Vyxeos(cytarabine:daunorubicin) liposome injection                                                                                                                                                                    | IV (90 min infusion) 1st Induction: 100 units/m 2 /day, Days 1, 3 and 5 2nd Induction: 100 units/m 2 /day, Days 1 and 3 Consolidation (up to 2 courses): 65 units/m 2 /day, Days 1 and 3                              |

<div style=\"page-break-after: always\"></div>

Endpoints and

definitions

Database lock

## Results and Analysis

| Analysis description                            | Primary Analysis                | Primary Analysis            | Primary Analysis            |
|-------------------------------------------------|---------------------------------|-----------------------------|-----------------------------|
| Analysis population and time point description  | Intention to treat (N= 309)     | Intention to treat (N= 309) | Intention to treat (N= 309) |
| Descriptive statistics and estimate variability | Treatment group                 | Vyxeos                      | 7+3                         |
| Descriptive statistics and estimate variability | Number of subjects              | 153                         | 156                         |
| Descriptive statistics and estimate variability | Median OS (months)              | 9.56                        | 5.95                        |
| Descriptive statistics and estimate variability | 95% CI                          | 6.60 , 11.86                | 4.99 , 7.75                 |
| Descriptive statistics and estimate variability | Median EFS (months)             | 2.53                        | 1.31                        |
| Descriptive statistics and estimate variability | 95% CI                          | 2.07 , 4.99                 | 1.08 , 1.64                 |
| Descriptive statistics and estimate variability | Response Rate n (%)             | 73 (47.7)                   | 52 (33.3)                   |
| Descriptive statistics and estimate variability | Remission duration (months)     | 6.93                        | 6.11                        |
| Descriptive statistics and estimate variability | 95%                             | 4.60, 9.23                  | 3.45, 8.71                  |
| Descriptive statistics and estimate variability | MLFS n (%)                      | 87 (69)                     | 66(55.5)                    |
| Descriptive statistics and estimate variability | Stem cell transplant rate n (%) | 52 (34)                     | 39 (25)                     |
| Effect estimate per comparison                  | OS                              | Comparison groups           | Vyxeos vs 7+3               |
| Effect estimate per comparison                  | OS                              | HR                          | 0.69                        |
| Effect estimate per comparison                  | OS                              | 95% CI                      | 0.52 , 0.90                 |
| Effect estimate per comparison                  | OS                              | p-value (2-sided)           | 0.005                       |
| Effect estimate per comparison                  | EFS                             | Comparison groups           | Vyxeos vs 7+3               |
| Effect estimate per comparison                  | EFS                             | HR                          | 0.74                        |
| Effect estimate per comparison                  | EFS                             | 95% CI                      | 0.58 , 0.96                 |
| Effect estimate per comparison                  | EFS                             | p-value (2-sided)           | 0.021                       |
| Effect estimate per comparison                  | Response                        | Comparison groups           | Vyxeos vs 7+3               |
| Effect estimate per comparison                  | Rate                            | Odds ratio                  | 1.77                        |

Cytarabine plus Daunorubicin

(referred to as '7+3')

7 + 3 / 5 + 2, IV (control)

Primary

Overall Survival endpoint

Secondary endpoints

1st Induction:

Cytarabine 100 mg/m 2 /day, 7-day continuous infusion

Daunorubicin 60 mg/m 2 /day, Days 1, 2 and 3

2nd Induction:

Cytarabine 100 mg/m 2 /day, 5-day continuous infusion

Daunorubicin 60 mg/m 2 /day, Days 1 and 2

Consolidation (up to 2 courses):

Cytarabine 100

mg/m2/day, 5-day continuous infusion

Daunorubicin 60 mg/m 2 /day, Days 1 and 2

Duration from the date of randomization to death

(OS)

from any cause.

Event Free Survival

Duration from study randomization to the date of

(EFS)

induction treatment failure (persistent disease), relapse from CR or CRi or death from any cause,

whichever came first.

Proportion of subjects who achieved CR or CRi following induction treatment

Remission duration Duration from the date of achievement of a remission

(CR or CRi) until the date of relapse or death from any cause.

Proportion of subjects achieved a

MLFS. MLFS defined as bone marrow blasts &lt; 5% and the absence of Auer rods and/or extramedullary

disease.

The number and percentage of subjects transferred for HSCT after induction treatment

Response Rate

Morphologic

Leukemia-free state

(MLFS)

Stem Cell

Transplant Rate

31 December 2015

<div style=\"page-break-after: always\"></div>

|       |                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                         | 1.11, 2.81                                                                                                                                                                                                                                                                                                     |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       |                                                                                                                                                                                                                                                                                                                | p-value (2-sided)                                                                                                                                                                                                                                                                                              | 0.016                                                                                                                                                                                                                                                                                                          |
|       | Remission                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                              | Vyxeos vs 7+3                                                                                                                                                                                                                                                                                                  |
|       | Duration                                                                                                                                                                                                                                                                                                       | HR                                                                                                                                                                                                                                                                                                             | 0.77                                                                                                                                                                                                                                                                                                           |
|       |                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                         | 0.47 , 1.26                                                                                                                                                                                                                                                                                                    |
|       |                                                                                                                                                                                                                                                                                                                | p-value (2-sided)                                                                                                                                                                                                                                                                                              | 0.294                                                                                                                                                                                                                                                                                                          |
|       | MLFS                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                              | Vyxeos vs 7+3                                                                                                                                                                                                                                                                                                  |
|       |                                                                                                                                                                                                                                                                                                                | Odds ratio                                                                                                                                                                                                                                                                                                     | 1.78                                                                                                                                                                                                                                                                                                           |
|       |                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                         | 1.05, 3.03                                                                                                                                                                                                                                                                                                     |
|       |                                                                                                                                                                                                                                                                                                                | p-value (1-sided)                                                                                                                                                                                                                                                                                              | 0.017                                                                                                                                                                                                                                                                                                          |
|       | Stem Cell                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                              | Vyxeos vs 7+3                                                                                                                                                                                                                                                                                                  |
|       | Transplant                                                                                                                                                                                                                                                                                                     | Odds ratio                                                                                                                                                                                                                                                                                                     | 1.54                                                                                                                                                                                                                                                                                                           |
|       | Rate                                                                                                                                                                                                                                                                                                           | 95% CI                                                                                                                                                                                                                                                                                                         | 0.92, 2.56                                                                                                                                                                                                                                                                                                     |
|       |                                                                                                                                                                                                                                                                                                                | p-value (2-sided)                                                                                                                                                                                                                                                                                              | 0.097                                                                                                                                                                                                                                                                                                          |
| Notes | Stratification factors: Age (60-69 vs 70-75) and AML type t-AML ( MDS AML with documented history of MDS with prior treatment with hypomethylating agents vs MDS AML with documented history of MDS without prior treatment with hypomethylating agents vs de novo AML with karyotype characteristic of MDS vs | Stratification factors: Age (60-69 vs 70-75) and AML type t-AML ( MDS AML with documented history of MDS with prior treatment with hypomethylating agents vs MDS AML with documented history of MDS without prior treatment with hypomethylating agents vs de novo AML with karyotype characteristic of MDS vs | Stratification factors: Age (60-69 vs 70-75) and AML type t-AML ( MDS AML with documented history of MDS with prior treatment with hypomethylating agents vs MDS AML with documented history of MDS without prior treatment with hypomethylating agents vs de novo AML with karyotype characteristic of MDS vs |

## Clinical studies in special populations

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   |   Age 85+ (Older subjects number /total number) |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     | 298/323                                           | 30/41                                             |                                               0 |
| Non Controlled trials | 25/323                                            | 11/41                                             |                                               0 |

## Supportive studies

## · Study 204

This was a Phase 2 multicenter, randomised, open-label, parallel-arm, fixed-dose study in subjects between 60 and 75 years with newly diagnosed AML (de novo or secondary).

Subjects were randomised 2:1 to receive either CPX-351or standard induction (7 + 3) stratified by standard or high risk category: High risk: &gt; 70 years, prior hematologic disorder, ≥ 3 cytogenetic abnormalities at baseline and standard risk: all other subjects

The primary objective was to estimate the rate of response and confirm the safety of Vyxeos compared with 7 + 3 as first line therapy in elderly patients with standard or high risk AML. Secondary objectives were to determine OS, EFS and CR duration, the rate of aplasia after 1 or 2 inductions and  effectiveness of Vyxeos on response between de novo AML and secondary AML.

The primary endpoint CR used the same assessment criteria as that for Study 301.

Patients had a treatment phase (up to 2 inductions and 2 consolidations) and a follow-up Phase (from approx. 30 days after last induction or consolidation for up to 2 years from randomization).

<div style=\"page-break-after: always\"></div>

- Vyxeos arm: 100 units/m 2  IV over 90 minutes on Days 1, 3, and 5 for the first induction and on days 1 and 3 for second induction. For consolidation, 100 units/m 2 on Days 1 and 3.
- 7 + 3 arm: first induction with cytarabine 100 mg/m 2 /day on Days 1 through 7 by continuous infusion, and daunorubicin 45 to 60 mg/m 2 /day on Days 1, 2, and 3. For second induction and consolidation cytarabine was dosed on days 1 through 5 and daunorubicin on Days 1 and 2.

Subjects in the control arm were permitted to cross over to receive Vyxeos if a response was not achieved after 2 induction courses or after 1 induction if investigators determined response to a second induction would be unlikely. Efficacy data were analysed based on assigned treatment. The data after crossover were excluded from analyses. A total of 127 subjects were randomised, 86 to Vyxeos and 41 to 7 + 3.  The efficacy analysis set (any subject randomised and treated with Vyxeos or 7+3) included 125 subjects (84 subjects in Vyxeos, 41 subjects in 7 + 3). After 1 or 2 inductions, 10 subjects from the 7 + 3 group crossed over to the Vyxeos group. Mean (SD) age was 67.9 (4.69) years. Baseline demographics and disease characteristics (AML type, stratification risk, cytogenetic risk, and ECOG performance status) were well balanced across treatment groups.  The majority of patients were high risk (61%), intermediate cytogenetics risk (68%) and had de novo AML (65%).

## Results

The efficacy results are summarised below.

Table 25 Efficacy results (Efficacy Evaluable Analysis Set -Study 204)

|                                                           | Number of Subjects     | Number of Subjects     |
|-----------------------------------------------------------|------------------------|------------------------|
|                                                           | CPX-351 N= 84          | 7+3 N=41               |
| PrimaryEndpoint                                           |                        |                        |
| Morphologic Complete Remission (CR) n (%) 95% CI p-valuea | 41 (48.8) (37.7, 60.0) | 20 (48.8) (32.9, 64.9) |
| SecondaryEfficacyEndpoints                                |                        |                        |
| Remission Duration (days)                                 |                        |                        |
| n                                                         | 56 275                 | 21 235                 |
| Median                                                    |                        |                        |
| Min, Max                                                  | 40,730                 | 36,703                 |
| Time to Remission (days)                                  |                        |                        |
| n                                                         | 56                     | 21                     |
| Median                                                    | 49                     | 40                     |
| Min, Max                                                  | 32,163                 | 21, 89                 |
| PatientwithAplasiaDuring theStudy,n(%)                    | 60 (71.4)              | 17 (41.5)              |
| Aplasia at Day 14 (First Induction)                       | 55 (65.5)              | 15 (36.6)              |
| NumberwithStemCellTransplant                              | 13 (15.5%)             | 10 (24.4%)             |
| CR, n (%)                                                 | 41 (48.84)             | 20 (48.8)              |
| Received Stem Cell Transplant                             | 10 (24.4)              | 4 (20.0)               |
| Did not Receive Stem Cell Transplant                      | 31 (75.6)              | 16 (80.0)              |
| CRi, n (%)                                                | 15 (17.9)              | 2 (4.9)                |
| Received Stem Cell Transplant                             | 2 (13.3)               | 1 (50.0)               |
| Did not ReceiveStem Cell Transplant                       | 13 (86.7)              | 1 (50.0)               |
| < CRi, n (%)                                              | 28 (33.3)              | 20 (48.8)              |
| Received Stem Cell Transplant                             | 1 (3.6)                | 5 (25.0)               |
| Did not Receive Stem Cell Transplant                      | 27 (96.4)              | 15 (75.0)              |

<div style=\"page-break-after: always\"></div>

EFS at 1 year (Efficacy Evaluable Set) showed a median EFS 161 days for Vyxeos and 55 days for 7 + 3 (p=0.0971), HR 0.70 (95% CI (0.5, 1.1). Improved EFS for CPX 351 was seen in both age groups.

The Kaplan-Meier estimate for median survival could not be estimated for any treatment group as the median was not reached because of insufficient follow up. The HR of OS at 1 year for the Vyxeos versus 7 + 3 was 0.89 (95% CI 0.5, 1.6). The Vyxeos and 7 + 3 treatment groups had 39/84 (46.4%) and 18/41 (43.9%) deaths at 1 year, respectively.

## Study 205

This was a Phase 2 multicenter, randomised, open-label, parallel-arm, active controlled study in patients between the ages of 18 and 65 with AML in first relapse. Subjects were stratified according to the European Prognostic Index and age, and received either Vyxeos or intensive salvage therapy.

The primary objective was to estimate the efficacy of Vyxeos compared with intensive salvage therapy in patients with AML in first relapse. Primary endpoint was survival at 1-year but the study was not powered to detect a statistically significant difference. Secondary variables included CR (including CRi) rate and duration, EFS, rate of aplasia, and rate of transfer for stem cell transplant.

Subjects were permitted to receive up to 2 inductions and 2 consolidations. The study comprised a treatment phase (up to 2 inductions and up to 2 consolidations) and a follow-up phase, from the completion of the treatment phase, and lasted for 1 year from the date of randomization. Only subjects with recovery from all the therapy related nonhematologic AEs and documented CR or CRi were eligible for consolidation.

The dose of Vyxeos was 100 units/m 2  by 90 minute IV infusion, on Days 1, 3, and 5 for the first induction and on Days 1 and 3 for a second induction or consolidation. Intensive salvage therapy (was chosen by the investigator.

## Results

A total of 126 subjects were randomised, Vyxeos (81 subjects) and salvage therapy (45 subjects). The efficacy evaluable analysis set included the 81 subjects in the Vyxeos treatment and 44 subjects in the salvage group who received at least 1 dose of study medication.

The demographic characteristics of the subjects were similar in the 2 treatment groups. Subjects had a mean (SD) age of 50.2 (11.57) years, ranging from 20 to 66 years; most subjects (82%) were between 18 and 60 years old, had de novo AML (89.6%) or of intermediate cytogenetics risk (60.5%).

The proportion of subjects surviving at 1 year, the primary endpoint, was higher in the Vyxeos arm (35.8%, 29/81 subjects) than in the salvage therapy arm (27.3%, 12/44 subjects), but the difference was not statistically significant (p = 0.43; Fisher ' s Exact). The median survival was 259 days (8.51 months) in the Vyxeos and 191 days (6.28 months) in the salvage arm (p=0.19; based on log rank test; HR of survival by 1-year was 0.75 with 95% CI of [0.5, 1.2]).

The rates of CR (37.0% vs 31.8%, respectively), CRi (12.3% vs 9.1%), and CR or CRi (49.4% vs 40.9%) indicated clinical improvement in the Vyxeos arm compared with salvage therapy, but the differences were not significant. The median duration of remission for subjects who achieved CR or Cri  was 301 days in the Vyxeos arm and 259 days in the salvage arm. Median EFS was longer in the Vyxeos arm (75 days) than in the salvage (43 days), HR of 0.67 (95% CI of [0.4, 1.0], p=0.06) for EFS by 1-year.The rates of aplasia at any time during the study and at Day 14 (first induction) were higher in the Vyxeos arm than in the salvage arm (76.5% vs 54.5%, respectively, at any time and 75.3% vs 52.3%, respectively, at Day 14). The

<div style=\"page-break-after: always\"></div>

percentage of subjects transferred to stem cell transplant was similar in the 2 arms: 46.9% in the Vyxeos arm and 47.4% in the salvage arm.

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

This application is supported by a single phase III clinical study (301) and the overall design is considered adequate.

The patient population has been adequately selected and reflects those patients with high risk AML with documented prior haematological disorder as defined in the proposed indication. The pivotal study included only patients without prior anti-AML treatment and who were above 60 years of age. The comparator was the standard 7+ 3 regimen which is appropriate and allows a clear comparison of the liposomal formulation combination of cytarabine and daunorubicin versus the two components administered separately.  The choice of endpoints with OS as primary is satisfactory considering the poor prognosis in this type of AML population. All other secondary endpoints are also considered adequate.

There is sufficient follow up for data maturity and to allow comprehensive assessment of results. The conduct of the study appears adequate and there are no concerns. Overall, the study design is in line with the main CHMP anti-cancer guideline and followed previous CHMP scientific advice.

The phase II study 205 provides supportive data of Vyxeos in patients with AML (de novo or secondary) above 18 years of age and in first relapse.

The proposed dose of Vyxeos and the regimen schedule, as administered in the pivotal study, have been justified by a dose finding study (101), data from earlier phase II studies (204 and 205) and an exposure dose analysis and it is considered acceptable.

## Efficacy data and additional analyses

Both arms in the pivotal study were balanced with regards to baseline demography and disease characteristics. A significant improvement of 3.6 months in OS with Vyxeos compared to the 7+3 standard treatment has been demonstrated in the pivotal study ITT population (median OS 9.56 months vs 5.95 months; HR = 0.69, 95% CI : 0.52 to 0.90, 1-sided p = 0.003). This is a clinically relevant effect as the 7+3 treatment has been the standard for over four decades and no therapy has shown to offer superior efficacy. The OS benefit was seen across all randomization strata or those with the adverse risk FLT3 mutation, except for the MDS AML with prior hypomethylating agent therapy.

The favourable result is OS is supported by the outcome in secondary endpoints. A significantly greater proportion of subjects in the Vyxeos group achieved CR or CR+ CRi compared with the 7+3 group (CR 37.3% vs 25.6%; CR+CRi 47.7% vs. 33.3%). No clinical differences were seen in remission duration between Vyxeos vs 7+3 (median 6.93 months vs. 6.11 months). Favourable results for Vyxeos versus 7+3 treatment were also documented for EFS (median 2.53 months vs 1.31 months, HR = 0.74, 1-sided p = 0.011), achieving a morphologic leukaemia free state (69.0% vs. 55.5%) or the rate of bridging to transplant (52 [34.0%] vs. 39 [25.0%]).

More patients in the Vyxeos treatment group received a HSCT in CR or CRi compared with patients in CR or CRi for the 7+3 regimen (54.8% vs. 46.2%, respectively).

<div style=\"page-break-after: always\"></div>

An analysis landmarked at the time of SCT, showed that subjects who received a HSCT in the Vyxeos treatment group had significantly longer OS than the 7+3 group (HR=0.46, p = 0.009, 1-sided) with median survival not reached in the Vyxeos versus 10.25 months for 7+3. It is known that survival in high risk AML increases if the patient undergoes transplant, especially if achieved CR after induction.

Overall the results across randomization data favoured Vyxeos over 7+3, especially across age subgroups. Most but not all the analyses across stratification subgroups showed positive outcome for Vyxeos. For the subgroup of patients with prior MDS treated with hypomethylating agents the control arm had a longer median OS than the experimental arm (7.43 m vs 5.65 m) despite the slight favourable results for CPX 351 on CR/CRi, MLFS and patients receiving SCT. It is noted that the HR does not favour the control arm (0.98) and results in subgroups not powered for confirmatory efficacy should always be viewed with caution as some will be in the opposite direction just by chance.

Overall, the results from study 301 support the indication in untreated patients with high risk AML as defined by therapy-related or with myelodysplasia changes. Although this study was conducted in patients of 60 years up to 75 years no clinically differences in outcome were seen across both age subgroups (60-69 years/70-75 years). PK data did not show variability with regards to age covariate and free fractions of the active substances relative to the encapsulated active substances are similar in the studied population to that of adults below the age of 60 years. In addition, data from study 205 in AML patients in first relapse showed a beneficial trend with Vyxeos versus salvage therapy (consisting mainly of cytarabine and an anthracycline and another agent) in patients below 65 years, the majority below 60 years. Vyxeos is an optimised liposomal formulation of cytarabine and daunorubicin which is used to treat in AML of all ages fit for intensive chemotherapy although newly diagnosed younger patients may receive a more intensive treatment such as cytarabine + anthracycline + a third agent. On the other hand, there is no possible rationale why the results seen in study 301 cannot be extrapolated to adults of 18 years up to 60 years if they were to receive the standard 7+3. It appears there are no differences in disease biology with regards to t-AML and AML-MRC between age's subgroups in adults.

A point to mention is that Vyxeos is a more convenient therapy administered as 90 minutes' infusions on separate days instead of the 7-days or 5-days continuous infusion cytarabine (with additional daunorubicin administration) of the standard 7+3.

No data are available on the use of Vyxeos in children and this has been reflected in the SmPC.

## 2.5.4. Conclusions on the clinical efficacy

Efficacy of Vyxeos in the proposed dose/schedule in adult patients with untreated therapy-related AML or AML with myelodysplasia-related changes has been demonstrated.

## 2.6. Clinical safety

A total of 629 subjects were treated in the clinical studies and out of these, 403 subjects received at least one dose of Vyxeos.

Safety data are presented for the pooled safety population that included all subjects in clinical studies 101, 204, 205, 206 and 301 who received at least one dose of 100 or 101 units/m 2  of Vyxeos. The 101 units/m 2 dose is considered the same as the 100 units/m 2  dose. In Study 204, 10 subjects from the 7 + 3 group crossed over to Vyxeos and their data collected during treatment with 7 + 3 were summarised with 7 + 3, and data collected after cross over were summarised with Vyxeos.

<div style=\"page-break-after: always\"></div>

The pooled population includes a broad range of AML patients with different AML subtypes, newly diagnosed and relapsed patients and of an age range of 18 to 80 years.

## Patient exposure

The overall extend of exposure is displayed in Table 27.

Table 26 Overall Extent of exposure (Pooled safety population)

|                                                                    | Induction Period              | Induction Period              | ConsolidationPeriod                | ConsolidationPeriod                 | ConsolidationPeriod                  | Treatnent Period                     | Treatnent Period                     |
|--------------------------------------------------------------------|-------------------------------|-------------------------------|------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
|                                                                    | CPX-351 100 units/m² N=375    | All Controlsb N=236           | CPX-351 65 units/m² N=52           | CPX-351 100 umits/m² N=63           | All Controlsb N=55                   | CPX-351 N=375                        | All Controls N=236                   |
| Exposure (days) Mean (SD)                                          | 3.5 (0.92)                    | 8.9 (3.05)                    | 3.0 (1.08)                         | 2.6 (0.91)                          | 8.0 (2.85)                           | 4.3 (1.57)                           | 10.8 (4.54)                          |
| Median (Min, Max)                                                  | 3.0 (1, 8)                    | 8.0 (2, 16)                   | 2.5 (2, 6)                         | 2.0 (2, 4)                          | 6.0 (3, 14)                          | 3.0 (1.9)                            | 8.0 (2, 23)                          |
| Inductions 1 Inductiona                                            | 289 (77.1)                    | 170 (72.0) 66 (28.0)          | NA NA                              | NA NA                               | NA NA                                | 289 (77.1) 85 (22.7)                 | 170 (72.0)                           |
| 2 Inductions                                                       | 85 (22.7)                     |                               |                                    |                                     |                                      |                                      | 66 (28.0)                            |
| Consolidations 1 Consolidation                                     | NA                            | NA                            | 27 (51.9)                          | 45 (71.4)                           | 29 (52.7)                            | 72 (19.2)                            | 29 (12.3)                            |
| 2 Consolidations                                                   | NA                            | NA                            | 24 (46.2)                          | 18 (28.6) 0                         | 26 (47.3)                            | 42 (11.2) 1 (0.3)                    | 26 (11.0)                            |
| ≥3Consolidations CunulativeNunber of                               | NA                            | NA                            | 1(1.9)                             |                                     | 0                                    |                                      | 0                                    |
| Infusions per Subject Mean (SD) Median (Min, Max)                  | 3.5 (0.92) 3.0 (1, 8)         | 1.3 (0.45) 1.0 (1, 2)         | 3.1 (1.15)                         | 2.6 (0.91)                          | 1.5 (0.50)                           | 4.3 (1.59)                           | 1.6 (0.77)                           |
| CunulativeDoseof Daunorubicin (mg/m2)f Mean (SD) Median (Min, Max) | 152.11                        | 212.98                        | 3.0 (2. 6)                         | 2.0 (2, 4)                          | 1.0 (1, 2)                           | 3.0 (1, 9)                           | 1.0 (1, 4)                           |
|                                                                    | (40.556) 132.00 (43.8, 353.7) | (57.198) 180.00 (43.8, 308.9) | 85.30 (30.452) 86.98 (51.5, 165.8) | 107.61 (40.974) 88.00 (41.8, 179.8) | 162.34 (59.752) 120.00 (85.6, 261.5) | 181.79 (59.867) 133.63 (43.8, 387.6) | 243.78 (85.586) 181.82 (43.8, 531.7) |
| CPX-351(units/m2) Mean (SD)                                        |                               | NA                            |                                    |                                     | NA                                   |                                      | NA                                   |
|                                                                    | 345.71 (92.174)               |                               | 193.87 (69.209)                    | 244.58 (93.122)                     |                                      | 413.17 (136.062)                     |                                      |
| Median (Min, Max)                                                  | 300.00 (99.5, 803.8)          | NA                            | 197.68 (117.1, 376.9)              | 200.00 (95.0, 408.7)                | NA                                   | 303.70 (99.5, 880.9)                 | NA                                   |

The CPX-351 65 units/m² consolidation dose was tested in Study 206 and Study 301. The CPX-351 100 umits/m² consolidation dose was tested in Study 101 (101 umits/m), Study 204, and Study 205.

Abbreviations: Max =maximum; Min =minimum.

In the pivotal study 301 all subjects received an initial induction, approximately one-third in both arms received a second induction and more subjects in the Vyxeos group received both an initial and second consolidation than in the 7+3 (Table 28).

Table 27 Study 301: Exposure to experimental agents (safety population- CLTR0310-301)

|                                            | CPX-351 N=153   | 7+3 N=151   |
|--------------------------------------------|-----------------|-------------|
| First induction, n (%)                     | 153 (100)       | 151 (100)   |
| Second induction, n (%)                    | 48 (31)         | 51 (34)     |
| Fir'stconsolidation,n (%)                  | 49 (32)         | 32 (21)     |
| Second consolidation,n (%o)                | 23 (15)         | 12 (7.9)    |
| Cumulative dose                            |                 |             |
| CPX-351, median (units)                    | 814             |             |
| Cytarabine, median (mg)                    |                 | 1743.0      |
| Daunorubicin,median (mg)                   |                 | 447.0       |
| Length of treatment exposure,median (days) | 19.00           | 10.00       |
| Length of treatment phase, median (days)   | 62.00           | 41.00       |

Length of treatment exposure=last date of experimental agent administration-first date of experimental agent.

Length of treatment phase=date ofend of treatment phase-first dateofexperimental agent +1.

<div style=\"page-break-after: always\"></div>

## Adverse events

In the Pooled Safety population, all subjects reported at least 1 TEAE (Table 29).

Table 28 Overall Summary of Treatment Emergent AE (Pooled Safety Population)

|                               | Nunber of subjects, n (%)   | Nunber of subjects, n (%)   | Nunber of subjects, n (%)   | Nunber of subjects, n (%)   | Nunber of subjects, n (%)   | Nunber of subjects, n (%)   | Nunber of subjects, n (%)   |
|-------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                               | InductionPeriod             | InductionPeriod             | ConsolidationPerioda        | ConsolidationPerioda        | ConsolidationPerioda        | Treatiment Period           | Treatiment Period           |
|                               | CPX-351 100 units/m2 N=375  | All Controls N=236          | CPX-351 65 umits/m² N=52    | CPX-351 100 umits/m2 N=63   | All Controls N=55           | CPX-351 N=375               | All Controls N=236          |
| Any TEAEsb                    | 375 (100)                   | 236 (100)                   | 44 (84.6)                   | 61 (96.8)                   | 49 (89.1)                   | 375 (100)                   | 236 (100)                   |
| TEAEsby MaximunNCI-CTC        | 375 (100)                   | 236 (100)                   | 44 (84.6)                   | 61 (96.8)                   | 49 (89.1)                   | 375 (100)                   | 236 (100)                   |
| Grade\"                        |                             |                             |                             |                             |                             |                             |                             |
| Grade 1                       | 2 (0.5)                     | 4 (1.7)                     | 12 (23.1)                   | 6 (9.5)                     | 5 (9.1)                     | 2 (0.5)                     | 4 (1.7)                     |
| Grade 2                       | 31 (8.3)                    | 21 (8.9)                    | 4 (7.7)                     | 9 (14.3)                    | 14 (25.5)                   | 27 (7.2)                    | 20 (8.5)                    |
| Grade 3                       | 251 (66.9)                  | 158 (66.9)                  | 20 (38.5)                   | 36 (57.1)                   | 17 (30.9)                   | 239 (63.7)                  | 150 (63.6)                  |
| Grade 4                       | 63 (16.8)                   | 28 (11.9)                   | 7 (13.5)                    | 5 (7.9)                     | 9 (16.4)                    | 73 (19.5)                   | 33 (14.0)                   |
| Grade 5                       | 28 (7.5)                    | 25 (10.6)                   | 1(1.9)                      | 5 (7.9)                     | 4(7.3)                      | 34 (9.1)                    | 29 (12.3)                   |
| Grade 3 to 5                  | 342 (91.2)                  | 211 (89.4)                  | 28 (53.8)                   | 46 (73.0)                   | 30 (54.5)                   | 346 (92.3)                  | 212 (89.8)                  |
| TEAEs by Closest Relationship |                             |                             |                             |                             |                             |                             |                             |
| Not related                   | 13 (3.5)                    | 16 (6.8)                    | 8 (15.4)                    | 12 (19.0)                   | 10 (18.2)                   | 12 (3.2)                    | 16 (6.8)                    |
| Related                       | 362 (96.5)                  | 220 (93.2)                  | 36 (69.2)                   | 49 (77.8)                   | 39 (70.9)                   | 363 (96.8)                  | 220 (93.2)                  |
| SeriousTEAEs                  | 145 (38.7)                  | 76 (32.2)                   | 25 (48.1)                   | 33 (52.4)                   | 24 (43.6)                   | 189 (50.4)                  | 91 (38.6)                   |
| TEAEsleadingtodiscontinuation | 7 (1.9)                     | 3 (1.3)                     | 0                           | 0                           | 0                           | 7 (1.9)                     | 3 (1.3)                     |
| TEAEsleading to death         | 28 (7.5)                    | 25 (10.6)                   | 1 (1.9)                     | 5 (7.9)                     | 4 (7.3)                     | 34 (9.1)                    | 29 (12.3)                   |

Abbreviations: AE = adverse event; NCI-CTC = National Cancer Institute Common Terminology Criteria; SAE = serious adverse event; TEAE = treatment emergent adverse event.

The CPX-351 65 units/m consolidation dose was tested in Study 206 and Study 301. The CPX-351 100 umits/m² consolidation dose was tested in Study 101 (101 umits/m),Study204,and Study 205.

For SAEs orAEs identified as a bleeding event, a cardiac event,infection orrash, aTEAE is defined as anAE that startedafter the first dose of induction 1. For all other AEs, a TEAE is defined as an AE that started after the first dose of induction 1 and not more than 30 days after the last dose date.

If a subject experiences an AE with more than one relationship, the subject is counted only once in closest relationship category. Related category includes possibly, probably, and definitely related.

included subjects treated with 7+3 andSalvage therapy,during theConsolidationPeriod,Al1 Controls²included subjects treated with 5+ 2 andSalvage/ Other therapy; during the Treatment Period, *All Controls* included subjects treated with 7 + 3 and Salvage therapy.

<div style=\"page-break-after: always\"></div>

An overall summary of AEs for the safety population is displayed in Table 30.

Table 29 Study 301 Overall summary AE (safety analysis population)

|                                            | CPX-351 (N=153) n (&)   | 7+3 (N=151) n (%)   | AllPatients (N=304) n(&)   |
|--------------------------------------------|-------------------------|---------------------|----------------------------|
| Patients with AEs (any grade)              | 153 (100)               | 151 (100)           | 304 (100)                  |
| Patientsdiscontinueddue toanAE             | 3 (2.0)                 | 2 (1.3)             | 5 (1.6)                    |
| Patients with serious AEs                  | 06 (59)                 | 65 (43)             | 155 (51)                   |
| PatientswithGrade3AEs                      | 85 (56)                 | 92 (61)             | 177 (58)                   |
| PatientswithGrade4AEs                      | 25 (16)                 | 16 (11)             | 41 (13)                    |
| PatientswithGrade3or4AEs                   | 110 (72)                | 108 (72)            | 218 (72)                   |
| PatientswithGrade 5 AEs                    | 31 (20)                 | 29 (19)             | 60 (20)                    |
| PatientswithGrade5AEsduringTreatmentPeriod | 31 (20)                 | 29 (19)             | 60 (20)                    |
| PatientswithGrade5AEsduringFollow-up       | 19 (12)                 | 11 (7.3)            | 30 (9.9)                   |
| PatientswithrelatedAEs                     | 146 (95)                | 143 (95)            | 289 (95)                   |
| PatientswithGrade5 RelatedAEs              | 27 (18)                 | 27 (18)             | 54 (18)                    |
| PatientswithGrade 3，4or 5 AEs              | 141 (92)                | 137 (91)            | 278 (91)                   |

## · Common AEs

For Vyxeos the most frequently reported TEAEs by PT were febrile neutropenia (63.2%), nausea (51.2%), diarrhoea (45.6%), constipation (42.7%) and oedema peripheral (41.3%). In the All Controls group, the most frequently reported TEAEs by PT were diarrhoea (65.7%), febrile neutropenia (59.7%), nausea (53.4%), oedema peripheral (43.2%) and constipation (39.4%).

<div style=\"page-break-after: always\"></div>

Table 30 TEAEs reported in ≥ 10% of subjects in any treatment group, by system organ class and preferred term - treatment period (pooled safety population)

|                                                 |                     | Controls   | Controls   | Controls              |
|-------------------------------------------------|---------------------|------------|------------|-----------------------|
| SystemOrganClass PreferredTerm                  | CPX-351             | 7+3        | Salvage    | AllControls           |
|                                                 | N=375               | N=192      | N=44       | N=236                 |
| AnyTEAEsa                                       | 375 (100)           | 192 (100)  | 44 (100)   | 236 (100)             |
| BloodandLymphaticSystemDisorders                | 258 (68.8)          | 132 (68.8) | 19 (43.2)  | 151 (64.0) 141 (59.7) |
| Febrileneutropenia CardiacDisorders             | 237 (63.2)          | 126 (65.6) | 15 (34.1)  |                       |
|                                                 | 154 (41.1)          | 72 (37.5)  | 11 (25.0)  | 83 (35.2) 30 (12.7)   |
| Tachycardia                                     | 57 (15.2)           | 23 (12.0)  | 7 (15.9)   |                       |
| Atrialfibrillation                              | 26 (6.9)            | 20 (10.4)  | 1 (2.3)    | 21 (8.9)              |
| GastrointestinalDisorder's                      | 338 (90.1)          | 185 (96.4) | 39 (88.0)  | 224 (94.9)            |
| Nausea                                          | 192 (51.2)          | 103 (53.6) | 23 (52.3)  | 126 (53.4)            |
| Diarrhoea                                       | 171 (45.6)          | 129 (67.2) | 26 (59.1)  | 155 (65.7)            |
| Constipation                                    | 160 (42.7)          | 82 (42.7)  | 11 (25.0)  | 93 (39.4)             |
| Vomiting                                        | 103 (27.5)          | 43 (22.4)  | 16 (36.4)  | 59 (25.0)             |
| Abdominal pain                                  | 72 (19.2)           | 34 (17.7)  | 9 (20.5)   | 43 (18.2)             |
| Stomatitis                                      | 57 (15.2)           | 25 (13.0)  | 6 (13.6)   | 31 (13.1)             |
| Abdominal distention                            | 43 (11.5)           | 22 (11.5)  | 2 (4.5)    | 24 (10.2)             |
|                                                 |                     | 14 (7.3)   | 5 (11.4)   | 19 (8.1)              |
| Dyspepsia                                       | 32 (8.5)            |            |            |                       |
| GeneralDisorders andAdministrationSite          |                     |            |            |                       |
|                                                 | 338 (90.1)          | 171 (89.1) | 38 (86.4)  | 209 (88.6)            |
| Conditions Oedema peripheral                    | 155 (41.3)          | 91 (47.4)  | 11 (25.0)  | 102 (43.2)            |
| Fatigue                                         | 143 (38.1)          | 65 (33.9)  | 16 (36.4)  | 81 (34.3)             |
| Chills                                          | 117 (31.2)          | 54 (28.1)  | 10 (22.7)  | 64 (27.1)             |
| Pyrexia                                         | 109 (29.1)          | 39 (20.3)  | 13 (29.5)  | 52 (22.0)             |
| Mucosalinflammation                             | 54 (14.4)           | 32 (16.7)  | 9 (20.5)   | 41 (17.4)             |
| Asthenia                                        | 38 (10.1)           | 22 (11.5)  | 9 (20.5)   | 31 (13.1)             |
| InfectionsandInfestations                       | 289 (77.1)          | 130 (67.7) | 33 (75.0)  | 163 (69.1)            |
| Pneumonia                                       | 74 (19.7)           | 39 (20.3)  | 4 (9.1)    | 43 (18.2)             |
| Bacteraemia                                     | 40 (10.7)           | 6 (3.1)    | 4 (9.1)    | 10 (4.2)              |
| Injury,PoisoningandProceduralComplications      | 120 (32.0)          | 56 (29.2)  | 11 (25.0)  | 67 (28.4)             |
| Transfusionreaction                             | 29 (7.7)            | 16 (8.3)   | 6 (13.6)   | 22 (9.3)              |
| MetabolismandNutritionDisorder's                | 204 (54.4)          | 101 (52.0) | 27 (61.4)  | 128 (54.2)            |
| Decreased appetite                              | 127 (33.9)          | 76 (39.6)  | 14 (31.8)  | 90 (38.1)             |
| Hypokalaemia                                    | 47 (12.5)           | 14 (7.3)   | 5 (11.4)   | 19 (8.1)              |
| Fluid overload                                  | 23 (6.1)            | 21 (10.9)  | 2 (4.5)    | 23 (9.7)              |
| MusculoskeletalandConnectiveTissueDisorders     | 181 (48.3)          | 85 (44.3)  | 17 (38.0)  | 102 (43.2)            |
| Backpain                                        | 54 (14.4)           | 24 (12.5)  | 6 (13.6)   | 30 (12.7)             |
| Arthralgia                                      | 50 (13.3)           | 9 (4.7)    | 3 (6.8)    | 12 (5.1)              |
| Paininextremity                                 | 44 (11.7)           | 17 (8.9)   | 6 (13.6)   | 23 (9.7)              |
| NervousSystemDisorder's                         | 239 (63.7)          | 103 (53.0) | 27 (61.4)  | 130 (55.1)            |
| Headache                                        | 120 (32.0)          | 45 (23.4)  | 15 (34.1)  | 60 (25.4)             |
| Dizziness                                       | 74 (19.7)           | 43 (22.4)  | 5 (11.4)   | 48 (20.3)             |
| Dysgeusia                                       | 23 (6.1)            | 13 (6.8)   | 5 (11.4)   | 18 (7.6)              |
| PsychiatricDisorders                            | 195 (52.0)          | 94 (49.0)  | 14 (31.8)  | 108 (45.8)            |
| Insomnia                                        | 85 (22.7)           | 43 (22.4)  | 10 (22.7)  | 53 (22.5)             |
| Anxiety                                         | 65 (17.3)           | 25 (13.0)  | 6 (13.6)   | 31 (13.1)             |
| Confusionalstate                                | 44 (11.7)           | 26 (13.5)  | 1 (2.3)    | 27 (11.4)             |
| Respiratory,Thoracic and Mediastinal Disorder's | 292 (77.9)          | 141 (73.4) | 25 (56.8)  | 166 (70.3)            |
| Cough                                           | 118 (31.5)          | 37 (19.3)  | 10 (22.7)  | 47 (19.9)             |
| Epistaxis                                       | 111 (29.6)          | 35 (18.2)  | 12 (27.3)  | 47 (19.9)             |
| Dyspnoea                                        | 86 (22.9)           | 37 (19.3)  | 4 (9.1)    | 41 (17.4)             |
| Hypoxia                                         | 60 (16.0)           | 35 (18.2)  | 1 (2.3)    | 36 (15.3)             |
| Oropharyngeal pain                              | 60 (16.0)           | 22 (11.5)  | 6 (13.6)   | 28 (11.9)             |
| Pleural effusion                                | 52 (13.9)           | 32 (16.7)  | 2 (4.5)    | 34 (14.4)             |
| Skin andSubcutaneousTissueDisorder's            | 315 (84.0)          | 124 (64.6) | 26 (59.1)  | 150 (63.0)            |
|                                                 | 147 (39.2)          |            |            |                       |
| Rash                                            |                     | 48 (25.0)  | 10 (22.7)  | 58 (24.6)             |
| Petechiae                                       | 71 (18.9) 65 (17.3) | 23 (12.0)  | 6 (13.6)   | 29 (12.3) 23 (9.7)    |
| Hyperhidrosis                                   |                     | 19 (9.9)   | 4 (9.1)    | 15 (6.4)              |
| Alopecia                                        | 38 (10.1)           | 13 (6.8)   | 2 (4.5)    |                       |
| Vascular Disorders                              | 12 (3.2)            | 24 (12.5)  | 4 (9.1)    | 28 (11.9)             |
|                                                 | 172 (45.9)          | 87 (45.3)  | 13 (29.5)  | 100 (42.4)            |
| Hypotension                                     | 76 (20.3)           | 40 (20.8)  | 5 (11.4)   | 45 (19.1)             |
| Hypertension                                    | 57 (15.2)           | 29 (15.1)  | 6 (13.6)   | 35 (14.8)             |

Abbreviations: AE = adverse event; MedDRA =medical dictionary for regulatory activities; SAE = serious adverse event; TEAE =treatment emergent adverse event.

ForSAEsorAEsidentifiedasableedingevent,acardiacevent,infectionorrash,aTEAEisdefinedasanAE thatstartedafterthefirstdoseofinduction1.ForallotherAEs,aTEAEisdefinedasanAEthatstartedafterthe firstdoseofinduction1andnotmorethan30daysafterthelastdosedate.

Note: The°Al1 Controls'treatment groupincludes subjects from Study 204, Study 205, and Study 301whowere treated with 7 + 3 and / or Salvage therapy.

MedDRA version 16.0

<div style=\"page-break-after: always\"></div>

## · TEAEs ≥ Grade 3

A summary of the TEAEs of Grade ≥ 3 reported in at least 3% of subjects in any treatment group is displayed in Table 32.

Table 31 Treatment Emergent Adverse Events of Grade ≥ 3 Reported in at Least 3% of Subjects in any Treatment Group, by SOC and PT- Treatment Period (Pooled Safety Population)

|                                       |               | Controls   | Controls     | Controls          |
|---------------------------------------|---------------|------------|--------------|-------------------|
| System Organ Class PreferredTerm      | CPX-351 N=375 | 7+3 N=192  | Salvage N=44 | AllControls N=236 |
| Any TEAEs Grade ≥ 3 4, b              | 346 (92.3)    | 172 (89.6) | 40 (90.9)    | 212 (89.8)        |
| Blood and LymphaticSystemDisorders    | 245 (65.3)    | 131 (68.2) | 19 (43.2)    | 150 (63.0)        |
| Febrileneutropenia                    | 233 (62.1)    | 125 (65.1) | 15 (34.1)    | 140 (59.3)        |
| Neutropenia                           | 13 (3.5)      | 6 (3.1)    | 2 (4.5)      | 8 (3.4)           |
| Pancytopenia                          | 4 (1.1)       | 1 (0.5)    | 2 (4.5)      | 3 (1.3)           |
| Thrombocytopenia                      | 14 (3.7)      | 5 (2.6)    | 3 (6.8)      | 8 (3.4)           |
| CardiacDisorders                      | 30 (8.0)      | 25 (13.0)  | 2 (4.5)      | 27 (11.4)         |
| Atrial fibrillation                   | 10 (2.7)      | 6 (3.1)    | 0            | 6 (2.5)           |
| GastrointestinalDisorder's            | 59 (15.7)     | 31 (16.1)  | 3 (6.8)      | 34 (14.4)         |
| Diarrhoea                             | 11 (2.9)      | 11 (5.7)   | 1 (2.3)      | 12 (5.1)          |
| GeneralDisordersandAdministrationSite | 71 (18.9)     | 36 (18.8)  | 8 (18.2)     | 44 (18.0)         |
| Conditions Aesthenia                  | 3 (0.8)       | 1 (0.5)    | 2 (4.5)      | 3 (1.3)           |
| Fatigue                               | 31 (8.3)      | 10 (5.2)   | 1 (2.3)      | 11 (4.7)          |
| Mucosal inflammation                  | 4 (1.1)       | 5 (2.6)    | 2 (4.5)      | 7 (3.0)           |
| InfectionsandInfestations             | 217 (57.9)    | 95 (49.5)  | 27 (61.4)    | 122 (51.7)        |
| Bacteraemia                           | 36 (9.6)      | 4 (2.1)    | 4 (9.1)      | 8 (3.4)           |
| Bacterial sepsis                      | 7 (1.9)       | 1 (0.5)    | 3 (6.8)      | 4 (1.7)           |
| Cellulitis                            | 13 (3.5)      | 3 (1.6)    | 2 (4.5)      | 5 (2.1)           |
| Clostridiumdifficilecolitis           | 5 (1.3)       | 6 (3.1)    | 0            | 6 (2.5)           |
| Enterobacter sepsis                   | 2 (0.5)       | 0          | 2 (4.5)      | 2 (0.8)           |
| Enterococcalbacteraemia               | 14 (3.7)      | 10 (5.2)   | 3 (6.8)      | 13 (5.5)          |
| Escherichiabacteraemia                | 7 (1.9)       | 6 (3.1)    | 2 (4.5)      | 8 (3.4)           |
| Fungal sepsis                         | 1 (0.3)       | 0          | 2 (4.5)      | 2 (0.8)           |
| Klebsiella bacteraemia                | 4 (1.1)       | 7 (3.6)    | 0            | 7 (3.0)           |
| Klebsiella sepsis                     | 2 (0.5)       | 1 (0.5)    | 3 (6.8)      | 4 (1.7)           |
| Pneumonia                             | 60 (16.0)     | 27 (14.1)  | 3 (6.8)      | 30 (12.7)         |
| Pneumonia fungal                      | 12 (3.2)      | 4 (2.1)    | 0            | 4 (1.7)           |
| Sepsis                                | 22 (5.9)      | 12 (6.3)   | 0            | 12 (5.1)          |
| Staphylococcalbacteraemia             | 27 (7.2)      | 7 (3.6)    | 3 (6.8)      | 10 (4.2)          |
| Staphylococcal sepsis                 | 4 (1.1)       | 1 (0.5)    | 2 (4.5)      | 3 (1.3)           |
| Streptococcal bacteraemia             | 11 (2.9)      | 2 (1.0)    | 2 (4.5)      | 4 (1.7)           |
| Streptococcal sepsis                  | 9 (2.4)       | 2 (1.0)    | 2 (4.5)      | 4 (1.7)           |
| Urinary tract infection bacterial     | 2 (0.5)       | 4 (2.1)    | 2 (4.5)      | 6 (2.5)           |
| Urinary tract infection enterococcal  | 6 (1.6)       | 1 (0.5)    | 2 (4.5)      | 3 (1.3)           |
| Investigations                        | 35 (9.3)      | 22 (11.5)  | 3 (6.8)      | 25 (10.0)         |
| Ejection fraction decreased           | 8 (2.1)       | 7 (3.6)    | 0            | 7 (3.0)           |

<div style=\"page-break-after: always\"></div>

| MetabolismandNutritionDisorders                                          | 42 (11.2)   | 19 (9.9)   | 9 (20.5)   | 28 (11.9)   |
|--------------------------------------------------------------------------|-------------|------------|------------|-------------|
| Decreased appetite                                                       | 6 (1.6)     | 9 (4.7)    | 0          | 9 (3.8)     |
| Hypokalaemia                                                             | 21 (5.6)    | 5 (2.6)    | 3 (6.8)    | 8 (3.4)     |
| Hyponatraemia                                                            | 6 (1.6)     | 0          | 3 (6.8)    | 3 (1.3)     |
| Neoplasms Benign, Malignant and Unspecified (including cysts and polyps) | 6 (1.6)     | 2 (1.0)    | 2 (4.5)    | 4 (1.7)     |
| Acute myeloid leukaemia                                                  | 1 (0.3)     | 1 (0.5)    | 2 (4.5)    | 3 (1.3)     |
| NervousSystemDisorder's                                                  | 36 (9.0)    | 15 (7.8)   | 4 (9.1)    | 19 (8.1)    |
| Syncope                                                                  | 10 (2.7)    | 4 (2.1)    | 3 (6.8)    | 7 (3.0)     |
| PsychiatricDisorder's                                                    | 16 (4.3)    | 17 (8.9)   | 1 (2.3)    | 18 (7.6)    |
| Delirium                                                                 | 3 (0.8)     | 8 (4.2)    | 0          | 8 (3.4)     |
| Renal and UrinaryDisorders                                               | 28 (7.5)    | 14 (7.3)   | 3 (6.8)    | 17 (7.2)    |
| Renal failure                                                            | 5 (1.3)     | 6 (3.1)    | 1 (2.3)    | 7 (3.0)     |
| Renal failure acute                                                      | 17 (4.5)    | 8 (4.2)    | 2 (4.5)    | 10 (4.2)    |
| Respiratory, Thoracic and Mediastinal                                    | 76 (20.3)   | 45 (23.4)  | 2 (4.5)    | 47 (19.9)   |
| Disorders                                                                |             |            |            |             |
| Dyspnoea                                                                 | 17 (4.5)    | 5 (2.6)    | 0          | 5 (2.1)     |
| Hypoxia                                                                  | 36 (9.6)    | 24 (12.5)  | 1 (2.3)    | 25 (10.6)   |
| Pulmonary oedema                                                         | 5 (1.3)     | 9 (4.7)    | 0          | 9 (3.8)     |
| Respiratory failure                                                      | 14 (3.7)    | 9 (4.7)    | 0          | 9 (3.8)     |
| Skin and Subcutaneous Tissue Disorder's                                  | 43 (11.5)   | 10 (5.2)   | 1 (2.3)    | 11 (4.7)    |
| Rash                                                                     | 16 (4.3)    | 1 (0.5)    | 0          | 1 (0.4)     |
| VascularDisorder's                                                       | 44 (11.7)   | 19 (9.9)   | 3 (6.8)    | 22 (9.3)    |
| Hypertension                                                             | 23 (6.1)    | 10 (5.2)   | 3 (6.8)    | 13 (5.5)    |
| Hypotension                                                              | 15 (4.0)    | 3 (1.6)    | 0          | 3 (1.3)     |

treated with 7 + 3 and / or Salvage therapy.

In Study 301, similar percentages of subjects in the Vyxeos group (92%) and the 7 + 3 (91%) reported AEs Grade ≥ 3. The most frequently reported in both groups were febrile neutropenia (68% and 71%, in the Vyxeos and 7 + 3, respectively), pneumonia (20% and 15%), and hypoxia (13% and 15%).

## · Related TEAEs

The most frequently related TEAEs reported in Vyxeosgroup were febrile neutropenia (48.3%), nausea (41.1%), diarrhoea (34.4%), rash (32.3%) and fatigue (28.0%), and in the all controls group were diarrhoea (48.7%), febrile neutropenia (46.2%), nausea (44.9%), decreased appetite (33.1%) and fatigue (23.3%).

In study 301, AE related to study drug by the investigator were reported by 95% of subjects in each treatment group and the most frequent was febrile neutropenia (60% each arm). A summary of the related teae reported in at least 5% of subjects in any treatment group is displayed in Table 33.

<div style=\"page-break-after: always\"></div>

Table 32 Related TEAE Reported in at Least 5% of Subjects in Any Treatment Group, by System Organ Class and Preferred Term - (Pooled Safety Population)

|                                                   |                                            |                   | Number of subjects, n (%) Consolidation Period*   | Number of subjects, n (%) Consolidation Period*   | Number of subjects, n (%) Consolidation Period*   |                     |                              |
|---------------------------------------------------|--------------------------------------------|-------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------|------------------------------|
|                                                   | InductionPeriod CPX-351 100 units/m2 N=375 | All Controls      | CPX-351                                           | CPX-351                                           | AllControls                                       | CPX-351             | TreatmentPeriod All Controls |
|                                                   |                                            |                   | 65 units/m² 100 units/m²                          | 65 units/m² 100 units/m²                          | 65 units/m² 100 units/m²                          |                     |                              |
|                                                   |                                            | N=236             | N= 52                                             |                                                   |                                                   | N=375               | N=236                        |
| AnyRelatedTEAEs                                   | 362 (96.5)                                 | 220 (93.2)        | 36 (69.2)                                         | N=63 49 (77.8)                                    | N= 55 39 (70.9)                                   | 363 (96.8)          | 220 (93.2)                   |
| Blood and Lymphatic System                        | 187 (49.9)                                 | 114 (48.3)        | 14 (26.9)                                         | 17 (27.0)                                         | 15 (27.3)                                         | 197 (52.5)          | 116 (49.2)                   |
| Disorders Febrile neutropenia                     | 173 (46.1)                                 | 106 (44.9)        | 14 (26.9)                                         | 13 (20.6)                                         | 11 (20.0)                                         | 181 (48.3)          | 109 (46.2)                   |
| Cardiac Disorders                                 | 68 (18.1)                                  | 36 (15.3)         | 3 (5.8)                                           | 5 (7.9)                                           | 7 (12.7)                                          | 76 (20.3)           | 40 (16.9)                    |
| Atrial fibrillation                               | 16 (4.3)                                   | 7 (3.0)           | 0                                                 | 0                                                 | 3 (5.5)                                           | 16 (4.3)            | 9 (3.8)                      |
| Tachycardia                                       | 20 (5.3)                                   | 9 (3.8)           | 1(1.9)                                            | 2 (3.2)                                           | 1 (1.8)                                           | 23 (6.1)            | 10 (4.2)                     |
| GastrointestinalDisorder's                        | 271 (72.3)                                 | 192 (81.4)        | 18 (34.6)                                         | 29 (46.0)                                         | 26 (47.3)                                         | 274 (73.1)          | 194 (82.2)                   |
| Abdominal distension                              | 8 (2.1)                                    | 11 (4.7)          | 1 (1.9)                                           | 1(1.6)                                            | 2 (3.6)                                           | 10 (2.7)            | 13 (5.5)                     |
| Abdominal pain                                    | 32 (8.5)                                   | 26 (11.0)         | 2 (3.8)                                           | 2 (3.2)                                           | 3 (5.5)                                           | 36 (9.6)            | 28 (11.9)                    |
| Constipation                                      | 74 (19.7)                                  | 34 (14.4)         | 1 (1.9)                                           | 4 (6.3)                                           | 6 (10.9)                                          | 77 (20.5)           | 37 (15.7)                    |
| Diarrhoea                                         | 120 (32.0)                                 | 110 (46.6)        | 4 (7.7)                                           | 8 (12.7)                                          | 10 (18.2)                                         | 129 (34.4)          | 115 (48.7)                   |
| Dyspepsia                                         | 18 (4.8)                                   | 11 (4.7)          | 1 (1.9)                                           | 0                                                 | 3 (5.5)                                           | 19 (5.1)            | 14 (5.9)                     |
| Mouth haemonhage                                  | 16 (4.3)                                   | 5 (2.1)           | 2 (3.8)                                           | 2 (3.2)                                           | 1 (1.8)                                           | 19 (5.1)            | 6 (2.5)                      |
| Nausea                                            | 149 (39.7)                                 | 101 (42.8)        | 5 (9.6)                                           | 16 (25.4)                                         | 8 (14.5)                                          | 154 (41.1)          | 106 (44.9)                   |
| Stomatitis                                        | 46 (12.3)                                  | 25 (10.6)         | 0                                                 | 8 (12.7)                                          | 2 (3.6)                                           | 51 (13.6)           | 26 (11.0)                    |
| Vomiting                                          | 70 (18.7)                                  | 42 (17.8)         |                                                   |                                                   | 4 (7.3)                                           | 76 (20.3)           | 44 (18.6)                    |
|                                                   |                                            |                   | 3 (5.8)                                           | 8 (12.7)                                          |                                                   |                     |                              |
| GeneralDisordersandAdministration Site Conditions | 218 (58.1)                                 | 130 (55.1)        | 18 (34.6)                                         | 22 (34.9)                                         | 20 (36.4)                                         | 228 (60.8)          | 133 (56.4)                   |
| Asthenia                                          | 21 (5.6)                                   | 19 (8.1)          | 1 (1.9)                                           | 0                                                 | 1 (1.8)                                           | 22 (5.9)            | 19 (8.1)                     |
| Chills                                            | 46 (12.3)                                  | 19 (8.1)          | 3 (5.8)                                           | 4 (6.3)                                           | 2 (3.6)                                           | 51 (13.6)           | 21 (8.9)                     |
| Fatigue                                           | 97 (25.9)                                  | 48 (20.3)         | 8 (15.4)                                          | 10 (15.9)                                         | 10 (18.2)                                         | 105 (28.0)          | 55 (23.3)                    |
| Mucosal inflammation                              | 38 (10.1)                                  | 31 (13.1)         | 1 (1.9)                                           | 3 (4.8)                                           | 2 (3.6)                                           | 41 (10.9)           | 32 (13.6)                    |
| Oedema peripheral                                 | 58 (15.5)                                  | 40 (16.9)         | 4 (7.7)                                           | 2 (3.2)                                           | 3 (5.5)                                           | 61 (16.3)           | 43 (18.2)                    |
| Pyrexia                                           | 46 (12.3)                                  | 20 (8.5)          | 5 (9.6)                                           | 8 (12.7)                                          | 5 (9.1)                                           | 56 (14.9)           | 25 (10.6)                    |
| InfectionsandInfestations                         | 141 (37.0)                                 | 82 (34.7)         | 13 (25.0)                                         | 18 (28.0)                                         | 9 (16.4)                                          | 158 (42.1) 33 (8.8) | 88 (37.3)                    |
| Pneumonia                                         | 29 (7.7)                                   | 20 (8.5)          | 3 (5.8)                                           | 2 (3.2) 9 (14.3)                                  | 3 (5.5)                                           | 120 (32.0)          | 23 (9.7) 95 (40.3)           |
| MetabolismandNutritionDisorders                   | 112 (29.9)                                 | 85 (36.0)         | 5 (9.6)                                           |                                                   | 11 (20.0)                                         | 93 (24.8)           | 78 (33.1)                    |
| Decreased appetite                                | 86 (22.9)                                  | 73 (30.9)         | 4 (7.7)                                           | 8 (12.7)                                          | 6 (10.9)                                          |                     |                              |
| Hypokalaema                                       | 13 (3.5)                                   | 3 (1.3)           | 0                                                 | 0                                                 | 3 (5.5)                                           | 13 (3.5)            | 6 (2.5)                      |
| MusculoskeletalandConnective                      | 47 (12.5)                                  | 26 (11.0)         | 3 (5.8)                                           | 5 (7.9)                                           | 5 (9.1)                                           | 53 (14.1) 5 (1.3)   | 30 (12.7)                    |
| Tissue Disorder's Myalgia                         | 1 (0.3)                                    | 3 (1.3)           | 3 (5.8)                                           | 1 (1.6)                                           | 0                                                 |                     | 3 (1.3)                      |
| NervousSystemDisorders                            | 104 (27.7)                                 | 62 (26.3)         | 8 (15.4)                                          | 7 (11.1)                                          | 8 (14.5)                                          | 113 (30.1)          | 67 (28.4)                    |
| Dizziness                                         | 25 (6.7)                                   | 13 (5.5)          | 1 (1.9)                                           | 1 (1.6)                                           | 5 (9.1)                                           | 27 (7.2) 17 (4.5)   | 18 (7.6)                     |
| Dysgeusia                                         | 14 (3.7)                                   | 17 (7.2)          | 2 (3.8)                                           | 1 (1.6)                                           | 1 (1.8)                                           | 49 (13.1)           | 18 (7.6) 25 (10.6)           |
| Headache Psychiatric Disorders                    | 45 (12.0)                                  | 24 (10.2)         | 2 (3.8)                                           | 3 (4.8) 3 (4.8)                                   | 2 (3.6) 6 (10.9)                                  | 55 (14.7)           | 32 (13.6)                    |
|                                                   | 51 (13.0)                                  | 27 (11.4)         | 3 (5.8)                                           |                                                   | 2 (3.6)                                           | 15 (4.0)            | 12 (5.1)                     |
| Confusional state                                 | 14 (3.7)                                   | 10 (4.2)          | 1 (1.9)                                           | 0                                                 |                                                   | 23 (6.1)            |                              |
| Insomnia                                          | 21 (5.6)                                   | 10 (4.2)          | 2 (3.8)                                           | 1 (1.6)                                           | 2 (3.6)                                           | 151 (40.3)          | 12 (5.1)                     |
| Respiratory,Thoracic and Mediastinal Disorders    | 144 (38.4)                                 | 77 (32.6)         | 8 (15.4)                                          | 10 (15.9)                                         | 13 (23.6)                                         |                     | 83 (35.2)                    |
| Cough                                             | 32 (8.5)                                   | 16 (6.8)          | 2 (3.8)                                           | 1 (1.6)                                           | 2 (3.6)                                           | 33 (8.8)            | 18 (7.6)                     |
| Dyspnoea                                          | 29 (7.7)                                   | 18 (7.6)          | 1 (1.9)                                           | 1 (1.6) 3 (4.8)                                   | 3 (5.5)                                           | 31 (8.3) 57 (15.2)  | 20 (8.5)                     |
| Epistaxis                                         | 53 (14.1) 27 (7.2)                         | 18 (7.6) 18 (7.6) | 2 (3.8) 1 (1.9)                                   | 1 (1.6)                                           | 4 (7.3) 1 (1.8)                                   | 29 (7.7)            | 22 (9.3) 19 (8.1)            |
| Hypoxia Oropharyngeal pain                        | 18 (4.8)                                   | 14 (5.9)          | 1 (1.9)                                           | 3 (4.8)                                           | 2 (3.6)                                           | 22 (5.9)            | 16 (6.8)                     |
| Pleural effusion                                  |                                            |                   | 1 (1.9)                                           |                                                   |                                                   |                     |                              |
|                                                   | 24 (6.4)                                   | 13 (5.5)          |                                                   | 0                                                 | 1 (1.8)                                           | 25 (6.7)            | 14 (5.9)                     |
| Skin and SubcutaneousTissue                       |                                            |                   |                                                   |                                                   | 14 (25.5)                                         | 240 (64.0)          |                              |
|                                                   |                                            | 95 (40.3)         | 11 (21.2)                                         | 29 (46.0)                                         |                                                   |                     | 100 (42.4)                   |
| Disorders                                         | 230 (61.3) 9 (2.4)                         | 22 (9.3)          | 1 (1.9)                                           | 1 (1.6)                                           | 2 (3.6)                                           | 11 (2.9)            | 24 (10.2) 15 (6.4)           |
| Alopecia Petechiae Pruritus                       | 24 (6.4) 38 (10.1)                         | 14 (5.9) 14 (5.9) | 4 (7.7) 1(1.9)                                    | 4 (6.3) 0                                         | 2 (3.6) 0                                         | 32 (8.5) 39 (10.4)  | 14 (5.9)                     |
| Rash                                              | 111 (29.6)                                 | 36 (15.3)         | 4 (7.7)                                           | 19 (30.2)                                         |                                                   | 121 (32.3)          | 39 (16.5)                    |
| Rash maculo-papular                               | 26 (6.9)                                   | 10 (4.2)          |                                                   |                                                   | 4 (7.3)                                           |                     |                              |
| Rash erythematous                                 | 14 (3.7)                                   | 5 (2.1)           | 0 0                                               | 0                                                 | 1 (1.8)                                           | 26 (6.9)            | 11 (4.7)                     |
|                                                   |                                            |                   |                                                   | 2 (3.2)                                           | 3 (5.5)                                           | 16 (4.3)            | 7 (3.0)                      |
| Vascular Disorder's                               | 54 (14.4)                                  | 34 (14.4)         | 5 (9.6)                                           | 6 (9.5)                                           | 4 (7.3)                                           | 64 (17.1)           | 36 (15.3)                    |
| Hypotension                                       | 25 (6.7)                                   | 16 (6.8)          | 4 (7.7)                                           | 2 (3.2)                                           |                                                   |                     |                              |
|                                                   |                                            |                   |                                                   |                                                   |                                                   |                     | 18 (7.6)                     |
| Hypertension                                      | 15 (4.0)                                   | 12 (5.1)          | 0                                                 | 0                                                 | 2 (3.6) 1 (1.8)                                   | 30 (8.0) 15 (4.0)   | 12 (5.1)                     |

Abbreviations: NCI-CTC =National Cancer Institute Common Terminology Criteria; TEAE = treatment emergent adverse event.

The CPX-351 65 units/m² consolidation dose was tested in Study 206 and Study 301. The CPX-351 100units/m² consolidation dose was tested in Study 101 (101 units/m'), Study 204, and Study 205.

Note: If a subject experiences an AE with more than one relationship, the subject is counted only once in closest relationship category. Related category includes possibly, probably, and definitely related.

Note: The ^All Controls² group included subjects from Study 204, Study 205 and Study 301 treated as follows: during the Induction Period, *All Controls* included subjects treated with 7 + 3 and Salvage therapy; during the Consolidation Period, ^All Controls² included subjects treated with 5 + 2 and Salvage/ Other therapy; during the Treatment Period, ^All Controls' included subjects treated with 7 + 3 and Salvage

<div style=\"page-break-after: always\"></div>

## · AEs of special interest

## Infections

The incidence of infection was 94.1%  in the Vyxeos group compared with 1.9% in all controls regardless of treatment period. Most subjects experienced Grade 3 Infection AEs in both groups. The most frequently reported infection AE in both groups was febrile neutropenia (63.2% vs 59.7%, respectively). The incidence of other infection AEs was similar between Vyxeos vs all controls, with imbalances for pyrexia (29.1% vs 22.0%), bacteraemia (10.7% vs 4.2%), and clostridium difficile infection (5.3% vs 1.7%).

Pneumonia, sepsis and bacteriaemia were the most frequently seen serious infection ADRs in the clinical trial population. The incidence of infection events was 78.1%; the incidence of non-serious events of infections was 73.1%, the incidence of serious events of infections was 28.5%; the incidence of infections which led to discontinuation is 0.5%. The incidence of fatal infections was 6.9%. The fatal infections experienced were sepsis and pneumonia (SmPC,  section 4.8).

Bacterial and viral infection occurred with similar frequency between Vyxeos and All Controls (87.5% vs 84.7%, and 13.1% vs 10.2%, respectively). Fungal Infection occurred more frequently in subjects receiving Vyxeos (18.9%) than in control (11.9%). No viral or fungal infections led to discontinuation of study or death in any treatment group.

The most frequently reported bacterial Infection in Vyxeos and control was Febrile neutropenia (63.2% and 59.7% of subjects, respectively). The most common viral infection reported with Vyxeos was Herpes simplex (1.9%) and for All Controls it was oral herpes (3.0%). The most commonly reported fungal Infection was pneumonia fungal (3.5% in Vyxeos versus 1.7% all controls).

Almost all subjects in study 301 in both treatment groups had at least 1 infection AE (92.8% vs. 92.7% in the Vyxeos and 7+3 arms respectively) and most were Grade 3 to 5 (84% vs 86%). The most frequently reported were febrile neutropenia, chills, pneumonia, pyrexia, sepsis, cellulitis, and bacteraemia. The most notable difference between the arms was for bacteraemia (9.8% vs. 2.6%), especially for grade 5 infections (7.2% vs. 2.6%). No grade 4 or 5 viral infections and no grade 5 fungal infections were reported. There were no notable differences between arms in viral or fungal infections.

## Bleeding

A summary of bleeding AE by NCI-CTC Grade is displayed in Table 34.

Table 33 Summary of bleeding AE by NCI-CTC Grade - Treatment Period (Pooled Safety Population)

|                                     | Number of subjects, n (%)   | Number of subjects, n (%)   |
|-------------------------------------|-----------------------------|-----------------------------|
| SystemOrganClass PreferredTerm      | CPX-351 N= 375              | AllControls N = 236         |
| Subjects with Bleeding AEs, n (%)   | 259 (69.1)                  | 139 (58.9)                  |
| BleedingAEsbyNCI-CTCGrade           |                             |                             |
| Grade 1                             | 143 (38.1)                  | 86 (36.4)                   |
| Grade 2                             | 68 (18.1)                   | 39 (16.5)                   |
| Grade 3                             | 36 (9.6)                    | 10 (4.2)                    |
| Grade 4                             | 4 (1.1)                     | 1 (0.4)                     |
| Grade 5                             | 8 (2.1)                     | 3 (1.3)                     |
| Grade3-5                            | 48 (12.8)                   | 14 (5.9)                    |
| Serious Bleeding AEs                | 21 (5.6)                    | 9 (3.8)                     |
| BleedingAEsleadingtodiscontinuation | 1 (0.3)                     | 0                           |
| BleedingAEsleadingtodeath           | 8 (2.1)                     | 3 (1.3)                     |

<div style=\"page-break-after: always\"></div>

The most common haemorrhagic event was epistaxis, and the majority of these were considered not serious (29.1%). The incidence of haemorrhage events is 69.1%; the incidence of non-serious events of haemorrhage was 67.2 %; the incidence of serious events of haemorrhage is 5.6%; the incidence of haemorrhage which led to discontinuation is 0. The incidence of fatal haemorrhage was 2.1% .Serious or fatal haemorrhagic events, including fatal central nervous system (CNS) haemorrhages, associated with severe thrombocytopenia were seen in patients treated with Vyxeos (SmPC,  section 4.8).

In study 301 more subjects in Vyxeos than in the 7+3 group had a bleeding-related AE (74.5% vs. 59.6%, respectively), most were grade 1 to 2, and grade 3 to 5 occurred in 12% vs 8.6%, respectively. Four (2.6%) subjects in each arm had a grade 5 bleeding-related AE. The most frequent bleeding-related AEs were epistaxis, petechiae, mouth Haemorrhage and ecchymosis. The most notable difference between the Vyxeos and 7+3 groups was for epistaxis (35.9% vs. 17.9%, respectively), mouth haemorrhage (10.5% vs. 5.3%, respectively), and blood blister (9.2% vs. 3.3%, respectively).

## Cardiac

During treatment period, cardiac AEs were more frequent in the Vyxeos group than in the All Controls but the difference is driven by Grade 1 AEs while similar incidences were reported for Grade 3-5 AEs.

Table 23 Summary of Cardiac AE by NCI-CTC Grade -Treatment Period (Pooled Safety Population)

|                                        | Number of subjects, n (%)   | Number of subjects, n (%)   |
|----------------------------------------|-----------------------------|-----------------------------|
| System Organ Class Preferred Term      | CPX-351                     | All Controls                |
|                                        | N=375                       | N= 236                      |
| Subjects with Cardiac AEs, n (%)       | 188 (50.1)                  | 99 (41.9)                   |
| Cardiac AEs by NCI-CTC Grade           |                             |                             |
| Grade 1                                | 103 (27.5)                  | 36 (15.3)                   |
| Grade 2                                | 45 (12.0)                   | 31 (13.1)                   |
| Grade 3                                | 29 (7.7)                    | 14 (5.9)                    |
| Grade 4                                | 9 (2.4)                     | 12 (5.1)                    |
| Grade 5                                | 2 (0.5)                     | 6 (2.5)                     |
| Grade 3 to 5                           | 40 (10.7)                   | 32 (13.6)                   |
| SeriousCardiacAEs                      | 26 (6.9)                    | 26 (11.0)                   |
| Cardiac AEs leading to discontinuation | 3 (0.8)                     | 2 (0.8)                     |
| CardiacAEsleadingtodeath               | 2 (0.5)                     | 6 (2.5)                     |

Abbreviations: AE = adverse event; MedDRA = medical dictionary for regulatory affairs; NCI-CTC = national cancer institute common terminology criteria; SAE = serious adverse event; TEAE = treatment emergent adverse event.

Note: For SAEs or AEs identified as a bleeding event, a cardiac event, infection or rash, a TEAE is defined as an AE that started after the first dose ofinduction 1. For all other AEs, a TEAE is defined as an AE that started after the first dose of induction 1 and not more than 30 days after the last dose date.

once in maximum grade under that category.

Note: The ^All Controls' treatment group includes subjects from Study 204, Study 205, and Study 301 who were treated with 7 + 3 and / or Salvage therapy.

MedDRA version 16.0

The most frequently reported serious ADRs were decreased ejections fraction and congestive cardiac failure. The incidence of all cardiotoxicity events was 72.0%; the incidence of non-serious events of cardiotoxicity was 68.5 %; the incidence of serious events of cardiotoxicity was 9.1%; the incidence of cardiotoxicity which led to discontinuation is 0. 5%. Incidence of fatal cardiotoxicity events is 0.5%. Cardiac arrest was reported

<div style=\"page-break-after: always\"></div>

as a fatal event; the patient experienced thrombocytopenia and neutropenia which contributed to cardiac arrest (SmPC, section 4.8).

The most frequently reported Cardiac AE (Vyxeos vs all controls) were tachycardia (15.2% vs 12.7%, respectively), followed by chest pain (7.2% vs 5.9%) and atrial fibrillation (6.9% vs 8.9%) and there were small imbalances in pericardial effusion (5.1% vs 2.5%) and cardiac murmur (4.3% vs 0.8%).

Grade 5 AEs were reported for 2 subjects in Vyxeos and included cardio-respiratory arrest (n = 1) and sudden cardiac death (n = 1).

The most frequently reported Serious Cardiac AEs was ejection fraction decreased (2.4% for Vyxeos vs 3.4% all controls).

The incidence of normal and abnormal ECGs was similar between the Vyxeos group and All Controls.

Although an imbalance of ~10% incidence in Cardiac AEs was observed between Vyxeos and control groups during treatment (50.1% vs 41.9%), the incidence was similar during induction (45.3% vs 40.7%) while it was lower during consolidation for subjects receiving Vyxeos 65 units/m 2 versus All Controls versus Vyxeos 100 unit/m 2 (15.4% vs 21.8% vs 31.7%) driven primarily by a reduced incidence of atrial fibrillation, tachycardia and pericardial effusion.

Only 5 patients (3 in Vyxeos and 2 in all controls) had high prior use of anthracycline ( ≥ 500 mg/m 2 ). Within the subgroups with low (n=94) and medium (n=65) prior anthracycline use, subjects in the Vyxeos group experienced a higher incidence of Cardiac AEs compared with control (41.8% vs 25.9%, and 40.4% vs 16.7%, respectively) which was driven by the higher incidence of tachycardia in the Vyxeos (17.9% in low prior use and 21.3% in medium prior use).

In study 301 nearly all subjects (96.7%) were anthracycline naïve and there were no differences between groups having a cardiac AE (49.0% vs. 47.7%, respectively) and most were grade 1 to 2 (grade 3 to 5 reported for 16% vs 18%). The most frequently reported AEs for Vyxeos and 7+3 groups were tachycardia (15% vs 11.3%), atrial fibrillation (6.5% vs 10.6%), chest pain (7.8% vs 9.3%), ejection fraction decreased (5.9% vs 6.6%) and chest discomfort (5.9% vs 4%).

## Hypersensitivity

Hypersensitivity reactions were very common ADRs in Vyxeos clinical trials. The most frequently reported hypersensitivity ADRs was rash and the majority of these were not serious (38.9%). The incidence of all hypersensitivity events was 66.9%; the incidence of non-serious events of hypersensitivity events was 66.4 % of which 38.9 % were rash; the incidence of serious events of hypersensitivity is 1.1%; the frequency of hypersensitivity which led to discontinuation is 0. The frequency of fatal hypersensitivity events was 0 (SmPC, section 4.8).

Rash AEs were more common in the Vyxeos than in the All Controls group (58.4% vs 36.9%) during the treatment Period, mainly PT rash (39.2% vs 24.6%), but all AEs were ≤ Grade 3, no subjects discontinued due to rash and only 3 subjects (Vyxeos group) had a SAE rash.

The incidence of rash was higher during induction for both Vyxeos and controls groups (56.5% vs 36.4%) and during consolidation the 65 units/m2 dose demonstrated a lower incidence (11.5%) compared with the 100 units/m2 (38.1%) and was similar to the All Control (16.4%).

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious adverse event

More SAEs were reported in the Vyxeos group than the all controls (50.4% vs 38.6%).

Table 34. Serious TEAE in at least 2% of subjects in any treatment group, by SOC and PTtreatment period (pooled safety population)

|                                                                   |                  | Controls   | Controls        | Controls           |
|-------------------------------------------------------------------|------------------|------------|-----------------|--------------------|
| System OrganClass Preferred Term                                  | CPX-351 N=375    | 7+3 N=192  | Salvage N=44    | All Controls N=236 |
| AnySeriousTEAEs                                                   | 189 (50.4)       | 72 (37.5)  | 19 (43.2)       | 91 (38.0)          |
| Blood and lymphaticsystemdisorders                                | 50 (13.3)        | 13 (6.8)   | 4 (9.1)         | 17 (7.2)           |
| Febrile neutropenia                                               | 38 (10.1)        | 10 (5.2)   | 2 (4.5)         | 12 (5.1)           |
| Neutropenia                                                       | 2 (0.5)          | 0          | 1 (2.3)         | 1 (0.4)            |
| Pancytopenia                                                      | 1 (0.3)          | 0          | 1 (2.3)         | 1 (0.4)            |
| Cardiac disorder's                                                | 16 (4.3)         | 17 (8.9)   | 2 (4.5)         | 19 (8.1)           |
| Arrhythmia supraventricular                                       | 0                | 0          | 1 (2.3)         | 1 (0.4)            |
| Cardiac failure                                                   | 2 (0.5)          | 1 (0.5)    | 1 (2.3)         | 2 (0.8)            |
| Sinus bradycardia                                                 | 0                | 0          | 1 (2.3)         | 1 (0.4)            |
| Generaldisordersandadministrationsite conditions                  | 21 (5.0)         | 5 (2.0)    | 1 (2.3)         | 6 (2.5)            |
| Death                                                             | 0                | 0          | 1 (2.3)         | 1 (0.4)            |
| Pyrexia                                                           | 11 (2.9)         | 0          | 0               | 0                  |
| Infectionsandinfestations                                         | 92 (24.5)        | 30 (15.6)  | 10 (22.7)       | 40 (16.9)          |
| Aspergillosis                                                     | 0                | 0          | 1 (2.3)         | 1 (0.4)            |
| Bacteraemia                                                       | 8 (2.1)          | 0          | 1 (2.3)         | 1 (0.4)            |
| Bacterial sepsis                                                  | 4 (1.1)          | 0          | 2 (4.5)         | 2 (0.8)            |
| Catheter site infection                                           | 1 (0.3)          | 0          | 1 (2.3)         | 1 (0.4)            |
| Cellulitis                                                        | 6 (1.6)          | 1 (0.5)    | 1 (2.3)         | 2 (0.8)            |
| Enterobacter sepsis                                               | 1 (0.3)          | 0          | 1 (2.3)         | 1 (0.4)            |
| Fungal sepsis                                                     | 0                | 0          | 1 (2.3)         | 1 (0.4)            |
| Klebsiella sepsis                                                 | 0                | 1 (0.5)    | 1 (2.3)         | 2 (0.8)            |
| Pneumonia                                                         | 20 (5.3)         | 6 (3.1)    | 2 (4.5)         | 8 (3.4)            |
| Pseudomonasinfection                                              | 0                | 0          | 1 (2.3)         | 1 (0.4)            |
| Respiratory syncytial virus infection                             | 0                | 0          | 1 (2.3)         | 1 (0.4)            |
| Sepsis                                                            | 16 (4.3)         | 6 (3.1)    | 0               | 6 (2.5)            |
| Staphylococcal bacteraemia                                        | 4 (1.1)          | 2 (1.0)    | 2 (4.5)         | 4 (1.7)            |
| Staphylococcal sepsis                                             | 1 (0.3)          | 0          | 1 (2.3)         | 1 (0.4)            |
| Streptococcalbacteraemia                                          | 2 (0.5)          | 0          | 2 (4.5)         | 2 (0.8)            |
| Investigations                                                    | 15 (4.0)         | 9 (4.7)    | 0               | 9 (3.8)            |
| Ejection fraction decreased                                       | 9 (2.4)          | 8 (4.2)    | 0               | 8 (3.4)            |
| Neoplasmsbenign,malignant and unspecified (incl cysts and polyps) | 5 (1.3)          | 2 (1.0)    | 2 (4.5)         | 4 (1.7)            |
| Acute myeloid leukaemia                                           | 1 (0.3)          | 1 (0.5)    | 2 (4.5)         | 3 (1.3)            |
|                                                                   | 16 (4.3)         | 2 (1.0)    | 2 (4.5)         | 4 (1.7)            |
| Nervoussystem disorders                                           | 2 (0.5)          |            | 1 (2.3)         | 1 (0.4)            |
| Convulsion Syncope                                                | 5 (1.3)          | 0 0        | 1 (2.3)         | 1 (0.4)            |
| Renalandurinarydisorders                                          | 6 (1.0)          | 3 (1.0)    | 1 (2.3)         | 4 (1.7)            |
| Renal failure acute                                               | 6 (1.6)          | 2 (1.0)    | 1 (2.3)         | 3 (1.3)            |
| Respiratory,thoracicandmediastinaldisorders                       | 36 (9.0)         | 23 (12.0)  | 0               | 23 (9.7)           |
| Acute respiratory failure                                         | 9 (2.4)          | 3 (1.6)    | 0               | 3 (1.3)            |
| Pulmonaryoedema                                                   | 1 (0.3)          | 4 (2.1)    | 0               | 4 (1.7)            |
| Respiratoryfailure                                                | 11 (2.9) 5 (1.3) | 7 (3.6)    | 0               | 7 (3.0) 1 (0.4)    |
| Skinandsubcutaneoustissuedisorders Blister                        | 0                | 0 0        | 1 (2.3) 1 (2.3) | 1 (0.4)            |

Abbreviations: AE =adverse event;MedDRA =medical dictionary for regulatory activities; SAE=serious adverse event; TEAE = treatment emergent adverse event.

treated with 7 + 3 and / or Salvage therapy.

MedDRA version 16.0

<div style=\"page-break-after: always\"></div>

In study 301 more subjects in the Vyxeos group had an SAE than in the 7+3 (59% vs. 43%, respectively) and the most commonly reported SAEs for CPX 351 were febrile neutropenia (7.8%), sepsis (7.8%) and respiratory failure (7.2%).

Table 35 Study 301 Number of Subjects with TEAE by PT in ≥ 3% (Safety Population)

| Preferred Term            | CPX-351 N =153 (%) u   | 7+3 N = 151 n (%)   | All Subjects N=304 n (%)   |
|---------------------------|------------------------|---------------------|----------------------------|
| Any serious adverse event | 90 (59)                | 65 (43)             | 155 (51)                   |
| Febrile Neutropenia       | 12 (7.8)               | 8 (5.3)             | 20 (6.6)                   |
| Respiratory Failure       | 11 (7.2)               | 8 (5.3)             | 19 (6.3)                   |
| EjectionFractionDecreased | 9 (5.9)                | 9 (6.0)             | 18 (5.9)                   |
| Sepsis                    | 12 (7.8)               | 5 (3.3)             | 17 (5.6)                   |
| Pneumonia                 | 10 (6.5)               | 6 (4.0)             | 16 (5.3)                   |
| Disease Progression       | 6 (3.9)                | 6 (4.0)             | 12 (3.9)                   |
| Acute Respiratory Failure | 6 (3.9)                | 3 (2.0)             | 9 (3.0)                    |

## Deaths

During the Study Period (Treatment + Follow-up), fewer deaths were reported with Vyxeos compared with 7 + 3 (59.7% vs.74%, respectively) (Table 37).

Table 36 Deaths by Period (Pooled safety population)

|                     | Induction Period           | Induction Period   | ConsolidationPerioda     | ConsolidationPerioda      | ConsolidationPerioda   | Study Perioda   | Study Perioda   |
|---------------------|----------------------------|--------------------|--------------------------|---------------------------|------------------------|-----------------|-----------------|
|                     | CPX-351 100 umits/m2 N=375 | 7+3 N=192          | CPX-351 65 units/m² N=52 | CPX-351 100 units/m2 N=63 | 5+2 N=32               | CPX-351 N=375   | 7+3 N=192       |
| Deaths              | 29 (7.7)                   | 18 (9.4)           | 1 (1.9)                  | 8 (12.7)                  | 3 (9.4)                | 224 (59.7)      | 142 (74.0)      |
| DeathsduetoTEAEs    | 24 (6.4)                   | 18 (9.4)           | 1 (1.9)                  | 4 (6.3)                   | 3 (9.4)                | 70 (18.7)       | 36 (18.8)       |
| ≤7 days             |                            |                    |                          |                           |                        |                 |                 |
| Deaths              | 0                          | 0                  | 0                        | 0                         | 0                      | 0               | 0               |
| Deaths due to TEAEs | 0                          | 0                  | 0                        | 0                         | 0                      | 0               | 0               |
| 8 to 30 days        |                            |                    |                          |                           |                        |                 |                 |
| Deaths              | 14 (3.7)                   | 15 (7.8)           | 1 (1.9)                  | 2 (3.2)                   | 2 (6.3)                | 21 (5.6)        | 19 (9.9)        |
| Deaths due toTEAEs  | 14 (3.7)                   | 15 (7.8)           | 1 (1.9)                  | 2 (3.2)                   | 2 (6.3)                | 21 (5.6)        | 19 (9.9)        |
| ≤30 days            |                            |                    |                          |                           |                        |                 |                 |
| Deaths              | 14 (3.7)                   | 15 (7.8)           | 1 (1.9)                  | 2 (3.2)                   | 2 (6.3)                | 21 (5.6)        | 19 (9.9)        |
| Deaths due to TEAEs | 14 (3.7)                   | 15 (7.8)           | 1 (1.9)                  | 2 (3.2)                   | 2 (6.3)                | 21 (5.6)        | 19 (9.9)        |
| 31 to 60 days       |                            |                    |                          |                           |                        |                 |                 |
| Deaths              | 9 (2.4)                    | 2 (1.0)            | 0                        | 0                         | 0                      | 26 (6.9)        | 19 (9.9)        |
| Deaths due to TEAEs | 9 (2.4)                    | 2 (1.0)            | 0                        | 0                         | 0                      | 23 (6.1)        | 9 (4.7)         |
| ≤ 60 days           |                            |                    |                          |                           |                        |                 |                 |
| Deaths              | 23 (6.1)                   | 17 (8.9)           | 1(1.9)                   | 2 (3.2)                   | 2 (6.3)                | 47 (12.5)       | 38 (19.8)       |
| Deaths due to TEAEs | 23 (6.1)                   | 17 (8.9)           | 1 (1.9)                  | 2 (3.2)                   | 2 (6.3)                | 44 (11.7)       | 28 (14.6)       |
| 61 to 90 days       |                            |                    |                          |                           |                        |                 |                 |
| Deaths              | 1 (0.3)                    | 1 (0.5)            | 0                        | 2 (3.2)                   | 1 (3.1)                | 18 (4.8)        | 12 (6.3)        |
| Deaths due to TEAEs | 1 (0.3)                    | 1 (0.5)            | 0                        | 2 (3.2)                   | 1 (3.1)                | 12 (3.2)        | 4 (2.1)         |
| >90 days            |                            |                    |                          |                           |                        |                 |                 |
| Deaths              | 5 (1.3)                    | 0                  | 0                        | 4 (6.3)                   | 0                      | 159 (42.4)      | 92 (47.9)       |
| Deaths duetoTEAEs   | 0                          | 0                  | 0                        | 0                         | 0                      | 14 (3.7)        | 4 (2.1)         |

Note: The *All Controls² group included subjects from Study 204, Study 205 and Study 301 treated as follows: during the Induction Period, *All Controls*

included subjects treated with 7 + 3 and Salvage therapy; during the Consolidation Period, *Al1 Controls² included subjects treated with 5 + 2 and Salvage /

Note:Thenumber of dayswascalculatedrelativetothefirstdoseoftheinductionorconsolidationperiod.

In study 301 fewer deaths were reported in the Vyxeos group (69.3%) compared with the 7 + 3 (84.8%).

<div style=\"page-break-after: always\"></div>

Table 37. Study 301: Deaths by period (safety analysis population)

| Period                  | CPX-351 N=153   | 7+3 N=151   |
|-------------------------|-----------------|-------------|
| Numberofsubjectswhodied | 106 (69.3)      | 128 (84.8)  |
| ≤7 days                 | 0               | 0           |
| 8 to 30 days            | 9 (5.9)         | 16 (10.6)   |
| 31 to 60 days           | 12 (7.8)        | 16 (10.6)   |
| ≤ 60 days               | 21 (13.7)       | 32 (21.2)   |
| Treatment Phase         | 12 (7.8)        | 17 (11.3)   |
| Follow-upPhase          | 93 (60.8)       | 109 (72.2)  |

Note: Percentages are based on the number of subjects in each treatment group of the Safety Analysis Population.

The Follow-up Phase began approximately 30 days after completion of all therapy.

Note: Periods start on first day of treatment.

Note: An additional 3 deaths were observed after the end of the Follow-up Phase: 1 in the CPX-351 treatment group and 2 in the 7 + 3 treatment group.

## Laboratory findings

## Haematology

Treatment with either Vyxeos or 7+3 led to neutropenia and thrombocytopenia within 5 to 7 days of the first induction course. The time to recovery in absolute neutrophils count (ANC) was delayed for a median of 7 days (i.e. recovery longer than 28 days) for subjects receiving Vyxeos compared with 7 + 3. During consolidation treatment, time to ANC recovery was similar for subjects receiving 65 and 100 units/m 2  Vyxeos.

Platelet nadir was observed around day 14 regardless of treatment, but time to recovery is delayed for Vyxeos compared with 7 + 3.

For subjects in Vyxeos arm who received only 1 induction, the median time from the start of induction to recovery from neutropenia (ANC value ≥ 1000/μL) was 37 days (vs. 29 days in control) and recovery from thrombocytopenia ( ≥ 100,000/μL) was 40 days (vs. 30 days in control). Similarly, the median time to recovery for all subjects in the ITT population was longer in the Vyxeos group than in the control (44 vs. 35 days for ANC and 49 vs. 44 days for platelets, respectively).

Although subjects treated with 2 inductions spend longer periods of time with neutropenia and thrombocytopenia no clinically meaningful differences were observed in the time to recovery from neutropenia and thrombocytopenia compared to those who received one induction.

There were no clinically relevant changes in hemoglobin for Vyxeos compared with control treatment.

In study 301 all subjects had a haematological toxicity of any grade during study and no notable differences were seen between Vyxeos and 7+3. Most subjects had grade 4 event, regardless of the grade they had prior to treatment, mainly neutropaenia (99% each arm) and thrombocytopaenia (98% vs 99%).

## Chemistry

No clinically relevant changes in serum creatinine or serum bilirubin were observed. There was no indication of a difference in transaminase elevations during Study 301 for either study treatment.

<div style=\"page-break-after: always\"></div>

## Serum Copper

Since Vyxeos contains copper encapsulated in the liposome, which acts as a chelating agent to maintain a slow release rate for daunorubicin, subjects were monitored for serum copper concentrations during each of the clinical studies in the Vyxeos program.

In the Pooled Safety Population, upon administration of Vyxeos, a rise in serum copper levels during induction and consolidation periods was evident compared with control but, by the last observation post baseline median levels had begun to return to normal ranges.

Study 206 included specific PK analysis of serum copper following administration of 3 doses of 100 units/m 2 Vyxeos every other day that resulted in increases in serum copper concentrations which returned to baseline levels within 10 to 11 days after the last dose.

## Safety in special populations

## · Age

The overall Summary of TEAE by geriatric status is displayed in Table 39.

## Table 38 Overall Summary of TEAE by geriatric status - Study Period (Pooled Safety Population)

|                                  | CPX-351            | CPX-351             | All Controls      | All Controls       |
|----------------------------------|--------------------|---------------------|-------------------|--------------------|
|                                  | Age<65 Years N=163 | Age≥65 Year's N=212 | Age<65 Years N=93 | Age≥65 Years N=143 |
| Any TEAEsa                       | 163 (100)          | 212 (100)           | 93 (100)          | 143 (100)          |
| TEAEs by Maximum NCI-CTC Gradeb  | 163 (100)          | 212 (100)           | 93 (100)          | 143 (100)          |
| Grade 1                          | 1 (0.6)            | 1 (0.5)             | 2 (2.2)           | 1 (0.7)            |
| Grade 2                          | 11 (6.7)           | 13 (6.1)            | 5 (5.4)           | 14 (9.8)           |
| Grade 3                          | 93 (57.1)          | 123 (58.0)          | 63 (67.7)         | 77 (53.8)          |
| Grade 4                          | 26 (16.0)          | 37 (17.5)           | 9 (9.7)           | 20 (14.0)          |
| Grade 5                          | 32 (19.6)          | 38 (17.9)           | 14 (15.1)         | 31 (21.7)          |
| Grade 3 to 5                     | 151 (92.6)         | 198 (93.4)          | 86 (92.5)         | 128 (89.5)         |
| TEAEs by Closest Relationship    |                    |                     |                   |                    |
| Not related                      | 6 (3.7)            | 6 (2.8)             | 10 (10.8)         | 6 (4.2)            |
| Related                          | 157 (96.3)         | 206 (97.2)          | 83 (89.2)         | 137 (95.8)         |
| SeriousTEAEs                     | 92 (56.4)          | 126 (59.4)          | 37 (39.8)         | 66 (46.2)          |
| TEAEs leading to discontinuation | 3 (1.8)            | 5 (2.4)             | 1 (1.1)           | 2 (1.4)            |
| TEAEsleadingtodeath              | 32 (19.6)          | 38 (17.9)           | 14 (15.1)         | 31 (21.7)          |

Abbreviations: AE = adverse event; MedDRA = medical dictionary for regulatory activities; NCI-CTC = National Cancer Institute Common Terminology Criteria; SAE = serious adverse event; TEAE = treatment emergent adverse event.

Grade 3 AEs occurred with similar frequency between age groups for most SOC categories. For Vyxeos, a higher incidence was observed in subjects &gt; 65 years for respiratory, thoracic and mediastinal disorders (17.2% of subjects &lt; 65, and 25.0% of subjects &gt; 65), and vascular disorders (9.2% of subjects &lt; 65, and 14.2% of subjects &gt; 65) driven primarily by a higher incidence in ≥ 65 years of atrial fibrillation (0.6% vs 4.2%), hypoxia (5.5% vs 12.7%) and hypertension (4.3% vs 8.0%).

Fewer deaths were reported for subjects treated with Vyxeos compared with All Controls, regardless of age group. U p to 60 days following treatment those &lt; 65 years had comparable death rates between the 2

<div style=\"page-break-after: always\"></div>

treatment groups (both had death rate of 12.9%) but subjects ≥ 65 years, the Vyxeos group experienced a reduced death rate compared with All Controls (12.3% vs 23.1%).

No major differences were observed for related AEs and AEs leading to discontinuation by age category.

Table 39 TEAE of Special Interest by Geriatric Status and Sponsor-defined Class -Study Period (Pooled Safety Population)

|                          | CPX-351              | CPX-351               | All Controls        | All Controls           |
|--------------------------|----------------------|-----------------------|---------------------|------------------------|
|                          | Age < 65 Years N=163 | Age ≥ 65 Year's N=212 | Age< 65 Year's N=93 | Age ≥ 65 Year's N =143 |
| Infection Events         | 156 (95.7)           | 198 (93.4)            | 87 (93.5)           | 132 (92.3)             |
| BacterialInfectionEvents | 147 (90.2)           | 182 (85.8)            | 79 (84.9)           | 124 (86.7)             |
| ViralInfectionEvents     | 19 (11.7)            | 30 (14.2)             | 10 (10.8)           | 14 (9.8)               |
| Fungal Infection Events  | 24 (14.7)            | 48 (22.6)             | 14 (15.1)           | 16 (11.2)              |
| Bleeding Events          | 96 (58.9)            | 164 (77.4)            | 54 (58.1)           | 86 (60.1)              |
| Cardiac Events           | 84 (51.5)            | 107 (50.5)            | 38 (40.9)           | 66 (46.2)              |
| Rash Events              | 108 (66.3)           | 111 (52.4)            | 32 (34.4)           | 56 (39.2)              |

Abbreviations: MedDRA = medical dictionary for regulatory activities.

Note: The ^All Controls' treatment group includes subjects from Study 204, Study 205, and Study 301 who were treated with 7 + 3 and / or Salvage therapy.

MedDRA version 16.0.

## · Race

Within the pooled population, related AEs and SAEs analysed by race category showed no major differences.

## · Gender

In the Vyxeos group, TEAEs leading to death were more frequent for female (23.3%) than male (15.3%) subjects; the opposite was true for the all controls (22.5% males vs 14.3% females). No major differences were observed for related AEs and SAEs.

## · Renal function

In the pooled safety population Vyxeos group, 181 subjects (48.3%) had normal renal function (CrCL ≥ 90 mL/min), 139 (37.1%) had mild renal impairment (CrCL from 60 to 89 mL/min), 54 (14.4%) had moderate renal impairment (CrCL from 30 to 59 mL/min), and 1 (0.2%) had severe renal impairment (CrCL from 15 to 29 mL/min). Overall there were insufficient numbers of subjects to evaluate possible relationships between renal function category and TEAEs leading to discontinuation or death. The incidence of SAEs was higher for the Vyxeos treatment group than the All Controls treatment group, regardless of renal function category. No notable differences were observed among renal categories in the incidence of any TEAEs Grade 3 to 5 or SAEs for either the Vyxeos or all controls (data not shown).

## · Hepatic impairment

In the pooled safety population, the majority of subjects who received Vyxeos had bilirubin less than 1.2 mg/dL (332 subjects; 88.5%) and the remainder had bilirubin within the range of 1.2 to 3 mg/dL (42 subjects; 11.2%). There were no patients with end stage disease or bilirubin higher than 3 mg/dL. Consequently, results of this subgroup analysis should be interpreted with caution.

A higher incidence of SAEs was reported for Vyxeos group compared with all controls, regardless of hepatic function category. Few differences in the AE profile were observed for the Vyxeos treatment or when comparing the Vyxeos treatment group with all controls by hepatic function category.

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

There were no adverse events attributable to drug-drug interactions during the Vyxeos clinical development program.

## Discontinuation due to adverse events

In the Pooled Safety population, less than 3% discontinuations due to TEAEs were reported and all occurred during induction (Table 41).

Table 40 TEAE leading to discontinuation, by SOC and PT-treatment period (pooled safety population)

| SystemOrganClass                                    |               | Controls   | Controls     | Controls           |
|-----------------------------------------------------|---------------|------------|--------------|--------------------|
| Preferred Term                                      | CPX-351 N=375 | 7+3 N=192  | Salvage N=44 | All Controls N=236 |
| Any TEAEs Leading to Discontinuation                | 7 (1.9)       | 3 (1.0)    | 0            | 3 (1.3)            |
| Bloodandlymphaticsystemdisorders                    | 1 (0.3)       | 0          | 0            | 0                  |
| Thrombocytopenia                                    | 1 (0.3)       | 0          | 0            | 0                  |
| Cardiac Disorders                                   | 3 (0.8)       | 0          | 0            | 0                  |
| Cardiac failure                                     | 1 (0.3)       | 0          | 0            | 0                  |
| Cardiomyopathy                                      | 1 (0.3)       | 0          | 0            | 0                  |
| Pericardial effusion                                | 1 (0.3)       | 0          | 0            | 0                  |
| General disordersand administration site conditions | 2 (0.5)       | 0          | 0            | 0                  |
| Mucosalinflammation                                 | 1 (0.3)       | 0          | 0            | 0                  |
| Pyrexia                                             | 1 (0.3)       | 0          | 0            | 0                  |
| Infections and infestations                         | 2 (0.5)       | 0          | 0            | 0                  |
| Pneumomia                                           | 1 (0.3)       | 0          | 0            | 0                  |
| Staphylococcalbacteraemia                           | 1 (0.3)       | 0          | 0            | 0                  |
| Investigations                                      | 1 (0.3)       | 2 (1.0)    | 0            | 2 (0.8)            |
| Alanine aminotransferase increased                  | 1 (0.3)       | 0          | 0            | 0                  |
| Aspartate aminotransferase increased                | 1 (0.3)       | 0          | 0            | 0                  |
| Ejection fraction decreased                         | 0             | 2 (1.0)    | 0            | 2 (0.8)            |
| Psychiatric disorders                               | 0             | 1(0.5)     | 0            | 1 (0.4)            |
| Psychotic disorder                                  | 0             | 1 (0.5)    | 0            | 1 (0.4)            |
| Renal and urinarydisorder's                         | 2 (0.5)       | 0          | 0            | 0                  |
| Renal failure acute                                 | 2 (0.5)       | 0          | 0            | 0                  |
| Respiratory,thoracic and mediastinal disorder's     | 1 (0.3)       | 0          | 0            | 0                  |
| Respiratory failure                                 | 1 (0.3)       | 0          | 0            | 0                  |

treated with 7 + 3 and / or Salvage therapy.

MedDRA version 16.0

In study 301 five subjects discontinued the study due to AEs, 3 subjects in the CPX-301 group (2%) due to cardiac failure, cardiomyopathy and acute renal failure (1 subject each), and 2 subjects (1.3%) in the 7 + 3 group due to SAE of ejection fraction decreased.

<div style=\"page-break-after: always\"></div>

## 2.6.1. Discussion on clinical safety

At least 403 subjects received one dose of Vyxeos and included a broad population of AML patients, both newly diagnosed and relapsed, and of an age range of 18 years up to 80 years. The proposed target population and dose regimen is well represented from 153 subjects treated with Vyxeos in the pivotal study 301. The safety database in the proposed target population is considered adequate for assessment.

Patients receiving Vyxeos in the proposed regimen and doses were exposed to a reduced total dose of cytarabine and daunorubicin compared to the standard 7+3 regimen despite having received a longer duration of treatment (study 301 median duration treatment with Vyxeos 62 days versus 41 days with 7+3). This would imply an advantage of Vyxeos therapy, especially with regards to cumulative dose exposure to anthracyclines, and is considered as a clinical benefit.

The safety profile of Vyxeos appears in accordance with that expected from non-clinical data and is similar to the administration of the two components as 7+3.

The incidence of AE was similar between treatment groups except for a moderate higher incidence of serious AE with Vyxeos. However, the reported AE leading to discontinuation was low in all treatment groups (&lt; 2%). It is reassuring to observe that despite the higher exposure and cumulative dose with Vyxeos the reported frequency of AE is not worse than 7+3.

Overall, the AE profile seen with Vyxeos was similar to all controls or 7+3 regimen. The most common AE reported with Vyxeos were febrile neutropenia, nausea, diarrhoea and constipation, and there are no differences across age subgroups.

The most frequently occurring adverse reactions (ADRs) were hypersensitivity including rash, febrile neutropenia, oedema, diarrhoea/colitis, mucositis, fatigue, musculoskeletal pain, abdominal pain, decreased appetite, headache, cough, chills, arrhythmia, pyrexia, sleep disorders, and hypotension (SmPC, section 4.8).

Vyxeos is associated with a more prolonged myelosuppression than 7+3, due to its PK properties of releasing a 'full' cargo of daunorubicin and cytarabine to the bone marrow. Subsequently, it is not surprising that the recovery of neutropaenia and thrombocytopaenia takes longer for Vyxeos, around 7-10 days extra. Although bleeding AE are reported with a higher incidence with Vyxeos than 7+3 most events are of low grade. In addition, infections were reported with similar incidence in both arms (around 92%-93%) but the difference between Vyxeos and 7+3 was seen in serious infections (32% vs 21%), especially bacteriaemia. The risk of serious infections appears to be managed with supportive care as it did not translate into a higher discontinuation of study treatment or overall AE related mortality (see section 4.8).

Severe myelosuppression (including fatal infections and haemorrhagic events) has been reported in patients after administration of a therapeutic dose of Vyxeos. Serious or fatal haemorrhagic events, including fatal central nervous system (CNS) haemorrhages, associated with severe thrombocytopenia, have occurred in patients treated with Vyxeos. Baseline assessment of blood counts should be obtained, and patients should be carefully monitored during treatment with Vyxeos for possible clinical complications due to myelosuppression. Due to the long plasma half-life of Vyxeos, time to recovery of ANC and platelets may be prolonged and require additional monitoring (SmPC section 4.4 and 4.8).

Prophylactic anti-infectives may be administered during the period of profound neutropenia until ANC returns to 500/μL or greater. If myelosuppressive complications occur, appropriate supportive measures should be used, e.g., anti-infectives, colony-stimulating factors, transfusions. Blood counts should be regularly monitored until recovery (SmPC section 4.4).

<div style=\"page-break-after: always\"></div>

Serious hypersensitivity reactions, including anaphylactic reactions, have been reported with daunorubicin and cytarabine. For moderate hypersensitivity symptoms (e.g., moderate rash, flushing, mild dyspnoea, chest discomfort) the treatment should be stopped. Intravenous diphenhydramine (20-25 mg or equivalent) and intravenous dexamethasone (10 mg) should be given. The infusion should not be restarted. When the patient is retreated, Vyxeos should be given at the same dose and rate and with premedication (see section 4.8).

For severe/life-threatening hypersensitivity symptoms (e.g., hypotension requiring vasopressor therapy, angioedema, respiratory distress requiring bronchodilation therapy, generalised urticaria), the treatment should be stopped. Intravenous diphenhydramine (20-25 mg) and dexamethasone (10 mg) should be given, and epinephrine (adrenaline) or bronchodilators should be added if indicated. Infusion should not be reinitiated, and no retreat is recommended. Treatment with Vyxeos should be permanently discontinued. Patients should be monitored until symptoms resolve (SmPC sections 4.2 and 4.4). Of note rash, a known AE of cytarabine infusions was also reported at a higher incidence with Vyxeos but none of the events were of Grade 4/5, and it is easily managed with slowing the infusion or pre-medication.

A dedicated study (206) showed no evidence of an effect of Vyxeos on cardiac ventricular repolarization. Whilst in the pooled safety population, that included some patients with prior anthracycline use, there was an increase in cardiac AE in the Vyxeos versus controls (50% vs 42%) the majority were of Grade 1 or 2 and serious AE were lower with Vyxeos (7% vs 11%). Tachycardia was the most common AE reported in all treatment groups. It seems there is no difference for prior anthracycline exposed patients versus anthracycline naïve, although only 5 patients in the data had received high dose of anthracyclines (above 500 mg/m2) and 159 patients had low or medium prior exposure. Nearly all patients were anthracycline naïve in the pivotal study 301 and there were no clinically significant differences observed between Vyxeos and 7+3 with most cardiac events of Grade1-2 and in line with the pooled safety population analysis. Long term cardiotoxicity effects are unknown (see section 4.8).

Cardiotoxicity is a known risk of anthracycline treatment. Prior therapy with anthracyclines (including patients who have previously received the recommended maximum cumulative doses of doxorubicin or daunorubicin hydrochloride), pre-existing cardiac disease (including impaired cardiac function), previous radiotherapy of the mediastinum, or concomitant use of cardiotoxic products may increase the risk of daunorubicin-induced cardiac toxicity. Total cumulative doses of non-liposomal daunorubicin greater than 550 mg/m 2  have been associated with an increased incidence of treatment-induced congestive heart failure. This limit appears lower (400 mg/m 2 ) in patients who received radiation therapy to the mediastinum. The relationship between cumulative Vyxeos dose and the risk of cardiac toxicity has not been determined (SmPC section 4.4).

A baseline cardiac evaluation with an electrocardiogram (ECG) and a multi-gated radionuclide angiography (MUGA) scan or an echocardiography (ECHO) is recommended, especially in patients with risk factors for increased cardiac toxicity. Cardiac function should be closely monitored.Treatment with Vyxeos should be discontinued in patients with impaired cardiac function unless the benefit of initiating or continuing treatment outweighs the risk (SmPC section 4.4).

A comparison of Vyxeos with 7+3 in both, pooled analysis population or pivotal study 301 showed there were fewer deaths reported for the experimental treatment across the treatment and follow up phases. The primary cause of death during the first 30 or 60 days of the study 301 was progressive leukaemia and AE. By the end of study 301 similar proportions of patients died due to AE (~ 20%); although more grade 5 infections occurred with Vyxeos vs 7+3 (10 subjects/6.5% vs 4 subjects/2.6%) most of these deaths were not considered related to study treatment.

<div style=\"page-break-after: always\"></div>

The incidence of serious AE was higher for Vyxeos than 7+3 in pooled analysis population and study 301 (59% vs 43%), and the most common AE reported in study 301 were febrile neutropenia and sepsis due to the prolonged myelosuppression. The most serious and frequently occurring ADRs were infection, haemorrhage, and cardiotoxicity (SmPC, section 4.8).

Daunorubicin has been associated with local tissue necrosis at the site of medicinal product extravasation. In clinical studies with Vyxeos, one event of extravasation occurred, but no necrosis was observed. Care should be taken to ensure that there is no extravasation of medicinal product when Vyxeos is administered. Vyxeos should be administered intravenously only. Vyxeos should not be  administered via an intramuscular, intrathecal, or subcutaneous route (SmPC, sections 4.2 and 4.4).

There is no evidence of clinically significant abnormal serum copper levels due to the copper encapsulated in the liposome. In clinical trials the copper levels remained below 530 microg/mL (4 times above the ULN). Each vial contains 100 mg of copper gluconate, which corresponds to 14 mg of elemental copper. Vyxeos should only be used in patients with a history of Wilson's disease or other copper-related disorder if the benefits outweigh the risks (SmPC section 4.4).

Administration of live or live-attenuated vaccines in patients that are immunocompromised by chemotherapeutic agents may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving Vyxeos. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished (SmPC section 4.4).

It should be taken into consideration that the absorption of oral accompanying medicinal products may be considerably influenced by gastrointestinal mucositis and/or diarrhoea frequently occurring in association with intensive chemotherapy (SmPC section 4.4).

No relevant changes were noted for chemistry laboratory investigations or urine analysis. Vyxeos treatment did not affect s-Crea or s-Bil implying no harmful renal or hepatic effects. There was no indication of a difference in transaminase elevations during Study 301 for either study treatment.

Vyxeos may induce hyperuricemia secondary to rapid lysis of leukaemic cells. Blood uric acid levels should be monitored and appropriate therapy initiated in the event that hyperuricemia develops (SmPC section 4.4).

Hepatic or renal impairment may increase the risk of toxicity associated with daunorubicin and cytarabine. Evaluation of hepatic and renal function using conventional clinical laboratory tests is recommended prior to administration of Vyxeos and periodically during treatment. There is no experience with Vyxeos in patients with baseline serum bilirubin greater than 50 µmol/L, severe renal impairment (creatinine clearance less than 30 mL/min), or end stage renal disease. Vyxeos should only be used in patients with a severe hepatic and/or renal impairment if the benefits outweigh the risks (SmPC, section 4.4).

Although there was a higher incidence of bleeding events in patients above 65 years, the overall safety profile of Vyxeos is considered similar across age subgroups (&lt; or &gt; 65 years) which is important given the intensity of the proposed chemotherapy regimen.

There were no adverse events attributable to drug-drug interactions during the Vyxeos clinical development program.

Throughout all analyses the consolidation dose of 65 mg/m 2  showed an improved safety profile compared to 100 mg/m 2  providing a strong justification for the proposed consolidation dosage.

For the purpose of this application in AML patients with poor survival prognosis, the lack of long term safety data is not a concern.

<div style=\"page-break-after: always\"></div>

Vyxeos must not be substituted or interchanged with other daunorubicin and/or cytarabine containing products.  Due to substantial differences in the pharmacokinetic parameters, the dose and schedule recommendations for Vyxeos are different from those for daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. The medicinal product name and dose should be verified prior to administration to avoid dosing errors. (SmPC section 4.4).

Women of childbearing potential should avoid becoming pregnant while receiving Vyxeos. Women of childbearing potential should use effective contraception while they or their male partner undergo treatment. Women of childbearing potential should not receive treatment until pregnancy is excluded. Women of childbearing potential should undergo pregnancy testing before initiation of Vyxeos. Men with sexual partners of reproductive potential and women should use effective contraception during treatment and for 6 months following the last dose of Vyxeos (SmPC section 4.6).

There are no data on the use of Vyxeos in pregnant women. Based on results from animal studies and its mechanism of action, Vyxeos should not be used during pregnancy, unless the clinical condition of the woman requires treatment and justifies the potential risk to the foetus (SmPC section 4.6).

If the medicinal product is used during pregnancy, or if the patient becomes pregnant while receiving Vyxeos, the woman should be informed of the potential hazard to the foetus. In any case, cardiologic examination and a blood count are recommended in foetuses and newborns born to mothers who received treatment during pregnancy SmPC section 4.6).

It is not known whether Vyxeos is excreted in human milk. Because many medicinal products are excreted in human milk and because of the potential for serious adverse reactions in nursingbreast feeding infants from Vyxeos, mothers should be advised to discontinue nursingbreast feeding during Vyxeos therapy (SmPC section 4.6).

Vyxeos has minor influence on the ability to drive and use machines. Fatigue and dizziness have been reported with the use of Vyxeos. Therefore, caution is recommended when driving or operating machines (SmPC section 4.7).

If overdose occurs, exacerbation of adverse reactions associated with Vyxeos is expected and supportive treatment (incuding anti-infectives, blood and platelet transfusions, colony-stimulating factors, and intensive care as needed) should be provided until the patient recovers. Patients should be observed carefully over time for signs of cardiotoxicity and provide appropriate supportive therapy as clinically indicated (SmPC section 4.9).

It is contraindicated in patients with history of serious hypersensitivity to the active substances or to any of the excipients listed in section 6.1

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## 2.6.2. Conclusions on the clinical safety

Overall, the safety profile of Vyxeos is similar to standard 7+3 and is considered acceptable. The most common AEs reported with Vyxeos are febrile neutropenia, nausea, diarrhoea and constipation. Vyxeos produces a prolonged myelosuppression and a higher incidence of low grade bleeding events and serious infections that can be managed with appropriate supportive care.

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

## Safety concerns

No important safety concerns were identified. As this drug combination (cytarabine and daunorubicin) has been in use for several decades the risks are well known, and they are also clearly presented in the PI. No critical difference between Vyxeos and the therapy with conventional daunorubicin/cytarabine combination is expected in this respect.

## Pharmacovigilance plan

N/A

## Risk minimisation measures

No additional risk minimisation measures are applicable.

## Conclusion

The CHMP and PRAC considered that the risk management plan version 0.2 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

Based on different PUSR frequencies for daunorubicin and cytarabine, the CHMP is of the opinion that a separate entry in the EURD list for Vyxeos (cytarabine:daunorubicin) liposome for injection is needed, as it cannot follow the already existing entry for daunorubicin / cytarabine. The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request the alignment of the new PSUR cycle with the international birth date (IBD). The IBD is 3.08.2017. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Vyxeos (daunorubicin and cytarabine) is proposed for the treatment of adults with newly-diagnosed therapyrelated acute myeloid leukaemia (t-AML) or AMLwith myelodysplasia-related changes (AML-MRC).

## 3.1.2. Available therapies and unmet medical need

In the EU (European Union), approved agents include decitabine (Dacogen) which is authorised for the treatment of adult patients with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy. Azacitidine (Vidaza) is also authorised for the treatment of adult patients who are not eligible for HSCT with AML with 20-30 % blasts and multi-lineage dysplasia, according to WHO classification and AML with &gt;30% marrow blasts according to the WHO classification. In addition, histamine dihydrochloride (Ceplene) is authorised for adult patients with AML in first remission concomitantly treated with interleukin-2 (IL-2). Midostaurin (Rydapt) is authorised in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy followed by midostaurin single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation positive. Finally, Mylotarg is authorised in combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia (APL).

AML has a poor prognosis with survival of 37.9% after one year and 17.1% after 5 years from diagnosis that decreases steeply with age, from 49.6% (patients aged 15-44 years) to 3.8% (patients aged ≥ 75 years). Amongst all AML types, high-risk AML as defined by therapy-related AML or AML with myelodysplasia-related changes carries a very poor prognosis and represents an unmet medical need.

## 3.1.3. Main clinical studies

The main clinical study was study CLTR0310-301 a phase III, multicenter, randomised, trial of Vyxeos (cytarabine: daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60 -75 years of age with untreated high risk (secondary) AML study.

## 3.2. Favourable effects

- Improved median OS by 3.6 months (ITT population median OS 9.56 months CPX 351 versus 5.95 months 7+3; HR 0.69, 95% CI: 0.52 to 0.90; 2-sided p = 0.005).
- Improved median EFS by 1.2 months (ITT population: median EFS 2.53 months CPX 351 versus 2.31 months7+3; HR 0.74, 95% CI: 0.58 to 0.96; 2-sided p = 0.021).
- Improved MLFS (ITT population: 69% Vyxeos vs. 55.5%7+3; OR 1.78, 95% CI: 1.05 to 3.03, 1sided p = 0.017)
- Improved rate of HSCT (ITT population: 34% Vyxeos vs. 25% 7+3; OR 1.54, 95% CI: 0.92 to 2.56; 2-sided p = 0.097).

<div style=\"page-break-after: always\"></div>

- Easier dosing schedule with Vyxeos of three (or two) 90-minutes infusions every other day compared to 7-days (or 5-days) continuous infusion of cytarabine along with subsequent administration of daunorubicin at induction. Patients can receive Vyxeos consolidation in the out-patient setting.

## 3.3. Uncertainties and limitations about favourable effects

There are no important uncertainties or limitations about the favourable effects.

## 3.4. Unfavourable effects

Due to the neutropenia experienced with Vyxeos, infections of various types were very common ADRs. Pneumonia, sepsis and bacteriaemia were the most frequently seen serious infection ADRs in the clinical studies population. The incidence of infection events was 78.1%; the incidence of non-serious events of infections was 73.1%, the incidence of serious events of infections was 28.5%; the incidence of infections which led to discontinuation was 0.5%.

A variety of haemorrhagic events were seen in clinical studies. The most common haemorrhagic event was epistaxis, and the majority of these were considered not serious (29.1%). The incidence of haemorrhage events was 69.1%; the incidence of non-serious events of haemorrhage was 67.2 %; the incidence of serious events of haemorrhage was 5.6%; the incidence of haemorrhage which led to discontinuation was 0. The incidence of fatal haemorrhage was 2.1%.

Hypersensitivity reactions were very common ADRs in Vyxeos clinical studies. The most frequently reported hypersensitivity ADRs was rash and the majority of these were not serious (38.9%). The incidence of all hypersensitivity events was 66.9%; the incidence of non-serious events of hypersensitivity was 66.4 %, of which 38.9 % were rash; the incidence of serious events of hypersensitivity was 1.1%. There were no hypersensitivity events which led to discontinuation and no fatal hypersensitivity events were recorded (see section 4.4).

## 3.5. Uncertainties and limitations about unfavourable effects

There are no important uncertainties and limitations about the unfavourable effects.

## 3.6. Effects Table

Table 41 Effects Table for Vyxeos for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)-study CLTR0310-301(data cut-off: 31 December 2015).

| Effect                | Short description                                | Unit               | Treatment          | Control            | Uncertaintie s / Strength of evidence   | Referen ces        |
|-----------------------|--------------------------------------------------|--------------------|--------------------|--------------------|-----------------------------------------|--------------------|
| Favourable Effects    | Favourable Effects                               | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                      | Favourable Effects |
| Overall survival (OS) | Time form randomizatio n to death from any cause | Months             | 9.56 (6.60- 11.86) | 5.95 (4.99-7.75)   | HR 0.69(0.52- 0.90), 2-sided p=0.005    |                    |
| Event free survival   | Time from randomizatio                           | Months             | 2.53 (2.07-4.99)   | 1.31 (1.08-1.64)   | HR 0.74 (0.58-0.96),                    |                    |

<div style=\"page-break-after: always\"></div>

| Effect                   | Short description                                                                                                   | Unit                     | Treatment                | Control                  | Uncertaintie s / Strength of evidence   | Referen ces              |
|--------------------------|---------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|-----------------------------------------|--------------------------|
| (EFS)                    | n to the date of induction treatment failure, relapse from CR or CRi or death from any cause, whichever came first. |                          |                          |                          | 2-sided p=0.021                         |                          |
| Unfavourable Effects (1) | Unfavourable Effects (1)                                                                                            | Unfavourable Effects (1) | Unfavourable Effects (1) | Unfavourable Effects (1) | Unfavourable Effects (1)                | Unfavourable Effects (1) |
| Infection                | Grade 3-5                                                                                                           | %                        | 58.7                     | 50.5                     |                                         |                          |
| Haemorrhag e             | Grade 3-5                                                                                                           | %                        | 13.1                     | 6.8                      |                                         |                          |
| Rash                     | Grade 3-5                                                                                                           | %                        | 4                        | 0.5                      |                                         |                          |
| Febrile Neutropenia      | Grade ≥ 3                                                                                                           | %                        | 62.1                     | 65.1                     |                                         |                          |
| Pneumonia                | Grade ≥ 3                                                                                                           | %                        | 16                       | 14.1                     |                                         |                          |
| Hypoxia                  | Grade ≥ 3                                                                                                           | %                        | 9.6                      | 12.5                     |                                         |                          |

Notes: (1) The frequencies of the unfavourable effects were derived from the frequency of all adverse events in the pooled safety population.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Vyxeos has demonstrated a clinically significant improvement in overall survival compared to the standard of care 7+3 in the proposed population of patients with newly diagnosed AML with MRC and therapy related AML. This is remarkable given the very poor prognosis of these patients and their unmet medical need. Secondary endpoints support the primary outcome, in particular an increased rate of HSCT which is potentially the only curative treatment in AML.

The safety profile appears similar to the known profile of 7+3 except for a more prolonged myelosuppression due to the liposomal formulation and an increase in serious AE, in particular infections. These appear to be managed with appropriate supportive care as the rate of discontinuations is low. There is no evidence of increased cardiac toxicity and in fact, despite longer exposure to treatment the cumulative doses of daunorubicin are lower than with 7+3.

## 3.7.2. Balance of benefits and risks

In view of the effect in terms of OS and the known ADRs for such a combination (cytarabine and daunorubicin), the benefit-risk balance in the proposed indication is considered positive.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

The pivotal study showed no clinically relevant differences in outcome across age subgroups (60-69 years/70-75 years) although it excluded patients below 60 years of age. Vyxeos is an optimised liposomal formulation of cytarabine and daunorubicin which is used as standard therapy in patients of all ages. Most patients that receive the standard treatment need to be fit for intensive chemotherapy, and therefore, whether the patient's performance status and their suitability to receive the treatment is based on clinical judgement and the physician's decision. In some younger patients with newly diagnosed AML, other treatments, like 7+3 plus a third agent, are sometimes used. However, for patients below 60 years scheduled to receive the standard 7+3, Vyxeos seems an optimised formulation which is very likely to be superior to 7+3 given the results in &gt; 60 years from the pivotal study. It appears there are no differences in disease biology for t-AML or AML-MRC between adult ages subgroups. Prognosis is very poor, and these subtypes of AML represent an unmet medical need irrespective of age. The exposure response analysis conducted in adult patients, included few patients below age of 60 and it indicated the proposed dose is the most appropriate. PK data did not show variability with regards to age covariate and results from studies 101 and 206 showed that free fractions of daunorubicin and cytarabine in patients below 60 years are similar to those above 60 years. It is debated in the literature whether a higher cytarabine dose should be administered to younger patients with the aim to improve efficacy. However, there are discrepant results across published studies which have led to different dosages used across institutions. As the Vyxeos liposomal formulation delivers a higher 'cargo' of daunorubicin and cytarabine to the bone marrow the dose of cytarabine seems acceptable for younger adults. Overall, extrapolation of data from the pivotal study can reasonably be made to adults below the age of 60 years.

## 3.8. Conclusions

The overall B/R of Vyxeos is positive.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Vyxeos is not similar to Vidaza, Ceplene, Dacogen, Rydapt and Mylotarg, within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Vyxeos is favourable in the following indication:

Vyxeos is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product

<div style=\"page-break-after: always\"></div>

Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the  agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## Appendix

1. CHMP AR on similarity dated 31 May 2018

<div style=\"page-break-after: always\"></div>

## REFERENCES

1. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-1376.
2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.
3. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.
4. Pincheira J, de la Torre C, Rodríguez N, Valenzuela CY. Response of the G2-prophase checkpoint to genotoxic drugs in lymphocytes from healthy individuals. Biological research. 2012; 45(2):177-182.
5. Kihlman et al. Deoxyadenosine as an inducer of chromosomal aberrations in vicia faba. Journal of cellular and comparative physiology. 1963; 62:267-272.
6. Kouri RE, Kurtz SA, Price PJ, Benedict WF. 1-beta-D-arabinofuranosylcytosine-induced malignant transformation of hamster and rat cells in culture. Cancer Research. 1975; 35(9):2413-9.
7. Hayashi M, Sofuni T, Kodama Y, Ishidate M Jr, Tamura H. Micronucleus test with 1-beta-Darabinofuranosylcytosine administered by intraperitoneal injection and oral gavage. Mutation research. 1989; 223(4):345-8.
8. Beaula Helen KD, Subramanyam S. Genotoxic evaluation of Ara-C by multiple parameters. Mutation research. 1991; 263(3):185-96.
9. Weisburger EK. History of the Journal of the National Cancer Institute. Journal of the National Cancer Institute. 1977; 59(2 Suppl):601-4.
10.  Berger MR, Schmähl D. Study on the long-term toxic efficacy of cytosine-arabinoside in Sprague-Dawley rats. Cancer letters. 1988; 43(1-2):59-64.
11.  Sternberg SS, Philips FS, Cronin AP. Renal tumors and other lesions in rats following a single intravenous injection of daunomycin. Cancer research. 1972; 32(5):1029-36.
12.  Bucclarelli E. Mammary tumor induction in male and female Sprague-Dawley rats by adriamycin and daunomycin. Journal of the National Cancer Insitute. 1981; 66(1):81-4.
13.  Howell SK, Stephens LC, Wang YM. Daunorubicin-induced mammary tumors in the rat. European journal of cancer &amp; clinical oncology. 1989; 25(11):1549-54.